CLARK RYAN C (US)
ERNST JUSTIN (US)
PACKARD GARRICK K (US)
BUSCH BRETT (US)
NAGAMIZO JOE FRED (US)
KALITA BISWAJIT (IN)
DURAISWAMY ATHISAYAMANI JEYARAJ (IN)
WO1993020078A1 | 1993-10-14 | |||
WO2007022269A2 | 2007-02-22 |
DATABASE REGISTRY 29 September 2015 (2015-09-29), ANONYMOUS : " 1H-Benzimidazole-5-carbonitrile, 2-(3,4-dihydroxy-5-methoxyphenyl)-1- propyl- (CA INDEX NAME)", XP055896202, retrieved from STN Database accession no. 1808803-82-8
WANG KAI, GUENGERICH F. PETER: "Bioactivation of Fluorinated 2-Aryl-benzothiazole Antitumor Molecules by Human Cytochrome P450s 1A1 and 2W1 and Deactivation by Cytochrome P450 2S1", CHEMICAL RESEARCH IN TOXICOLOGY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, vol. 25, no. 8, 20 August 2012 (2012-08-20), US , pages 1740 - 1751, XP055896205, ISSN: 0893-228X, DOI: 10.1021/tx3001994
ZHANG ZHICHAO, PENGCHEN SU, XIANGQIAN LI, TING SONG, GAOBO CHAI, XIAOYAN YU, KEREN ZHANG: "Novel Mcl-l/Bcl-2 Dual Inhibitors Created by the Structure-Based Hybridization of Drug-Divided Building Blocks and a Fragment Deconstructed from a Known Two-Face BH3 Mimetic", ARCH. PHARM. CHEM. LIFE SCI., vol. 348, no. 2, 13 January 2015 (2015-01-13), pages 89 - 99, XP055896208, DOI: 10.1002/ardp.201400296
CLAIMS WHAT IS CLAIMED IS: 1. A compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof: Ring B is phenyl or a 6-membered heteroaryl; R1 is hydrogen, deuterium, halogen, -CN, -OR11, -SR11, -S(=O)R10, -S(=O)2R10, -NO2, -NR12R13, - NHS(=O)2R10, -S(=O)2NR12R13, -C(=O)R10, -OC(=O)R10, -C(=O)OR11, -OC(=O)OR11, - C(=O)NR12R13, -OC(=O)NR12R13, -NR11C(=O)NR12R13, -NR11C(=O)R10, -NR11C(=O)OR11, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R1a; each R2 is independently hydrogen, deuterium, halogen, -CN, -ORb, -SRb, -S(=O)Ra, -S(=O)2Ra, -NO2, - NRcRd, -NHS(=O)2Ra, -S(=O)2NRcRd, -C(=O)Ra, -OC(=O)Ra, -C(=O)ORb, -OC(=O)ORb, - C(=O)NRcRd, -OC(=O)NRcRd, -NRbC(=O)NRcRd, -NRbC(=O)Ra, -NRbC(=O)ORb, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2- C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R2a; n is 1-3; Y1 is O, S, or NRY1; Y2 is N or CRY2; provided that when Y2 is CRY2, Y1 is not O; RY1 is hydrogen, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -C(=O)Ra, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more RY1a; RY2 is hydrogen, deuterium, halogen, -CN, -ORb, -NO2, -NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more RY2a; R3 is hydrogen, deuterium, halogen, -CN, -ORb, -NO2, -NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R3a; R4 is hydrogen, deuterium, halogen, -CN, -ORb, -NO2, -NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R4a; R6 is -C(=O)Ra, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R6a; or R4 and R6 are taken together to form a heterocycloalkyl optionally substituted with deuterium, halogen, -CN, -ORb, -NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; each R1a is independently deuterium, halogen, -CN, -OR11, -SR11, -S(=O)R10, -S(=O)2R10, -NO2, - NR12R13, -NHS(=O)2R10, -S(=O)2NR12R13, -C(=O)R10, -OC(=O)R10, -C(=O)OR11, -OC(=O)OR11, - C(=O)NR12R13, -OC(=O)NR12R13, -NR11C(=O)NR12R13, -NR11C(=O)R10, -NR11C(=O)OR11, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R1b; or two R1a on the same carbon are taken together to form an oxo; each R10 is independently C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R10a; each R11 is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R11a; each R12 and R13 is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R12a; or R12 and R13 are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R13a; each RY1a, RY2a, R2a, R3a, R4a, R6a, R10a, R11a, R12a, R13a, and R1b is independently deuterium, halogen, -CN, -ORb, -SRb, -S(=O)Ra, -S(=O)2Ra, -NO2, -NRcRd, -NHS(=O)2Ra, -S(=O)2NRcRd, -C(=O)Ra, - OC(=O)Ra, -C(=O)ORb, -OC(=O)ORb, -C(=O)NRcRd, -OC(=O)NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; or two RY1a, two RY2a, two R2a, two R3a, two R4a, two R5a, two R6a, two R10a, two R11a, two R12a, two R13a, and two R1b on the same carbon are taken together to form an oxo, a cycloalkyl, or a heterocycloalkyl; each Ra is independently C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, - NH2, -C(=O)Me, -C(=O)OH, -C(=O)OMe, C1-C6alkyl, or C1-C6haloalkyl; each Rb is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, - NH2, -C(=O)Me, -C(=O)OH, -C(=O)OMe, C1-C6alkyl, or C1-C6haloalkyl; and each Rc and Rd is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, -NH2, -C(=O)Me, -C(=O)OH, -C(=O)OMe, C1-C6alkyl, or C1-C6haloalkyl; or Rc and Rd are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, -NH2, -C(=O)Me, -C(=O)OH, -C(=O)OMe, C1-C6alkyl, or C1-C6haloalkyl; provided that the compound of Formula (I) is not 2. The compound of claim 1, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein the compound of Formula (I) is of Formula (Ia): Formula (Ia). 3. The compound of claim 1, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein the compound of Formula (I) is of Formula (Ib): Formula (Ib). 4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: 5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: . 6. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: is . 7. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: . 8. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: . 9. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: Y1 is S and Y2 is N. 10. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: Y1 is O and Y2 is N. 11. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: Y1 is NRY1 and Y2 is N. 12. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: Y1 is NRY1 and Y2 is CRY2. 13. The compound of any one of claims 1-8 or 12, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: RY1 is hydrogen, C1-C6alkyl, or heterocycloalkyl. 14. The compound of any one of claims 1-8 or 12 or 13, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: RY1 is hydrogen. 15. The compound of any one of claims 1-8 or 12 or 13, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: RY1 is heterocycloalkyl. 16. The compound of any one of claims 1-8 or 12-15, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: RY2 is hydrogen, deuterium, halogen, -CN, -ORb, -NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more RY2a. 17. The compound of any one of claims 1-8 or 12-16, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: RY2 is hydrogen, halogen, C1-C6alkyl, or C1-C6haloalkyl. 18. The compound of any one of claims 1-8 or 12-17, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: RY2 is hydrogen. 19. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R3 is hydrogen, deuterium, halogen, -CN, -ORb, -NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, or C1-C6deuteroalkyl. 20. The compound of any one of claims 1-19, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R3 is hydrogen or halogen. 21. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R3 is hydrogen. 22. The compound of any one of claims 1-21, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R4 is hydrogen, deuterium, halogen, -CN, -ORb, -NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, or C1-C6deuteroalkyl. 23. The compound of any one of claims 1-22, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R4 is hydrogen or halogen. 24. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R4 is hydrogen. 25. The compound of any one of claims 1-24, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R6 is C1-C6alkyl. 26. The compound of any one of claims 1-25, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R6 is methyl. 27. The compound of any one of claims 1-26, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R2 is independently hydrogen, deuterium, halogen, -CN, -ORb, -NRcRd, -C(=O)Ra, - C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, or C1-C6deuteroalkyl. 28. The compound of any one of claims 1-27, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R2 is independently hydrogen, deuterium, halogen, -CN, -ORb, -NRcRd, C1-C6alkyl, C1-C6haloalkyl, or C1-C6deuteroalkyl. 29. The compound of any one of claims 1-28, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R2 is independently hydrogen, halogen, C1-C6alkyl, or C1-C6haloalkyl. 30. The compound of any one of claims 1-29, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R2 is independently hydrogen or halogen. 31. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R2 is hydrogen. 32. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: n is 1 or 2. 33. The compound of any one of claims 1-32, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: n is 1. 34. The compound of any one of claims 1-33, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R1 is hydrogen, deuterium, halogen, -CN, -OR11, -NR12R13, -C(=O)R10, -C(=O)OR11, - C(=O)NR12R13, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R1a. 35. The compound of any one of claims 1-34, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R1 is hydrogen, deuterium, halogen, -CN, -OR11, -NR12R13, -C(=O)R10, -C(=O)OR11, - C(=O)NR12R13, C1-C6alkyl, C1-C6haloalkyl, or C1-C6deuteroalkyl. 36. The compound of any one of claims 1-35, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R1 is hydrogen, halogen, C1-C6alkyl, or C1-C6haloalkyl. 37. The compound of any one of claims 1-36, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R1 is hydrogen or halogen. 38. The compound of any one of claims 1-37, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R1 is hydrogen. 39. The compound of any one of claims 1-34, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R1 is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R1a. 40. The compound of any one of claims 1-34 or 39, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R1 is heterocycloalkyl optionally substituted with one or more R1a. 41. The compound of any one of claims 1-34 or 39 or 40, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R1 is heterocycloalkyl optionally substituted with one or more R1a; wherein the heterocycloalkyl is piperidinyl or piperazinyl. 42. The compound of any one of claims 1-34 or 39-41, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R1 is piperidinyl optionally substituted with one or more R1a. 43. The compound of any one of claims 1-34 or 39-41, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R1 is piperazinyl optionally substituted with one or more R1a. 44. The compound of any one of claims 1-34 or 39-43, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R1a is independently deuterium, halogen, -CN, -OR11, -S(=O)2R10, -NR12R13, -NHS(=O)2R10, -S(=O)2NR12R13, -C(=O)R10, -C(=O)OR11, -C(=O)NR12R13, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R1b; or two R1a on the same carbon are taken together to form an oxo. 45. The compound of any one of claims 1-34 or 39-44, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R1a is independently halogen, -CN, -OR11, -S(=O)2R10, -NR12R13, -NHS(=O)2R10, - S(=O)2NR12R13, -C(=O)R10, C1-C6alkyl, C1-C6haloalkyl, or heteroaryl; wherein each alkyl and heteroaryl is independently optionally substituted with one or more R1b; or two R1a on the same carbon are taken together to form an oxo. 46. The compound of any one of claims 1-34 or 39-45, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R1a is independently -C(=O)R10. 47. The compound of any one of claims 1-34 or 39-46, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R10 is independently C1-C6alkyl, C2-C6alkenyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R10a. 48. The compound of any one of claims 1-34 or 39-47, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R10 is independently C1-C6alkyl, C2-C6alkenyl, C1-C6aminoalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, aryl, and heteroaryl is independently optionally substituted with one or more R10a. 49. The compound of any one of claims 1-33 or 38-47, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R10 is independently aryl optionally substituted with one or more R10a. 50. The compound of any one of claims 1-33 or 38-48, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R10a is independently deuterium, halogen, -CN, -ORb, -NRcRd, -C(=O)Ra, -C(=O)ORb, - C(=O)NRcRd, C1-C6alkyl, or C1-C6haloalkyl. 51. The compound of any one of claims 1-34 or 39-50, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R10a is independently halogen, -ORb, -C(=O)ORb, or C1-C6alkyl. 52. A compound of Formula (II) or (III), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof: Ring C is cycloalkyl or heterocycloalkyl; each RC is independently deuterium, halogen, -CN, -OR11, -SR11, -S(=O)R10, -S(=O)2R10, -NO2, - NR12R13, -NHS(=O)2R10, -S(=O)2NR12R13, -C(=O)R10, -OC(=O)R10, -C(=O)OR11, -OC(=O)OR11, - C(=O)NR12R13, -OC(=O)NR12R13, -NR11C(=O)NR12R13, -NR11C(=O)R10, -NR11C(=O)OR11, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more RCa; or two RC on the same carbon are taken together to form an oxo; m is 1-3, each R2 is independently hydrogen, deuterium, halogen, -CN, -ORb, -SRb, -S(=O)Ra, -S(=O)2Ra, -NO2, - NRcRd, -NHS(=O)2Ra, -S(=O)2NRcRd, -C(=O)Ra, -OC(=O)Ra, -C(=O)ORb, -OC(=O)ORb, - C(=O)NRcRd, -OC(=O)NRcRd, -NRbC(=O)NRcRd, -NRbC(=O)Ra, -NRbC(=O)ORb, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2- C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R2a; n is 1-3; RY1 is hydrogen, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -C(=O)Ra, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more RY1a; R3 is hydrogen, deuterium, halogen, -CN, -ORb, -NO2, -NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R3a; R4 is hydrogen, deuterium, halogen, -CN, -ORb, -NO2, -NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R4a; R5 is hydrogen, deuterium, halogen, -CN, -ORb, -NO2, -NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R5a; R6 is -C(=O)Ra, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R6a; or R4 and R6 are taken together to form a heterocycloalkyl optionally substituted with deuterium, halogen, -CN, -ORb, -NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; or R4 and R5 are taken together to form a heterocycloalkyl optionally substituted with deuterium, halogen, -CN, -ORb, -NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; each R10 is independently C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R10a; each R11 is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R11a; each R12 and R13 is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R12a; or R12 and R13 are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R13a; each RY1a, R2a, R3a, R4a, R5a, R6a, R10a, R11a, R12a, R13a, and RCa is independently deuterium, halogen, -CN, -ORb, -SRb, -S(=O)Ra, -S(=O)2Ra, -NO2, -NRcRd, -NHS(=O)2Ra, -S(=O)2NRcRd, -C(=O)Ra, - OC(=O)Ra, -C(=O)ORb, -OC(=O)ORb, -C(=O)NRcRd, -OC(=O)NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; or two RY1a, two R2a, two R3a, two R4a, two R5a, two R6a, two R10a, two R11a, two R12a, two R13a, and two RCa on the same carbon are taken together to form an oxo, a cycloalkyl, or heterocycloalkyl; each Ra is independently C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, - NH2, -C(=O)Me, -C(=O)OH, -C(=O)OMe, C1-C6alkyl, or C1-C6haloalkyl; each Rb is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, - NH2, -C(=O)Me, -C(=O)OH, -C(=O)OMe, C1-C6alkyl, or C1-C6haloalkyl; and each Rc and Rd is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, -NH2, -C(=O)Me, -C(=O)OH, -C(=O)OMe, C1-C6alkyl, or C1-C6haloalkyl; or Rc and Rd are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, -NH2, -C(=O)Me, -C(=O)OH, -C(=O)OMe, C1-C6alkyl, or C1-C6haloalkyl. 53. The compound of claim 52, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein the compound of Formula (II) is of Formula (IIa): Formula (IIa). 54. The compound of claim 52, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein the compound of Formula (II) is of Formula (IIb): Formula (IIb). 55. The compound of claim 52, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein the compound of Formula (II) is of Formula (IIc): Formula (IIc). 56. The compound of claim 51, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein the compound of Formula (II) is of Formula (IId): Formula (IId). 57. The compound of claim 51, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein the compound of Formula (III) is of Formula (IIIa): Formula (IIIa). 58. The compound of claim 51, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein the compound of Formula (III) is of Formula (IIIb): Formula (IIIb). 59. The compound of claim 51, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein the compound of Formula (III) is of Formula (IIIc): Formula (IIIc). 60. The compound of claim 51, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein the compound of Formula (III) is of Formula (IIId): Formula (IIId). 61. The compound of any one of claims 52-60, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: RY1 is hydrogen, C1-C6alkyl, or heterocycloalkyl. 62. The compound of any one of claims 52-61, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: RY1 is hydrogen. 63. The compound of any one of claims 52-62, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: RY1 is heterocycloalkyl. 64. The compound of any one of claims 52-63, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R3 is hydrogen, deuterium, halogen, -CN, -ORb, -NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, or C1-C6deuteroalkyl. 65. The compound of any one of claims 52-64, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R3 is hydrogen or halogen. 66. The compound of any one of claims 52-65, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R3 is hydrogen. 67. The compound of any one of claims 52-66, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R4 is hydrogen, deuterium, halogen, -CN, -ORb, -NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, or C1-C6deuteroalkyl. 68. The compound of any one of claims 52-67, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R4 is hydrogen or halogen. 69. The compound of any one of claims 52-68, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R4 is hydrogen. 70. The compound of any one of claims 52-69, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R5 is hydrogen, deuterium, halogen, -CN, -ORb, -NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, or C1-C6deuteroalkyl. 71. The compound of any one of claims 52-70, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R5 is hydrogen or halogen. 72. The compound of any one of claims 52-71, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R5 is hydrogen. 73. The compound of any one of claims 52-72, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R6 is C1-C6alkyl. 74. The compound of any one of claims 52-73, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R6 is methyl. 75. The compound of any one of claims 52-74, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R2 is independently hydrogen, deuterium, halogen, -CN, -ORb, -NRcRd, -C(=O)Ra, - C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, or C1-C6deuteroalkyl. 76. The compound of any one of claims 52-75, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R2 is independently hydrogen, deuterium, halogen, -CN, -ORb, -NRcRd, C1-C6alkyl, C1-C6haloalkyl, or C1-C6deuteroalkyl. 77. The compound of any one of claims 52-76, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R2 is independently hydrogen, halogen, C1-C6alkyl, or C1-C6haloalkyl. 78. The compound of any one of claims 52-77, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R2 is independently hydrogen or halogen. 79. The compound of any one of claims 52-78, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R2 is hydrogen. 80. The compound of any one of claims 52-79, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: n is 1 or 2. 81. The compound of any one of claims 52-79, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: n is 1. 82. The compound of any one of claims 52-81, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: Ring C is heterocycloalkyl. 83. The compound of any one of claims 52-81, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: Ring C is cycloalkyl. 84. The compound of any one of claims 52-83, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each RC is independently deuterium, halogen, -CN, -OR11, -S(=O)2R10, -NR12R13, -NHS(=O)2R10, -S(=O)2NR12R13, -C(=O)R10, -C(=O)OR11, -C(=O)NR12R13, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more RCa; or two RC on the same carbon are taken together to form an oxo. 85. The compound of any one of claims 52-83, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each RC is independently halogen, -CN, -OR11, -S(=O)2R10, -NR12R13, -NHS(=O)2R10, - S(=O)2NR12R13, -C(=O)R10, C1-C6alkyl, C1-C6haloalkyl, or heteroaryl; wherein each alkyl and heteroaryl is independently optionally substituted with one or more RCa; or two RC on the same carbon are taken together to form an oxo. 86. The compound of any one of claims 52-85, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each RC is independently -C(=O)R10. 87. The compound of any one of claims 52-86, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R10 is independently C1-C6alkyl, C2-C6alkenyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R10a. 88. The compound of any one of claims 52-87, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R10 is independently C1-C6alkyl, C2-C6alkenyl, C1-C6aminoalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, aryl, and heteroaryl is independently optionally substituted with one or more R10a. 89. The compound of any one of claims 52-88, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R10 is independently aryl optionally substituted with one or more R10a. 90. The compound of any one of claims 52-89, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R10a is independently deuterium, halogen, -CN, -ORb, -NRcRd, -C(=O)Ra, -C(=O)ORb, - C(=O)NRcRd, C1-C6alkyl, or C1-C6haloalkyl. 91. The compound of any one of claims 52-90, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R10a is independently halogen, -ORb, -C(=O)ORb, or C1-C6alkyl. 92. A compound of Formula (IV) and (V), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof: Formula (IV) Formula (V) wherein: Ring each R2 is independently hydrogen, deuterium, halogen, -CN, -ORb, -SRb, -S(=O)Ra, -S(=O)2Ra, -NO2, - NRcRd, -NHS(=O)2Ra, -S(=O)2NRcRd, -C(=O)Ra, -OC(=O)Ra, -C(=O)ORb, -OC(=O)ORb, - C(=O)NRcRd, -OC(=O)NRcRd, -NRbC(=O)NRcRd, -NRbC(=O)Ra, -NRbC(=O)ORb, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2- C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R2a; n is 1-3; RY1 is hydrogen, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -C(=O)Ra, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more RY1a; R3 is hydrogen, deuterium, halogen, -CN, -ORb, -NO2, -NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R3a; R4 is hydrogen, deuterium, halogen, -CN, -ORb, -NO2, -NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R4a; R5 is hydrogen, deuterium, halogen, -CN, -ORb, -NO2, -NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R5a; R6 is -C(=O)Ra, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R6a; or R4 and R6 are taken together to form a heterocycloalkyl optionally substituted with deuterium, halogen, -CN, -ORb, -NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; or R4 and R5 are taken together to form a heterocycloalkyl optionally substituted with deuterium, halogen, -CN, -ORb, -NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; each RY1a, R2a, R3a, R4a, R5a, R6a, R10a, R11a, R12a, R13a, and RCa is independently deuterium, halogen, -CN, -ORb, -SRb, -S(=O)Ra, -S(=O)2Ra, -NO2, -NRcRd, -NHS(=O)2Ra, -S(=O)2NRcRd, -C(=O)Ra, - OC(=O)Ra, -C(=O)ORb, -OC(=O)ORb, -C(=O)NRcRd, -OC(=O)NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; or two RY1a, two R2a, two R3a, two R4a, two R5a, and two R6a on the same carbon are taken together to form an oxo; each Ra is independently C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, - NH2, -C(=O)Me, -C(=O)OH, -C(=O)OMe, C1-C6alkyl, or C1-C6haloalkyl; each Rb is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, - NH2, -C(=O)Me, -C(=O)OH, -C(=O)OMe, C1-C6alkyl, or C1-C6haloalkyl; and each Rc and Rd is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, -NH2, -C(=O)Me, -C(=O)OH, -C(=O)OMe, C1-C6alkyl, or C1-C6haloalkyl; or Rc and Rd are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OMe, -NH2, -C(=O)Me, -C(=O)OH, -C(=O)OMe, C1-C6alkyl, or C1-C6haloalkyl. 93. The compound of claim 92, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein the compound of Formula (IV) is of Formula (IVa): Formula (IVa). 94. The compound of claim 92, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein the compound of Formula (IV) is of Formula (IVb): Formula (IVb). 95. The compound of claim 92, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein the compound of Formula (IV) is of Formula (IVc): Formula (IVc). 96. The compound of claim 92, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein the compound of Formula (IV) is of Formula (IVd): Formula (IVd). 97. The compound of claim 92, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein the compound of Formula (V) is of Formula (Va): Formula (Va). 98. The compound of claim 92, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein the compound of Formula (V) is of Formula (Vb): Formula (Vb). 99. The compound of claim 92, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein the compound of Formula (V) is of Formula (Vc): Formula (Vc). 100. The compound of claim 92, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein the compound of Formula (V) is of Formula (Vd): Formula (Vd). 101. The compound of any one of claims 92-100, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: RY1 is hydrogen, C1-C6alkyl, or heterocycloalkyl. 102. The compound of any one of claims 92-101, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: RY1 is hydrogen. 103. The compound of any one of claims 92-102, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: RY1 is heterocycloalkyl. 104. The compound of any one of claims 92-103, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R3 is hydrogen, deuterium, halogen, -CN, -ORb, -NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, or C1-C6deuteroalkyl. 105. The compound of any one of claims 92-104, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R3 is hydrogen or halogen. 106. The compound of any one of claims 92-105, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R3 is hydrogen. 107. The compound of any one of claims 92-106, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R4 is hydrogen, deuterium, halogen, -CN, -ORb, -NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, or C1-C6deuteroalkyl. 108. The compound of any one of claims 92-107, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R4 is hydrogen or halogen. 109. The compound of any one of claims 92-108, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R4 is hydrogen. 110. The compound of any one of claims 92-109, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R5 is hydrogen, deuterium, halogen, -CN, -ORb, -NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, or C1-C6deuteroalkyl. 111. The compound of any one of claims 92-110, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R5 is hydrogen or halogen. 112. The compound of any one of claims 92-111, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R5 is hydrogen. 113. The compound of any one of claims 92-112, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R6 is C1-C6alkyl. 114. The compound of any one of claims 92-113, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: R6 is methyl. 115. The compound of any one of claims 92-114, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R2 is independently hydrogen, deuterium, halogen, -CN, -ORb, -NRcRd, -C(=O)Ra, - C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, or C1-C6deuteroalkyl. 116. The compound of any one of claims 92-115, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R2 is independently hydrogen, deuterium, halogen, -CN, -ORb, -NRcRd, C1-C6alkyl, C1-C6haloalkyl, or C1-C6deuteroalkyl. 117. The compound of any one of claims 92-116, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R2 is independently hydrogen, halogen, C1-C6alkyl, or C1-C6haloalkyl. 118. The compound of any one of claims 92-117, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R2 is independently hydrogen or halogen. 119. The compound of any one of claims 92-118, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: each R2 is hydrogen. 120. The compound of any one of claims 92-119, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: n is 1 or 2. 121. The compound of any one of claims 92-120, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: n is 1. 122. The compound of any one of claims 1-121, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: RY1 is cycloalkyl or heterocycloalkyl; wherein the cycloalkyl and heterocycloalkyl is optionally substituted with one or more RY1a. 123. The compound of any one of claims 1-122, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: RY1 is cycloalkyl optionally substituted with one or more RY1a. 124. The compound of any one of claims 1-122, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: RY1 is a bicyclic cycloalkyl optionally substituted with one or more RY1a. 125. The compound of any one of claims 1-122, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: RY1 is heterocycloalkyl optionally substituted with one or more RY1a. 126. The compound of any one of claims 1-122, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: . 127. The compound of any one of claims 1-122, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein: . 128. A compound selected from the group consisting of a compound found in table 1, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof. 129. A pharmaceutical composition comprising the compound of any one of claims 1-128, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and a pharmaceutically acceptable excipient. 130. A method of treating cancer in a subject in need thereof, the method comprising administering the compound of any one of claims 1-128, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof. 131. The method of claim 130, wherein the cancer is characterized by a deficiency in one or more DNA repair pathways. 132. The method of claim 130, wherein the DNA repair deficiency is a deficiency in the base excision repair (“BER”) pathway, the Fanconi anaemia-mediated repair (“FA”) pathway, the homologous recombination (“HR”) pathway, the nucleotide excision repair (“NER”) pathway, the non- homologous end joining (“NHEJ”) pathway, the mismatch repair (“MMR”) pathway, the RecQ- mediated repair (“RecQ”) pathway, or the double-stranded breaks (“DSB”) pathway. 133. The method of claim 131 or claim 132, wherein the DNA repair deficiency is a deficiency in the homologous recombination (“HR”) pathway. 134. The method of any one of claims 131-133, wherein the DNA repair deficiency is a BRCA1 mutation. 135. The method of any one of claims 131-134, further comprising administering a DNA repair inhibitor. 136. The method of claim 135, wherein the DNA repair inhibitor is a poly ADP ribose polymerase (“PARP”) inhibitor. 137. The method of any one of claims 131-134, further comprising administering an alkylating agent. 138. The method of claim 137, wherein the alkylating agent is cyclophosphamide, chlormethine, uramustine, melphalan, chlorambucil, ifosfamide, bendamustine, carmustine, lomustine, nimustine, fotemustine, streptozocin, or busulfan. 139. The method of any one of claims 131-134, further comprising administering a DNA damaging agent. 140. The method of claim 139, wherein the DNA damaging agent is camptothecin, etoposide, oxaliplatin, cisplatin, or doxorubicin. 141. The method of any one of claims 131-134, wherein the compound is administered in conjunction with high-dose radiotherapy. 142. The method of claim 141, wherein the high-dose radiotherapy is administered as a single dose and/or hypofractionated. 143. The method of any one of claims 131-140, wherein the compound is administered in conjunction with Stereotactic Body Radiation Therapy (SBRT). |
Step 1: Methyl 3-fluoro-4-nitrobenzoate [00256] To a stirred solution of 3-fluoro-4-nitrobenzoic acid (10.0 g, 54.0 mmol) in methanol (100mL) was added hydrogen chloride (6.00 mL) in 0 °C. The mixture was heated at 80 °C for 16 hours. The mixture was monitored by TLC (40 % Ethyl acetate in Hexane) and LCMS. After completing the starting material, the mixture was concentrated under reduced pressure. The reaction mixture was basified with saturated sodium bicarbonate up to pH~8 and extracted with ethyl acetate, washed with brine, dried over sodium sulfate and concentrated to afford methyl 3-fluoro-4-nitrobenzoate (9.50 g, 88% Yield) as an off white solid. LCMS (ESI)m/z 200 [M+H]+ Step 2: methyl 3-[(3-methyloxetan-3-yl) amino]-4-nitrobenzoate [00257] To a stirred solution of methyl 3-fluoro-4-nitrobenzoate (2.30 g, 11.5 mmol) in 1- methylpyrrolidin-2-one (20.0 mL) was added ethylbis(propan-2-yl) amine (6.04 mL, 3 eq., 34.6 mmol) and 3-methyloxetan-3-amine (1.01 g, 1 eq., 11.5 mmol) at room temperature. The reaction mixture was heated at 120°C for 16 hours. The reaction mixture was quenched with water and extracted in ethyl acetate, washed with brine, dried over sodium sulfate and concentrated. The crude product was purified by flash chromatography to afford methyl 3-[(3-methyloxetan-3-yl) amino]-4-nitrobenzoate (1.30 g, 42.27% Yield) as a yellow solid. LCMS (ESI)m/z 267.1 [M+H]+ Step 3: Methyl 4-amino-3-[(3-methyloxetan-3-yl) amino] benzoate [00258] To a stirred solution of methyl 3-[(3-methyloxetan-3-yl) amino]-4-nitrobenzoate (1.30 g, 4.88 mmol) in methanol (20.0 mL) was added ammonium chloride (1.31 g, 5 eq., 24.4 mmol) followed by zinc (3.19 g, 10 eq., 48.8 mmol) at 0°C. The reaction mixture stirred at room temperature for 16 hours. The progress of the reaction mixture was monitored by TLC. After completion of the starting material, the reaction mixture was dissolved in water and extracted with ethyl acetate, washed with brine, dried over sodium sulfate and concentrated to afford methyl 4-amino-3-[(3-methyloxetan-3-yl) amino] benzoate (1.00 g, Crude) as a yellow color. The crude was taken in next step without purification. LCMS (ESI)m/z 237.1 [M+H]+ Step 4: Methyl 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methylo xetan-3-yl)-1H-1,3- benzodiazole-6-carboxylate [00259] A mixture of solution of 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (100 mg, 0.273 mmol), methyl 4-amino-3-[(3-methyloxetan-3-yl) amino] benzoate (77.4 mg, 1.2 eq., 0.328 mmol) and sodium metabisulphite (77.8 mg, 1.5 eq., 0.409 mmol) in DMSO (5.00 mL) was heated at 80 °C for 3 hours. The reaction mixture was diluted with water, extracted with ethyl acetate, washed with brine, dried over anhydrous sodium sulphate and concentrated. The crude was purified by flash column chromatography with 45-50 % ethyl acetate in hexane to afford methyl 2-[3,4-bis(benzyloxy)-2-fluoro-5- methoxyphenyl]-1-(3-methyloxetan-3-yl)-1H-1,3-benzodiazole-6 -carboxylate (135 mg, 80% Yield) as yellow semi solid. LCMS (ESI)m/z 583.2[M+1]+ Step 5: 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methylo xetan-3-yl)-1H-1,3- benzodiazole-6-carboxylic acid [00260] To a stirred solution of methyl 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazole-6-carboxylate (180 mg, 0.309 mmol) in THF (10.0 mL) and methanol (10.0 mL) was added lithium hydrate hydroxide (38.9 mg, 3 eq., 0.927 mmol) in water (10.0 mL) at room temperature. The reaction mixture was heated at 60 °C for 3 hours. The reaction mixture was concentrated and then diluted with water and acidified with saturated citric acid solution, then extracted with ethyl acetate, dried over anhydrous sodium sulphate, and concentrated to afford 2-[3,4- bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methyloxetan-3 -yl)-1H-1,3-benzodiazole-6-carboxylic acid (150 mg, 82.83% Yield) as a pale brown solid. LCMS (ESI)m/z 569[M+1]+ Step 1: 4-[6-(azetidine-1-carbonyl)-1-(3-methyloxetan-3-yl)-1H-1,3-b enzodiazol-2-yl]-3-fluoro-6- methoxybenzene-1,2-diol [00261] A suspension of 6-(azetidine-1-carbonyl)-2-[3,4-bis(benzyloxy)-2-fluoro-5-me thoxyphenyl]-1- (3-methyloxetan-3-yl)-1H-1,3-benzodiazole (40.0 mg, 0.065 mmol) and 10% palladium hydroxide on carbon (100 mg, 0.702 mmol) in THF (20.0 mL) was stirred under hydrogen pressure (1atm) for 2.5 hours at room temperature. The reaction mixture was filtered through celite, and the filtrate was concentrated. The crude was purified by preparative HPLC to afford 4-[6-(azetidine-1-carbonyl)-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazol-2-yl]-3-fluoro-6-metho xybenzene-1,2-diol (0.005g, 18% Yield) as white solid. 1 H NMR (400 MHz, DMSO-d 6 ): δ ppm 2.02 (s, 3H), 2.24 (m, 2H), 3.77 (s, 3H), 4.05 (t, J = 7.6 Hz, 2H), 4.31 (t, J = 7.2 Hz, 2H), 4.41-4.40 (d, J = 5.6 Hz, 2H), 4.73-4.71 (d, J = 5.6 Hz, 2H), 6.59- 6.57 (d, J = 6 Hz, 1H), 7.37 (s, 1H), 7.50-7.52 (d, J = 8 Hz, 1H), 7.71-7.73 (d, J = 8.8 Hz, 1H), 9.5 (bs, 2H). LCMS (ESI)m/z 428.2 [M+H] + Example 178: Synthesis of 6-methoxy-4-[1-(2-methoxyethyl)-1H-1,3-benzodiazol-2-yl]-3- methylbenzene-1,2-diol; acetic acid
Step 1: N-(5-methanesulfonyl-2-nitrophenyl)-3-methyloxetan-3-amine [00262] To a stirred solution of 2-fluoro-4-methanesulfonyl-1-nitrobenzene (500 mg, 2.28 mmol) in DMSO (5 mL) was added ethyl bis(propan-2-yl) amine (1.20 mL, 3 eq., 6.84 mmol) and 3-methyloxetan- 3-amine (401 µL, 2 eq., 4.56 mmol) at room temperature. The reaction mixture was heated at 90°C for 1 hour. The reaction mixture was quenched with water and extracted in ethyl acetate, washed with brine, dried over sodium sulfate and concentrated to afford N-(5-methanesulfonyl-2-nitrophenyl)-3- methyloxetan-3-amine (420 mg, 64.31% Yield) as yellow solid. The crude product was taken as a next step without purification. LCMS (ESI)m/z 287.2[M+1]+ Step 2: 5-methanesulfonyl-N1-(3-methyloxetan-3-yl) benzene-1,2-diamine [00263] A mixture of N-(5-methanesulfonyl-2-nitrophenyl)-3-methyloxetan-3-amine (300 mg, 1.05 mmol) palladium (10%w/w, 112 mg, 0.105 mmol) in methanol (5.00 mL) and ethyl acetate (5.00 mL) was stirred under hydrogen pressure (1 atm) at room temperature for 8 hours. The progress of the reaction mixture was monitored by TLC. After completion of the starting material, reaction mixture was filtered and the filtrate was concentrated to afford 5-methanesulfonyl-N1-(3-methyloxetan-3-yl) benzene- 1,2-diamine (270 mg, Crude) as a yellow liquid. LCMS (ESI)m/z 256.9[M+1]+ Step 3: 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-6-methanesul fonyl-1-(3-methyloxetan-3- yl)-1H-1,3-benzodiazole [00264] A mixture of 5-methanesulfonyl-N1-(3-methyloxetan-3-yl) benzene-1,2-diamine (115 mg, 1.1 eq., 450 µmol), 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (150 mg, 409 µmol) and sodium metabisulphite(117 mg, 1.5 eq., 614 µmol) in DMSO (10 mL) was stirred at 80°C for 5 hours. The reaction was monitored by TLC. After completion of the starting material, diluted with water and extracted in ethyl acetate, dried over sodium sulfate and concentrated. The crude was purified by flash chromatography to afford 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-6-methanesul fonyl-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazole (70.0 mg, 28.37% Yield)as a black liquid. LCMS (ESI)m/z 603.3 [M+H]+ Step 4: 3-fluoro-4-[6-methanesulfonyl-1-(3-methyloxetan-3-yl)-1H-1,3 -benzodiazol-2-yl]-6- methoxybenzene-1,2-diol [00265] A suspension of 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-6-methanesul fonyl-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazole (70.0 mg, 116 µmol) and palladium(2+) hydroxide 20%w/w (711 µg, 0.01 eq., 1.16 µmol) in THF (10 mL) was stirred under hydrogen pressure (1atm) for 8 hours. The progress of the reaction mixture monitored by TLC and LCMS. The reaction mixture was filtered, and the filtrate was concentrated. The crude compound was purified by preparative HPLC to afford 3- fluoro-4-[6-methanesulfonyl-1-(3-methyloxetan-3-yl)-1H-1,3-b enzodiazol-2-yl]-6-methoxybenzene-1,2- diol (22.0 mg, 44.84% Yield) as a white solid. 1 H NMR (400 MHz, DMSO-d6): δ ppm 2.08(s, 3H), 3.30(s, 3H), 3.80(s, 3H), 4.43(d, J = 6.4 Hz, 2H), 4.79 (d, J = 6 Hz, 2H), 6.65(d, J = 6 Hz, 1H), 7.73(s, 1H), 7.85-7.82(m, 1H), 7.48(d, J = 8.4 Hz, 1H), 9.52(bs, 2H). LCMS (ESI)m/z 423.1 [M+H]+ Melting point: 257.6°C. Example 179: Synthesis of 6-methoxy-4-[1-(2-methoxyethyl)-1H-1,3-benzodiazol-2-yl]-3- methylbenzene-1,2-diol; acetic acid Step 1: Methyl 3-[(3-methyloxetan-3-yl)amino]-4-nitrobenzoate [00266] To a stirred solution of 3-fluoro-4-nitrobenzonitrile (500 mg, 3.01 mmol) in 1-methylpyrrolidin- 2-one (2.00 mL) was added ethylbis(propan-2-yl) amine (1.57 mL, 3 eq., 9.03 mmol) and 3- methyloxetan-3-amine (265 µL, 3.01 mmol) at room temperature. The reaction mixture was heated at 120°C for 16 hours. The reaction mixture was quenched with water and extracted in ethyl acetate, dried over sodium sulfate and concentrated. The crude product was purified by flash chromatography to afford 3-[(3-methyloxetan-3-yl) amino]-4-nitrobenzonitrile (290 mg, 41%Yield) as a yellow solid. 1 H NMR (400 MHz, DMSO-d6): δ ppm 1.65 (s, 1 H), 4.58 – 4.57 (d, J = 6 Hz, 2 H), 4.66 – 4.64 (d, J = 6.4 Hz, 2 H), 6.76 (s, 1 H), 7.08 – 7.06 (d, J = 9.6 Hz, 1 H), 8.21 - 8.19 (d, J = 8.8 Hz, 1 H), 8.4 (s, 1 H), Step 2: 4-amino-3-[(3-methyloxetan-3-yl)amino]benzonitrile [00267] To a stirred solution of 3-[(3-methyloxetan-3-yl)amino]-4-nitrobenzonitrile (200 mg, 858 µmol) in methanol (10 mL) was added ammonium chloride (229 mg, 5 eq., 4.29 mmol) followed by zinc (392 mg, 7 eq., 6.00 mmol) at 0°C and stirred at room temperature for 16 hours. The progress of the reaction mixture was monitored by TLC. After completion of the starting material, the reaction mixture was dissolved in water and extracted in ethyl acetate, washed with brine, dried over sodium sulfate and concentrated to afford 4-amino-3-[(3-methyloxetan-3-yl)amino] benzonitrile (170 mg, Crude) as a purple solid.. The crude was taken in next step without purification. LCMS (ESI)m/z 204.1 [M+H]+ Step 3: 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methylo xetan-3-yl)-1H-1,3- benzodiazole-6-carbonitrile [00268] A mixture of 4-amino-3-[(3-methyloxetan-3-yl)amino]benzonitrile (110 mg, 1.2 eq., 541 µmol), 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (160 mg, 437 µmol) and sodium metabisulphite (125 mg, 1.5 eq., 655 µmol) in DMSO (5 mL) was stirred 80°C for 2hours.The progress of the reaction mixture was monitored by TLC. After completion of the starting material, the reaction mixture was dissolved in water and extracted in ethyl acetate, washed with brine, dried over sodium sulfate and concentrated. The crude was purified by flash chromatography to afford 2-[3,4-bis(benzyloxy)-2-fluoro- 5-methoxyphenyl]-1-(3-methyloxetan-3-yl)-1H-1,3-benzodiazole -6-carbonitrile (80.0 mg, crude) as a white solid. LCMS (ESI)m/z 549.9[M+H]+ Step 4: 2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(3-methyloxetan -3-yl)-1H-1,3-benzodiazole- 6-carbonitrile [00269] To a stirred solution of 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methylo xetan-3- yl)-1H-1,3-benzodiazole-6-carbonitrile (60.0 mg, 109 µmol) in TFA was stirred at 80°C for 2 hours. The progress of the reaction mixture monitored by TLC and LCMS. After completion of the starting material, the mixture was concentrated. The crude was purified by following preparative HPLC to afford 2-(2- fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(3-methyloxetan-3-yl )-1H-1,3-benzodiazole-6-carbonitrile (15.0 mg, 37.2% Yield) as a white solid. 1 H NMR (400 MHz, DMSO-d 6 ): δ ppm 2.04(s, 3H), 3.74(s, 3H), 4.42(d, J = 6 Hz, 2H), 4.51(d, J = 6 Hz, 2H), 6.61(d, J = 6 Hz, 1H), 7.67-7.64(m, `1H), 7.85(d, J = 8.4 Hz, 1H), 9.34 (s, 1H), 9.51(sb, 2H). LCMS (ESI)m/z 370.1[M+H]+ Melting point : 209 °C Example 180: Synthesis of 6-methoxy-4-[1-(2-methoxyethyl)-1H-1,3-benzodiazol-2-yl]-3- methylbenzene-1,2-diol Step 1: 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methylo xetan-3-yl)-1H-1,3- benzodiazole-6-carboxamide [00270] To a stirred solution of 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methylo xetan-3- yl)-1H-1,3-benzodiazole-6-carbonitrile (150 mg, 273 µmol) in DMSO (5.00 mL) was added hydrogen peroxide (8.19 µL, 1.5 eq., 409 µmol) followed by dipotassium carbonate at 0 °C. Then the mixture was stirred at room temperature for 16 hours. The progress of the reaction mixture was monitored by TLC. After completion of the starting material, the reaction mixture was poured into chilled water; the precipitated solids were filtered and dried to afford 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1- (3-methyloxetan-3-yl)-1H-1,3-benzodiazole-6-carboxamide (120 mg, 77.465 Yield) as a white solid. LCMS (ESI)m/z 568.6[M+H] +. Step 2: 2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(3-methyloxetan -3-yl)-1H-1,3-benzodiazole- 6-carboxamide [00271] A suspension of 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methylo xetan-3-yl)-1H- 1,3-benzodiazole-6-carboxamide (120 mg, 211 µmol) and palladium hydroxide (80.0 mg, 755 µmol) in THF (20.0 mL) was stirred under hydrogen pressure (1 atm) for 2.5 hours. Reaction mixture was filtered through celite. and the filtrate was concentrated. The crude was purified by preparative HPLC to afford 2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(3-methyloxetan -3-yl)-1H-1,3-benzodiazole-6- carboxamide (35.0 mg, 43%Yield) as an off white solid. 1 H NMR (400 MHz, CD3OD-d 6 ): δ ppm 2.04 (s, 3H), 3.77 (s, 3H), 4.40 (s, 2H), 4.71 (s, 2H), 6.60 (d, J = 8 Hz, 1H), 7.37 (s, 1H), 7.70 (d, J = 8 Hz,2 H), 7.83 (d, J = 8 Hz, 1H), 8.07 (s, 1H), 9.43 (s, 1H), 9.50(s, 1H). LCMS (ESI)m/z 387.4[M+H]+ Melting Point: 170.4°C Example 181: Synthesis of 6-methoxy-4-[1-(2-methoxyethyl)-1H-1,3-benzodiazol-2-yl]-3- methylbenzene-1,2-diol; acetic acid Step 1: 3-[(3-methyloxetan-3-yl)amino]-4-nitrobenzamide. [00272] To a suspension of 3-[(3-methyloxetan-3-yl)amino]-4-nitrobenzonitrile (550 mg, 2.36 mmol) in DMSO (2.00 mL) was added dipotassium carbonate (978 mg, 3 eq., 7.07 mmol) and hydrogen peroxides (70.7 µL, 1.5 eq., 3.54 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 hours . Reaction progress was monitored by LC-MS and TLC. After completion of starting material, reaction mass was quenched with water and extracted with ethyl acetate (2 X 100 ml). Combined organic layer was dried over sodium sulfate and concentrated. The crude compound was purified by flash chromatography to afford 3-[(3-methyloxetan-3-yl)amino]-4-nitrobenzamide (450 mg, 76% Yield) as a yellow solid. LCMS (ESI)m/z 252.2 [M+H]+ Step 2: 3-methyl-N-[2-nitro-5-(1,2,4-oxadiazol-5-yl) phenyl]oxetan-3-amine [00273] A mixture of 3-[(3-methyloxetan-3-yl) amino]-4-nitrobenzamide (450 mg, 1.79 mmol) and dimethylformamide dimethylacetal (5.00 mL) was stirred at 110° C for 1 hour. The reaction mixture was concentrated and the obtained residue was dissolved in 1,4-dioxane (5.00 mL). Then acetic acid (102 µL, 1.79 mmol), hydroxyazanium chloride (249 mg, 2 eq., 3.58 mmol) and 2 N NaOH Sol (3.00 mL) were added at room temperature. The mixture was stirred at 90° C for 30 min. The reaction mixture was concentrated, diluted with water, and extracted with dichloromethane, dried over sodium sulfate and concentrated. The crude was purified by flash chromatography to afford 3-methyl-N-[2-nitro-5-(1,2,4- oxadiazol-5-yl) phenyl]oxetan-3-amine (219 mg, 52% Yield) as a pale-yellow solid. LCMS (ESI)m/z 277.3 [M+H]+ Step 3: N1-(3-methyloxetan-3-yl)-5-(1,2,4-oxadiazol-5-yl) benzene-1,2-diamine [00274] To a suspension of 3-methyl-N-[2-nitro-5-(1,2,4-oxadiazol-5-yl) phenyl]oxetan-3-amine (350 mg, 1.27 mmol) in THF (4.00 mL) and water (1.00 mL) was added ammonium chloride (339 mg, 5 eq., 6.33 mmol) followed by zinc (249 mg, 3 eq., 3.80 mmol) at 0 °C and reaction mixture was stirred for 4 hours at room temperature. Reaction progress monitored by TLC and LC-MS. Reaction mass was quenched with water and extracted with ethyl acetate (2 X 25 ml). dried over sodium sulfate and concentrated to afford N1-(3-methyloxetan-3-yl)-5-(1,2,4-oxadiazol-5-yl) benzene-1,2-diamine (350 mg, crude). The crude compound was taken for next step without purification. LCMS (ESI)m/z 247.1 [M+H]+ Step 4: 2-fluoro-3,4-dihydroxy-5-methoxybenzaldehyde [00275] A suspension of 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (100 mg, 273 µmol) and palladium hydroxide (57.9 mg, 2 eq., 546 µmol) in THF (5.00 mL) was stirred under hydrogen pressure (1 atm) for 2 hours. The reaction mixture was filtered, and the filtrate was concentrated to afford 2- fluoro-3,4-dihydroxy-5-methoxybenzaldehyde (45 mg, crude) LCMS (ESI)m/z 187.1 [M+H]+ Step 5: 3-fluoro-6-methoxy-4-[1-(3-methyloxetan-3-yl)-6-(1,2,4-oxadi azol-5-yl)-1H-1,3- benzodiazol-2-yl] benzene-1,2-diol. [00276] A mixture of N1-(3-methyloxetan-3-yl)-5-(1,2,4-oxadiazol-5-yl) benzene-1,2-diamine (40.0 mg, 162 µmol), 2-fluoro-3,4-dihydroxy-5-methoxybenzaldehyde (45.3 mg, 1.5 eq., 244 µmol) and sodium metabisulphite (46.3 mg, 1.5 eq., 244 µmol) in DMSO (5.00 mL) was stirred 80°C for 12 hours. The progress of the reaction mixture was monitored by TLC. After completion of the starting material, the reaction mixture was dissolved in water and extracted in ethyl acetate (2 X20 ml), dried over sodium sulfate and concentrated. The crude was purified by preparative HPLC to afford 3-fluoro-6-methoxy-4- [1-(3-methyloxetan-3-yl)-6-(1,2,4-oxadiazol-5-yl)-1H-1,3-ben zodiazol-2-yl] benzene-1,2-diol (22.0 mg, 32% Yield) as an off white solid. 1 H NMR (400 MHz, DMSO-d6): δ ppm 2.08 (bs, 3H), 3.78 (bs, 3H), 4.37 (d, J = 6 Hz, 2H), 4.78 (d, J = 5.6 Hz, 2H), 6.64 (d, J = 6.4 Hz, 1H), 7.92 (d, J = 8.8 Hz, 2H), 8.04 (d, J = 8.4 Hz, 1H), 9.09 (bs, 1H), 9.51 (bs, 1H). LCMS (ESI)m/z 412.4 [M+H]+. Example 182: Synthesis of 6-methoxy-4-[1-(2-methoxyethyl)-1H-1,3-benzodiazol-2-yl]-3- methylbenzene-1,2-diol Step 1: 3-methyl-N-[2-nitro-5-(pyridin-2-yl)phenyl]oxetan-3-amine. [00277] To a suspension of N-(5-bromo-2-nitrophenyl)-3-methyloxetan-3-amine (500 mg, 1.74 mmol) in 1,4-dioxane (8.00 mL) and water (2.00 mL) was added (pyridin-2-yl) boronic acid (321 mg, 1.5 eq., 2.61 mmol) followed by addition of disodium carbonate (369 mg, 2 eq., 3.48 mmol) was degassed with argon for 10 minutes at room temperature. Then (1,1'-Bis (diphenylphosphino) ferrocene) palladium (II) dichloride (255 mg, 0.2 eq., 348 µmol) was added and stirred for 16 hours at 100°C. The reaction mixture was monitored by TLC (50% ethyl acetate in hexane). After completion of the reaction, the reaction mixture was quenched with water and extracted with ethyl acetate, washed with water & brine dried over sodium sulfate and concentrated. The crude was purified by flash column chromatography with 30-35 % ethyl acetate in hexane to afford 3-methyl-N-[2-nitro-5-(pyridin-2-yl) phenyl]oxetan-3-amine (290.0 mg, 58% Yield) LCMS (ESI)m/z 586 [M+H]+. Step 2: N1-(3-methyloxetan-3-yl)-5-(pyridin-2-yl) benzene-1,2-diamine. [00278] To a stirred solution of 3-methyl-N-[2-nitro-5-(pyridin-2-yl)phenyl]oxetan-3-amine (300 mg, 1.05 mmol) in THF (8.00 L) and water (2.00 L) was added ammonium chloride (56.2 mg, 1 eq., 1.05 mmol) and zinc Dust (68.8 mg, 1.05 mmol).The reaction mixture was stirred at room temperature for 4 hours. The reaction progress was monitored by TLC & LCMS. After completion of the reaction, the reaction mixture was quenched with water and extracted with ethyl acetate, washed with water & brine, dried over sodium sulfate and concentrated to afford N1-(3-methyloxetan-3-yl)-5-(pyridin-2-yl) benzene- 1,2-diamine (250 mg, crude) LCMS (ESI)m/z256.2 [M+H]+ Step 3: 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methylo xetan-3-yl)-6-(pyridin-2-yl)- 1H-1,3-benzodiazole. [00279] To a suspension of N1-(3-methyloxetan-3-yl)-5-(pyridin-2-yl) benzene-1,2-diamine (94.1 mg, 368 µmol),3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (135 mg, 1 eq., 368 µmol), sodium metabisulphite (70.0 mg, 368 µmol) in dimethylsulfoxide (5 mL) and stirred at 80°C for 16 h. The progress of the reaction mixture was monitored by TLC. After completion of the starting material, the reaction mixture was dissolved in water and extracted in ethyl acetate (2 X20 ml), dried over sodium sulfate and concentrated. The crude was purified by flash chromatography to afford 2-[3,4- bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methyloxetan-3 -yl)-6-(pyridin-2-yl)-1H-1,3- benzodiazole (95.0 mg, 42% Yield) as an off white solid. LCMS (ESI)m/z 602.3 [M+H]+ Step 4: 3-fluoro-6-methoxy-4-[1-(3-methyloxetan-3-yl)-6-(pyridin-2-y l)-1H-1,3-benzodiazol-2- yl]benzene-1,2-diol [00280] A suspension of 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methylo xetan-3-yl)-6- (pyridin-2-yl)-1H-1,3-benzodiazole (95.0 mg, 158 µmol) and palladium(2+) hydroxide (38.7 mg, 2 eq., 316 µmol) in THF (20.0 mL) was stirred under hydrogen pressure (1 atm) for 3 hours. The reaction mixture was filtered, and the filtrate was concentrated. The crude compound was purified by preparative HPLC to afford 3-fluoro-6-methoxy-4-[1-(3-methyloxetan-3-yl)-6-(pyridin-2-y l)-1H-1,3-benzodiazol-2- yl]benzene-1,2-diol (3.00 mg, 4% Yield) as a grey solid. 1 H NMR (400 MHz, CD3OD-d 6 ): δ ppm 2.04 (s, 3H), 3.77 (s, 3H), 4.40 (s, 2H), 4.71 (s, 2H), 6.60 (d, J = 8 Hz, 1H), 7.37 (s, 1H), 7.70 (d, J = 8 Hz, 2 H), 7.83 (d, J = 8 Hz, 1H), 8.07 (s, 1H), 9.43 (s, 1H), 9.50 (s, 1H). LCMS (ESI)m/z 421.4 [M+H]+ Example 183: Synthesis of 6-methoxy-4-[1-(2-methoxyethyl)-1H-1,3-benzodiazol-2-yl]-3- methylbenzene-1,2-diol Step 1: 4-(benzyloxy)-2-nitroaniline [00281] To a stirred solution of 4-amino-3-nitrophenol (750 mg, 4.87 mmol) in acetone (15.0 mL) was added dipotassium carbonate (560 µL, 1.2 eq., 5.84 mmol) followed by (bromomethyl)benzene (832 mg, 4.87 mmol) at 0 °C. The mixture was stirred for 16 hours at room temperature. After completion of the reaction, the solvent was removed, and diluted with ethyl acetate, washed with water and brine, dried over sodium sulfate and concentrated. The crude was purified by flash column chromatography with 10 - 15% ethyl acetate in hexane to afford 4-(benzyloxy)-2-nitroaniline (700 mg, 58% Yield). LCMS (ESI)m/z 245 [M+H]+. Step 2: 4-(benzyloxy)benzene-1,2-diamine [00282] To a stirred solution of 4-(benzyloxy)-2-nitroaniline (400 mg, 1.64 mmol) in acetic acid (5.00 mL) was added ammonium chloride (2.00 mL) and zinc (375 mg, 3.5 eq., 5.73 mmol) portion wise at 0 °C. The reaction mixture was stirred for 16 hours. The solvent was evaporated. The residue was diluted with water and 5 M NaOH was added to basify up to pH ~ 10. The insoluble material was removed by filtration through a pad of celite. The filtrate was extracted with DCM. The combined organic layers were washed with water and brine, dried over sodium sulfate and concentrated. The crude was purified by flash column chromatography with at 20 - 25% ethyl acetate in hexane to afford 4-(benzyloxy)benzene- 1,2-diamine (180 mg, 51%Yield) as a red solid. LCMS (ESI)m/z 215 [M+H]+. Step 3: 5-(benzyloxy)-2-[3,4-bis(benzyloxy)-5-methoxy-2-methylphenyl ]-1H-1,3-benzodiazole [00283] A mixture of 3,4-bis(benzyloxy)-5-methoxy-2-methylbenzaldehyde (200 mg, 552 µmol), 4- (benzyloxy)benzene-1,2-diamine (177 mg, 1.5 eq., 828 µmol) and sodium metabisulphite(157 mg, 1.5 eq., 828 µmol) in DMSO (3.00 mL) was stirred at 85 °C for 12 hours. The reaction mixture was diluted with water (15 mL), extracted with ethyl acetate (2 x 20 mL), dried over sodium sulphate and concentrated. The crude was purified by flash column chromatography with 20- 25% ethyl acetate in hexane to afford 5-(benzyloxy)-2-[3,4-bis(benzyloxy)-5-methoxy-2-methylphenyl ]- 1H-1,3-benzodiazole (200 mg, 65% Yield) as a yellow solid. LCMS (ESI)m/z 557 [M+H] +. Step 4: 4-(5-hydroxy-1H-1,3-benzodiazol-2-yl)-6-methoxy-3-methylbenz ene-1,2-diol; acetic acid [00284] A suspension of 5-(benzyloxy)-2-[3,4-bis(benzyloxy)-5-methoxy-2-methylphenyl ]-1H-1,3- benzodiazole (200 mg, 0.359 mmol) in THF (15.0 mL) and palladium hydroxide (100 mg, 702 µmol) was stirred under hydrogen pressure (1 atm) for 3 hours. The reaction mixture was filtered, and the filtrate was concentrated. The crude compound was purified by preparative HPLC to afford 4-(5- hydroxy-1H-1,3-benzodiazol-2-yl)-6-methoxy-3-methylbenzene-1 ,2-diol; acetic acid (52.0 mg, 41.7% Yield) as an off white solid. 1 H NMR (400 MHz, DMSO-d 6 ): δ ppm 1.93 (s, 3H), 2.34 (s, 3H), 3.82 (s, 3 H), 6.67 (m, J = 3.6 Hz , 1H), 6.80-6.82 (d, J = 5.6 Hz , 2H), 7.38- 7.40 (d, J = 8.4 Hz , 1H), 8.90 (s, 1H), 9.10 (bs, 2H), 11.97 (s, 1H). LCMS (ESI)m/z 287.2 [M+H]+. Example 184: Synthesis of 6-methoxy-4-[1-(2-methoxyethyl)-1H-1,3-benzodiazol-2-yl]-3- methylbenzene-1,2-diol
Step 1: 3-methyl-N-[2-nitro-5-(1H-pyrazol-1-yl)phenyl]oxetan-3-amine . [00285] To a suspension of N-(5-bromo-2-nitrophenyl)-3-methyloxetan-3-amine (400 mg, 1.39 mmol), 1H-pyrazole (190 mg, 2 eq., 2.79 mmol) and diiodocopper (44.2 mg, 0.1 eq., 139 µmol) in 1,4-dioxane (4.00 mL) was degassed with nitrogen gas for 10 min. Then 2-aminoacetic acid (10.5 mg, 0.1 eq., 139 µmol), dipotassium carbonate (578 mg, 3 eq., 4.18 mmol) was added and reaction mixture was stirred for 48 hours at 140°C. Reaction mass was quenched with water and extracted with ethyl acetate (2 X 50 ml), dried over sodium sulfate and concentrated. The crude was purified by flash chromatography to afford,3- methyl-N-[2-nitro-5-(1H-pyrazol-1-yl)phenyl]oxetan-3-amine (280 mg, 73% Yield) as yellow solid. LCMS (ESI)m/z 275.1 [M+H]+ Step 2: N1-(3-methyloxetan-3-yl)-5-(1H-pyrazol-1-yl)benzene-1,2-diam ine [00286] To a suspension of 3-methyl-N-[2-nitro-5-(1H-pyrazol-1-yl)phenyl]oxetan-3-amine (230 mg, 839 µmol) in THF (8.00 mL) and water (2.00 mL) was added ammonium chloride (44.9 mg, 839 µmol) followed by zinc dust (54.9 mg, 839 µmol) at 0 °C. The reaction mixture was stirred at room temperature for 4 hours. Reaction progress monitored by TLC and LC-MS. After completion of reaction mass was diluted with ethyl acetate and filtered on celite. The filtrate was extracted with ethyl acetate (2 X 100 ml), dried over sodium sulfate and concentrated to afford N1-(3-methyloxetan-3-yl)-5-(1H-pyrazol-1- yl)benzene-1,2-diamine (90.0 mg, Crude) as a brown solid. LCMS (ESI)m/z 244.9 [M+H]+. Step 3: 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methylo xetan-3-yl)-6-(1H-pyrazol-1- yl)-1H-1,3-benzodiazole. [00287] To a suspension of N1-(3-methyloxetan-3-yl)-5-(1H-pyrazol-1-yl)benzene-1,2-diam ine (90.0 mg, 368 µmol), 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (135 mg, 1 eq., 368 µmol), sodium metabisulphite (70.0 mg, 368 µmol) in dimethylsulfoxide (5 mL) was stirred at 80°C for 16 hours. The reaction mass was quenched with water and extracted with ethyl acetate (2 X 100 ml), dried over sodium sulfate and concentrated. The crude was purified by column chromatography with 50 % ethyl acetate in hexane to afford 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methylo xetan-3-yl)-6-(1H- pyrazol-1-yl)-1H-1,3-benzodiazole (90.0 mg, 41% Yield) as an off white solid. LCMS (ESI)m/z 591.2 [M+H]+. Step 4: 3-fluoro-6-methoxy-4-[1-(3-methyloxetan-3-yl)-6-(1H-pyrazol- 1-yl)-1H-1,3-benzodiazol-2- yl]benzene-1,2-diol [00288] A suspension of 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methylo xetan-3-yl)-6- (1H-pyrazol-1-yl)-1H-1,3-benzodiazole (90.0 mg, 152 µmol) and palladium hydroxide (70.0 mg, 660 µmol) in THF(15.0 mL) was stirred under hydrogen pressure (1 atm) for 3 hours. The reaction mixture was filtered, and the filtrate was concentrated. The crude compound was purified by preparative HPLC to afford 3-fluoro-6-methoxy-4-[1-(3-methyloxetan-3-yl)-6-(1H-pyrazol- 1-yl)-1H-1,3-benzodiazol-2- yl]benzene-1,2-diol (17.0 mg, 27% Yield) as an off white solid. 1 H NMR (400 MHz, DMSO-d6): δ ppm 2.06 (s, 3H), 3.81 (bs, 3H), 4.45 (d, J = 4 Hz, 2H), 4.78 (d, J = 4 Hz, 2H), 7.55 (s,1H), 7.76 (s,1H), 7.80 (s, 2H), 8.60 (s,1H), 9.46-9.41 (m, 2H). LCMS (ESI)m/z 411.2 [M+H]+. Example 185: Synthesis of 6-methoxy-4-[1-(2-methoxyethyl)-1H-1,3-benzodiazol-2-yl]-3- methylbenzene-1,2-diol Step 1: 2-{2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-meth yloxetan-3-yl)-1H-1,3- benzodiazol-6-yl}propan-2-ol [00289] To a stirred solution of methyl 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazole-6-carboxylate (150 mg, 257 µmol) in diethyl ether (3.00 mL) was added CH 3 MgBr (257 µL, 2 eq., 515 µmol) at -78 °C under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was monitored by TLC (50 % of Ethyl acetate in hexane). After completion of the reaction, reaction mixture was quenched with aqueous NH4Cl solution dropwise and then extracted with ethyl acetate, washed with brine, dried with sodium sulphate and concentrated. to afford 2-{2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazol-6-yl}propan-2-ol (50.0 mg, Crude) as a color less oil. LCMS (ESI)m/z 583 [M+H]+ Step 2: 3-fluoro-4-[6-(2-hydroxypropan-2-yl)-1-(3-methyloxetan-3-yl) -1H-1,3-benzodiazol-2-yl]-6- methoxybenzene-1,2-diol [00290] A suspension of 2-{2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-meth yloxetan-3-yl)- 1H-1,3-benzodiazol-6-yl}propan-2-ol (100 mg, 172 µmol) and palladium(2+) hydroxide (30.0 mg, 245 µmol) in THF (3.00 mL), was stirred under hydrogen pressure (1atm) for 3 hours, After completion of the reaction, the reaction mixture was filtered through celite bed, and the filtrate was concentrated. The crude was purified by preparative HPLC to afford 3-fluoro-4-[6-(2-hydroxypropan-2-yl)-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazol-2-yl]-6-methoxy benzene -1,2-diol (0.015 g, 22 % Yield) as white solid. 1 H NMR (400 MHz, DMSO-d6): δ ppm 1.21 (s, 1H), 1.469 (s, 5 H), 2.0 (s, 3 H), 3.76 (s, 3 H), 4.35 (d, J = 5.6 Hz, 2 H), 4.72 (d, J = 5.6, 2 H), 5.08 (s, 1 H), 6.54 (d, J = 6 Hz, 1 H), 7.21 (s, 1 H), 7.33 (d, J = 8.8 Hz, 1 H), 7.56 (d, J = 8.8 Hz, 1 H), 9.36 - 9.44 (m, 2 H). LCMS (ESI)m/z 403.2 [M+H]+ Example 186: Synthesis of 3-fluoro-6-methoxy-4-(6-((methylamino)methyl)-1-(3-methyloxe tan-3- yl)-1H-benzo[d]imidazol-2-yl)benzene-1,2-diol Step 1: {2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methyl oxetan-3-yl)-1H-1,3- benzodiazol-6-yl}methanol [00291] To a stirred solution of methyl 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazole-6-carboxylate (450 mg, 772 µmol) in THF (20.0 mL) was added Lithium aluminium hydride in THF (2M Solution) (579 µL, 1.5 eq., 1.16 mmol) at -78 °C. The reaction mixture was stirred for 4 hours at -78 °C. The reaction mixture quenched with ammonium chloride solution and extracted with ethyl acetate. dried over sodium sulfate and concentrated to afford {2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxy phenyl]-1-(3-methyloxetan-3-yl)-1H-1,3-benzodiazol-6-yl} methanol (350.0 mg, Crude) as color less oil. LCMS (ESI)m/z 555 [M+H]+ Step 2: 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methylo xetan-3-yl)-1H-1,3- benzodiazole-6-carbaldehyde [00292] To a stirred solution of {2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methyl oxetan-3- yl)-1H-1,3-benzodiazol-6-yl}methanol (350 mg, 631 µmol) in dichloromethane (5.00 mL) was added 1,1-bis(acetyloxy)-3-oxo-3H-1λ⁵,2-benziodaoxol-1-yl acetate (401 mg, 1.5 eq., 947 µmol) at 0 °C. The reaction mixture was stirred at 0 °C for 2 hours. The reaction mixture quenched with NaHCO3 and extracted into ethyl acetate, washed with brine, dried with sodium sulphate and concentrated. The crude was purified by flash column chromatography with 55-60% ethyl acetate in hexane to afford 2-[3,4- bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methyloxetan-3 -yl)-1H-1,3-benzodiazole-6- carbaldehyde (200 mg crude) as color less oil. LCMS (ESI)m/z 553 [M+H]+. Step 3: ({2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methy loxetan-3-yl)-1H-1,3- benzodiazol-6-yl} methyl)(methyl)amine [00293] To a stirred solution of 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methylo xetan-3- yl)-1H-1,3-benzodiazole-6-carbaldehyde (200 mg, 362 µmol) in methanol (15.0 mL) was added methanamine (1.81 mL, 10 eq., 3.62 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 hours, and then sodium borohydride (64.8 mg, 5 eq., 1.81 mmol) was added lot-wise and the mixture was further stirred for 16 hours at room temperature. The reaction was quenched with water and washed with diethyl ether. The organic layer was washed with water, dried over sodium sulfate and concentrated to afford ({2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methy loxetan-3-yl)- 1H-1,3-benzodiazol-6-yl} methyl)(methyl)amine as a yellow oil. LCMS (ESI)m/z 568[M+H]+ Step 4: Synthesis of 3-fluoro-6-methoxy-4-{6-[(methylamino)methyl]-1-(3-methyloxe tan-3-yl)-1H- 1,3-benzodiazol-2-yl}benzene-1,2-diol; trifluoroacetic acid [00294] A mixture of ({2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methy loxetan-3-yl)-1H- 1,3-benzodiazol-6-yl}methyl)(methyl)amine (80.0 mg, 141 µmol) and TFA (1.00 mL). was stirred at 60 °C for 3 hours. Then reaction mixture monitored by TLC and LCMS. The reaction mixture was concentrated. The crude was purified by preparative HPLC to afford 3-fluoro-6-methoxy-4-{6- [(methylamino)methyl]-1-(3-methyloxetan-3-yl)-1H-1,3-benzodi azol-2-yl}benzene-1,2-diol; trifluoroacetic acid (24.0 mg, 33.89% Yield) as an off white solid. 1 H NMR (400 MHz, DMSO-d 6 ): δ ppm 2.06 (s, 3H), 3.81 (bs, 3H), 4.45 (d, J = 4 Hz, 2H), 4.78 (d, J = 4 Hz, 2H), 7.55 (s,1H), 7.76 (s,1H), 7.80 (s, 2H), 8.60 (s,1H), 9.46-9.41 (m, 2H). LCMS (ESI)m/z 411.2 [M+H]+ Example 187: Synthesis of 4-(5-(azetidin-1-yl)-1-(oxetan-3-yl)-1H-benzo[d]imidazol-2-y l)-6- methoxy-3-methylbenzene-1,2-diol [00295] Step-1: To a solution of 4-bromo-1-fluoro-2-nitrobenzene (2.25 mL, 18.2 mmol) in Isopropyl Alcohol (30.0 mL), oxetan-3-amine (1.90 mL, 1.5 eq., 27.3 mmol) and N,N-Diisopropylethylamine (9.53 mL, 3 eq., 54.5 mmol) was added to the reaction mixture and stirred and heated at 90 °C for 16 h .After completion of the reaction , the reaction mixture was concentrated under reduced pressure to get the crude and water was added to the reaction mixture was filtered and solid obtained. The solid afford N-(4- bromo-2-nitrophenyl)oxetan-3-amine (3.30 g, 12.0 mmol) as yellow solid. Yield: 3.30 g, (65.8%) [00296] Step-2: To a stirred solution N-(4-bromo-2-nitrophenyl)oxetan-3-amine (2.70 g, 9.89 mmol) of in toluene (30.0 mL) , azetidine (1.99 mL, 3 eq., 29.7 mmol) was added at room temperature. The reaction mixture was degassed with argon for 5 min. XPhos (471 mg, 0.1 eq., 989 µmol) and Tris(dibenzylideneacetone)dipalladium(0) (453 mg, 0.05 eq., 494 µmol) were added to the above suspension, degassed for 5 min. The reaction mixture stirred and heated at 110°C for 16 h. After completion, the reaction mixture cooled to room temperature and passed through celite bed. The filtrate diluted with ethyl acetate and washed with water. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to give crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford N-[4-(azetidin-1-yl)-2-nitrophenyl]oxetan-3-amine (2.50 g, 9.63 mmol) as off violet color solid. Yield: 2.50 g, (97.38%) [00297] Step-3: To a solution of N-[4-(azetidin-1-yl)-2-nitrophenyl]oxetan-3-amine (700 mg, 2.81 mmol) in methanol (15.0 mL) was added 10% Palladium on carbon (50 % wet) (500 mg) at room temperature and the reaction mixture stirred for 3h under hydrogen atmosphere. After completion, the reaction mixture passed through celite bed. Filtrate was concentrated to get 4-(azetidin-1-yl)-N1-(oxetan- 3-yl)benzene-1,2-diamine (600 mg, 2.74 mmol) as brown semisolid. Yield: 0.60 g, Crude [00298] Step-4: To a stirred solution of 3,4-bis(benzyloxy)-5-methoxy-2-methylbenzaldehyde (397 mg, 0.8 eq., 1.09 mmol) and 4-(azetidin-1-yl)-N1-(oxetan-3-yl)benzene-1,2-diamine (600 mg, 2.74 mmol) in methanesulfinylmethane (5.00 mL) was added disodium sulfinatosulfonate (312 mg, 1.2 eq., 1.64 mmol) at room temperature. The resulting mixture stirred for 16 h at 85 °C. After completion, reaction mixture diluted with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulphate, filtered and concentrated to give crude. The crude purified by flash chromatography. The desired fractions concentrated to afford 5-(azetidin-1-yl)-2-[3,4-bis(benzyloxy)-5-methoxy-2- methylphenyl]-1-(oxetan-3-yl)-1H-1,3-benzodiazole (90.0 mg, 125 µmol) as light brown sticky. Yield: 0.09 g, 9.14% [00299] Step-5: To a solution of 5-(azetidin-1-yl)-2-[3,4-bis(benzyloxy)-5-methoxy-2-methylph enyl]-1- (oxetan-3-yl)-1H-1,3-benzodiazole (40.0 mg, 62.0 µmol) in Tetrahydrofuran (10.0 mL) was added 20% Palladium hydroxide (200 mg) at room temperature and the reaction mixture stirred for 2h under hydrogen atmosphere. After completion, the reaction mixture passed through celite bed. Filtrate was concentrated to get crude. The crude was purified by reverse phase HPLC and pure fractions were lyophilized to get 4-[5-(azetidin-1-yl)-1-(oxetan-3-yl)-1H-1,3-benzodiazol-2-yl ]-6-methoxy-3- methylbenzene-1,2-diol (16.0 mg, 41.1 µmol) as off white semisolid. Yield: 0.016 g, 66.35% [00300] ES MS M/Z = 382.199 (M +1) + , 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.96 (s, 1H), 8.65 (s, 1H), 7.82 (d, J = 8.4 Hz, 1H), 6.60 (s, 1H), 6.56 (d, J = 8.0 Hz, 1H), 6.43 (s, 1H), 5.25 (t, J = 6.4 Hz, 1H), 4.98 (s, 4H), 3.83 (t, J = 6.8 Hz, 4H), 3.74 (s, 4H), 2.32 (t, J = 6.8 Hz, 2H), 1.80 (s, 3H). Example 188: Synthesis of 4-(5-(azetidin-1-yl)-1-(oxetan-3-yl)-1H-benzo[d]imidazol-2-y l)-3-fluoro- 6-methoxybenzene-1,2-diol
[00301] Step-1: To a solution of 4-bromo-1-fluoro-2-nitrobenzene (2.25 mL, 18.2 mmol) in Isopropyl Alcohol (30.0 mL), oxetan-3-amine (1.90 mL, 1.5 eq., 27.3 mmol) and N,N-Diisopropylethylamine (9.53 mL, 3 eq., 54.5 mmol) was added to the reaction mixture and stirred and heated at 90 °C for 16 h .After completion of the reaction , the reaction mixture was concentrated under reduced pressure to get the crude and water was added to the reaction mixture was filtered and solid obtained. The solid afford N- (4-bromo-2-nitrophenyl)oxetan-3-amine (3.30 g, 12.0 mmol) as off yellow solid. Yield: 3.30 g, 65.8% [00302] Step-2: To a stirred solution N-(4-bromo-2-nitrophenyl)oxetan-3-amine (2.70 g, 9.89 mmol) of in toluene (30.0 mL) , azetidine (1.99 mL, 3 eq., 29.7 mmol) was added at room temperature. The reaction mixture was degassed with argon for 5 min. XPhos (471 mg, 0.1 eq., 989 µmol) and Tris(dibenzylideneacetone)dipalladium(0) (453 mg, 0.05 eq., 494 µmol) were added to the above suspension, degassed for 5 min. The reaction mixture stirred and heated at 110°C for 16 h. After completion, the reaction mixture cooled to room temperature and passed through celite bed. The filtrate diluted with ethyl acetate and washed with water. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to give crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford N-[4-(azetidin-1-yl)-2-nitrophenyl]oxetan-3-amine (2.50 g, 9.63 mmol) as off violet color solid. Yield: 2.50 g.97.38% [00303] Step-3: To a solution of N-[4-(azetidin-1-yl)-2-nitrophenyl]oxetan-3-amine (700 mg, 2.81 mmol) in methanol (15.0 mL) was added Palladium on carbon (500 mg) at room temperature and the reaction mixture stirred for 3h under hydrogen atmosphere. After completion, the reaction mixture passed through celite bed. Filtrate was concentrated to get 4-(azetidin-1-yl)-N1-(oxetan-3-yl)benzene-1,2-diamine (600 mg, 2.74 mmol) as brown semisolid. Yield: 600 mg, 97.43% [00304] Step-4: To a stirred solution 4-(azetidin-1-yl)-N1-(oxetan-3-yl)benzene-1,2-diamine (224 mg, 1.02 mmol) and 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (300 mg, 0.8 eq., 819 µmol) in methanesulfinylmethane (5.00 mL) and disodium sulfinatosulfonate (233 mg, 1.2 eq., 1.23 mmol) was added at room temperature. The resulting mixture stirred and heated at 85°C for 16 hr. After completion of reaction, the reaction mixture diluted with ice cold water and extracted with ethyl acetate. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to give crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 5-(azetidin-1-yl)-2-[3,4- bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(oxetan-3-yl)-1H- 1,3-benzodiazole (100 mg, 150 µmol) as off violet color solid. Yield: 100 mg, 14.68% [00305] Step-5: To a solution of 5-(azetidin-1-yl)-2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyph enyl]-1- (oxetan-3-yl)-1H-1,3-benzodiazole (80.0 mg, 141 µmol) in Tetrahydrofuran (10.0 mL) and Palladium hydroxide on carbon 20%w/w (150 mg, 1.7 eq., 245 µmol) was added at room temperature and the reaction mixture stirred for 2h under hydrogen atmosphere. After completion, the reaction mixture passed through celite bed. Filtrate was concentrated to get 4-[5-(azetidin-1-yl)-1-(oxetan-3-yl)-1H-1,3- benzodiazol-2-yl]-3-fluoro-6-methoxybenzene-1,2-diol (5.00 mg, 12.9 µmol) as white solid. Yield: 0.005 g, (9.15%) [00306] LCMS and NMR Data: ES MS M/Z = 386.13 (M +1) + ; UPLC: 99.69%; 1H NMR (400 MHz, DMSO-d6) δ 9.41 (d, J = 7.6 Hz, 2H) 6.67 (s, 1H), 6.58 (t, J = 7.1 Hz, 2H), 5.37 (s, 1H), 5.01 (d, J = 6.0 Hz, 4H) 3.81 (t, J = 6.8 Hz, 7H), 3.71 (s, 3H), 2.31 (t, J = 6.8 Hz, 2H). Example 189: Synthesis of 4-(5-(azetidin-1-yl)-1H-benzo[d]imidazol-2-yl)-6-methoxy-3- methylbenzene-1,2-diol [00307] Step-1: To a solution of 5-fluoro-2-nitroaniline (5.00 g, 32.0 mmol) in N-Methyl-2-pyrrolidone (50.0 mL), N,N-Diisopropylethylamine (5.59 mL, 32.0 mmol) and azetidine (2.74 g, 1.5 eq., 48.0 mmol) was added to the reaction mixture and stirred and heated at 90 °C for 16 h .After completion of the reaction , the water was added to the reaction mixture and compound was precipitated . Then reaction mixture was filtered and solid compound was dried under vacuum to afford 5-(azetidin-1-yl)-2- nitroaniline (5.40 g, 27.7 mmol) as off yellow solid. Yield: 5.40 g, (86.39%) [00308] Step-2: To a solution of 5-(azetidin-1-yl)-2-nitroaniline (500 mg, 2.59 mmol) in methanol (20.0 mL) was added Palladium on carbon (700 mg) at room temperature and the reaction mixture stirred for 2h under hydrogen atmosphere. After completion, the reaction mixture passed through celite bed. Filtrate was concentrated to get 4-(azetidin-1-yl)benzene-1,2-diamine (450 mg, 1.87 mmol) as brown sticky. Yield: 0.45 g, 72.44% [00309] Step-3: To a stirred solution of 4-(azetidin-1-yl)benzene-1,2-diamine (150 mg, 919 µmol) and 3,4-bis(benzyloxy)-5-methoxy-2-methylbenzaldehyde (266 mg, 0.8 eq., 735 µmol) in methanesulfinylmethane (10.0 mL) was added disodium sulfinatosulfonate (210 mg, 1.2 eq., 1.10 mmol) at room temperature. The resulting mixture stirred for 16 h at 85 °C. After completion, reaction mixture cooled to room temperature and diluted with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure to get crude. The crude purified by flash chromatography. The desired fractions concentrated to afford 5-(azetidin-1-yl)-2- [3,4-bis(benzyloxy)-5-methoxy-2-methylphenyl]-1H-1,3-benzodi azole (150 mg, 282 µmol) as off white solid. Yield: 0.15 g, 30.67% [00310] Step-4: To a solution of 5-(azetidin-1-yl)-2-[3,4-bis(benzyloxy)-5-methoxy-2-methylph enyl]- 1H-1,3-benzodiazole (150 mg, 297 µmol) in Tetrahydrofuran (10.0 mL) was added 20% Palladium hydroxide (100 mg, 0.48 eq., 143 µmol) at room temperature and the reaction mixture stirred for 3h under hydrogen atmosphere. After completion, the reaction mixture passed through celite bed. Filtrate was concentrated to get crude. Crude was purified by reverse phase HPLC and desired fractions were lyophilized to get 4-[5-(azetidin-1-yl)-1H-1,3-benzodiazol-2-yl]-6-methoxy-3-me thylbenzene-1,2-diol (14.0 mg, 40.9 µmol) as white solid. Yield: 0.014 g, 13.78% [00311] (ESI) m/z 326.06 [M+1] + ; 1H NMR (400 MHz, DMSO-d6) δ 11.99 (m, 1H), 8.89 (brs, 1H), 8.48 (brs, 1H), 7.42-7.26 (m, 1H), 6.80 (d, J = 8.48 Hz, 1H), 6.60-6.31 (m, 2H), 3.81-3.77 (m, 7H), 2.33- 2.28 (m, 5H). Example 190: Synthesis of 1-[2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(3-methyloxe tan-3-yl)- 1H-1,3-benzodiazol-5-yl]pyrrolidin-2-one [00312] Step-1: To a stirred solution of N-(4-bromo-2-nitrophenyl)-3-methyloxetan-3-amine (500 mg, 1.74 mmol) in 1,4-dioxane (8.00 mL), and Potassium carbonate (722 mg, 3 eq., 5.22 mmol) were added and reaction mixture was purged with argon for 5 min then Copper (I)Iodide (166 mg, 0.3 eq., 522 µmol) and 2-aminoacetic acid (78.4 mg, 0.6 eq., 1.04 mmol) were added and again purged with argon. The reaction mixture was heated to 130°C for 24 h. After completion of reaction, reaction mixture filtered through celite. The filtrate was distilled to obtain crude. The crude purified by flash chromatography. The desired fraction were concentrated to afford 1-{4-[(3-methyloxetan-3-yl)amino]-3- nitrophenyl}pyrrolidin-2-one (50.0 mg) as yellow solid. Yield: 50 mg, 9.86% [00313] Step-2: To a solution of 1-{4-[(3-methyloxetan-3-yl)amino]-3-nitrophenyl}pyrrolidin-2 -one (120 mg, 412 µmol) in methanol (20.0 mL) was added zinc (135 mg, 5 eq., 2.06 mmol) followed by addition of ammonium chloride (110 mg, 5 eq., 2.06 mmol) at room temperature and the reaction mixture stirred for 3h under hydrogen atmosphere. After completion, the reaction mixture diluted with dichloromethane and passed through celite bed. Then water was added to filtrate and extracted with 10% methanol in dichloromethane solution. The organic fraction collected, dried over anhydrous sodium sulphate, concentrated to obtain 1-{3-amino-4-[(3-methyloxetan-3-yl)amino]phenyl}pyrrolidin-2 -one as brown liquid. Yield: 106 mg, 98.47% [00314] Step-3: To a stirred solution of 1-{3-amino-4-[(3-methyloxetan-3-yl)amino]phenyl}pyrrolidin- 2-one (104 mg, 398 µmol)and 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (117 mg, 0.8 eq., 318 µmol) in methanesulfinylmethane (3.00 mL), disodium sulfinatosulfonate (113 mg, 1.5 eq., 597 µmol) was added at room temperature. The resulting mixture stirred for 16h at 80 °C. After completion, water and ethyl acetate was added to reaction mixture. The organic fractions were collected, dried over anhydrous sodium sulphate, filtered and concentrated to get crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 1-{2-[3,4-bis(benzyloxy)-2-fluoro-5- methoxyphenyl]-1-(3-methyloxetan-3-yl)-1H-1,3-benzodiazol-5- yl}pyrrolidin-2-one (145 mg, 239 µmol) as sticky solid. Yield: 145 mg, 59.96% [00315] Step-4: To 1-{2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-meth yloxetan-3-yl)-1H- 1,3-benzodiazol-5-yl}pyrrolidin-2-one (110 mg, 181 µmol) trifluoroacetic acid (1.00 mL) added at room temperature. The resulting reaction mixture stirred at 60 °C for 4 h. After the complete consumption of starting material, reaction mixture was concentrated to obtain the crude. The crude was purified by Reverse phase HPLC. The desired fraction were collected and lyophilized to obtain 1-[2-(2-fluoro-3,4- dihydroxy-5-methoxyphenyl)-1-(3-methyloxetan-3-yl)-1H-1,3-be nzodiazol-5-yl]pyrrolidin-2-one (10.0 mg, 23.4 µmol) as off white solid. Yield: 10 mg, 12.92% [00316] LCMS and NMR Data: ES MS M/Z = 428.24 [M +1] + , UPLC: 98.81% 1 H NMR (400 MHz, DMSO-d6) δ 9.64 (bs, 2H), 7.95 (s, 1H), 7.66 (d, J = 9.2 Hz, 1H), 7.37 (d, J = 4.0 Hz, 1H), 6.64 (d, J = 5.6 Hz, 1H), 4.73 (d, J = 5.6 Hz, 1H), 4.42 (d, J = 5.6 Hz, 1H), 3.92 (t, J = 7.2 Hz, 2H), 3.80 (s, 3H), 2.54-2.52 (m, 2H), 2.12-2.06 (m, 5H). Example 191: Synthesis of 1-(2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(oxetan-3-yl )-1H- benzo[d]imidazol-5-yl)pyrrolidin-2-one
[00317] Step-1: To a stirred solution of N-(4-bromo-2-nitrophenyl)oxetan-3-amine (800 mg, 2.93 mmol) in 1,4-dioxane (8.00 mL), pyrrolidin-2-one (374 mg, 1.5 eq., 4.39 mmol) and Potassium carbonate (1.21 g, 3 eq., 8.79 mmol) were added and reaction mixture was purged with argon for 5 min then Copper (I)Iodide (93.0 mg, 0.1 eq., 293 µmol) and 2-aminoacetic acid (44.0 mg, 0.2 eq., 586 µmol) were added and again purged with argon. The reaction mixture was heated to 130°C for 18 h. After completion of reaction, reaction mixture filtered through celite bed. The filtrate was distilled to obtain crude. The crude purified flash chromatography. The desired fraction were concentrated to afford 1-{3-nitro-4-[(oxetan-3- yl)amino]phenyl}pyrrolidin-2-one (500 mg, 1.68 mmol) as yellow solid. Yield: 500 mg, 57.25% [00318] Step-2: To a stirred solution of 1-{3-nitro-4-[(oxetan-3-yl)amino]phenyl}pyrrolidin-2-one (150 mg, 541 µmol) in methanol (5.00 mL), 10%Palladium on carbon (50% wet) (123.0 mg, 0.4 eq., 216 µmol) was charged and stirred under hydrogen atmosphere at room temperature for 1h. After completion of reaction, reaction mixture filtered through celite bed. The filtrate was distilled below 30 °C to obtain 1-{3-amino-4-[(oxetan-3-yl)amino]phenyl}pyrrolidin-2-one (130 mg, 499 µmol) as crude. Yield: 130 mg, 92.28% [00319] Step-3: To a stirred solution 1-{3-amino-4-[(oxetan-3-yl)amino]phenyl}pyrrolidin-2-one (130 mg, 526 µmol) and 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (154 mg, 0.8 eq., 421 µmol) in methanol (4.00 mL) was added Acetic acid (500 µL) at room temperature. The resulting mixture stirred for 16 h at 90 °C. After completion, reaction mixture concentrated under reduced pressure to get crude 1- {2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(oxetan-3 -yl)-1H-1,3-benzodiazol-5-yl}pyrrolidin- 2-one (110 mg, 84.5 µmol). Yield: 110 mg, 16.06% [00320] Step-4: To a stirred solution of 1-{2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(oxetan - -1,3-benzodiazol-5-yl}pyrrolidin-2-one (130 mg, 219 µmol) in Tetrahydrofuran (5.00 mL), 20%Palladium hydroxide (26.8 mg, 219 µmol) was charged and stirred under hydrogen atmosphere at room temperature for 2 h. After completion of reaction, reaction mixture filtered through celite bed. The filtrate was distilled below 30 °C to obtain crude. The crude was purified by Reverse prep HPLC to get 1- [2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(oxetan-3-yl)- 1H-1,3-benzodiazol-5-yl]pyrrolidin-2-one (40.0 mg, 95.8 µmol) as light brown solid. Yield: 40 mg, 43.75% [00321] ES MS M/Z = 414.17 [M + 1] + , UPLC: 99.01%. 1 HNMR (400 MHz, DMSO-d6): δ 9.46 (bs, 2H), 8.01 (d, J = 8.8 Hz, 1H), 7.93 (d, J = 2.0 Hz, 1H), 7.71 (dd, J = 9.2 Hz, 2.0 Hz, 1H), 6.64 (d, J = 6.0 Hz, 1H), 5.44 (bs, 1H), 5.07-5.00 (m, 4H), 3.94 (t, J = 6.8 Hz, 2H), 3.79 (s, 3H), 2.54-2.49 (m, 3H), 2.14- 2.07 (m, 2H). Example 192: Synthesis of 3-fluoro-6-methoxy-4-[1-(3-methyloxetan-3-yl)-5-(phenylamino )-1H- 1,3-benzodiazol-2-yl]benzene-1,2-diol [00322] Step-1: To a stirred solution of 4-bromo-1-fluoro-2-nitrobenzene (2.00 g, 9.09 mmol) in 1- methylpyrrolidin-2-one (10.0 mL) was added 3-methyloxetan-3-amine (1.14 mL, 1.5 eq., 13.6 mmol) and ethylbis(propan-2-yl)amine (4.76 mL, 3 eq., 27.3 mmol) and heated at 100 °C for 16h. After completion of reaction, reaction mixture diluted with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulphate, filtered and concentrated to afford N-(4-bromo-2-nitrophenyl)-3- methyloxetan-3-amine (2.48 g, 7.08 mmol) as orange solid. Yield: 2.48 g (77.91%) [00323] Step-2: To a stirred solution of aniline (227 mg, 2.44 mmol) and N-(4-bromo-2-nitrophenyl)-3- methyloxetan-3-amine (700 mg, 2.44 mmol) in 1,4-dioxane (5.00 mL) was added sodium 2- methylpropan-2-olate (474 mg, 2 eq., 4.88 mmol) at room temperature. The reaction mixture was degassed with argon for 5 min. Then Tris(dibenzylideneacetone)dipalladium(0) (112 mg, 0.05 eq., 122 µmol) and dicyclohexyl[2',4',6'-tris(propan-2-yl)-[1,1'-biphenyl]-2-yl ]phosphane (116 mg, 0.1 eq., 244 µmol) were added to the above suspension, degassed for 5 minutes and reaction mixture stirred was heated at 120°C for 16 h. After completion, the reaction mixture cooled to room temperature, diluted with water and extracted ethyl acetate. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to give crude. The crude purified by flash chromatography. The desired fractions concentrated to afford N1-(3-methyloxetan-3-yl)-2-nitro-N4-phenylbenzene-1,4-diamin e (300 mg, 601 µmol). Yield: 300 mg, 24.66% [00324] Step-3: To a solution of N1-(3-methyloxetan-3-yl)-2-nitro-N4-phenylbenzene-1,4-diamin e (300 mg, 601 µmol) in methanol (20.0 mL) was added zinc (197 mg, 5 eq., 3.01 mmol) followed by addition of ammonium chloride (161 mg, 5 eq., 3.01 mmol) at room temperature and the reaction mixture stirred for 3h at 50 °C. After completion, the reaction mixture diluted with dichloromethane and passed through celite bed. water was added to filtrate and extracted with 10% methanol in dichloromethane solution. The organic fraction collected, dried over anhydrous sodium sulphate, concentrated to obtain N1-(3- methyloxetan-3-yl)-N4-phenylbenzene-1,2,4-triamine (255 mg, 568 µmol) as brown liquid. Yield: 255 mg, 94.46% [00325] Step-4: To a stirred solution of N1-(3-methyloxetan-3-yl)-N4-phenylbenzene-1,2,4-triamine (250 mg, 557 µmol) and 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (163 mg, 0.8 eq., 446 µmol) in methanesulfinylmethane (3.00 mL), disodium sulfinatosulfonate (159 mg, 1.5 eq., 835 µmol) was added at room temperature. The resulting mixture stirred for 16h at 80 °C. After completion, water and ethyl acetate was added to reaction mixture. The organic fractions were collected, dried over anhydrous sodium sulphate, filtered and concentrated to get crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-N-phenyl-1H-1,3-benzodiazol-5-amine (270 mg, 414 µmol) as pink solid. Yield: 270 mg, 74.33% [00326] Step-5: To 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methylo xetan-3-yl)-N- phenyl-1H-1,3-benzodiazol-5-amine (250 mg, 406 µmol), trifluoroacetic acid (1.00 mL) added at room temperature. The resulting reaction mixture stirred at 60 °C for 4 h. After the complete consumption of starting material, reaction mixture was concentrated to obtain the crude. The crude was purified by reverse phase HPLC and desired fractions were collected and lyophilized to obtain 3-fluoro-6-methoxy- 4-[1-(3-methyloxetan-3-yl)-5-(phenylamino)-1H-1,3-benzodiazo l-2-yl]benzene-1,2-diol (63.0 mg, 141 µmol) as pink color ed solid. Yield: 63 mg, 34.65% [00327] LCMS and NMR Data: ES MS M/Z = 436.31 (M +1) + , UPLC: 97.24%; 1 H NMR (400 MHz, DMSO-d6) δ 9.77 (bs, 2H), 8.41 (bs, 1H), 7.39-7.35 (m, 2H), 7.29-7.25 (m, 2H), 7.20-7.16 (m, 1H), 7.11 (d, J = 8.0 Hz,1H), 6.89-6.85 (m, 1H), 6.69 (d, J = 5.6 Hz, 1H), 4.75 (d, J = 6.0 Hz, 1H), 4.43 (d, J = 6.0 Hz, 1H), 2.10 (s, 3H) Example 193: Synthesis of 5-[5-(azetidin-1-yl)-1-cyclobutyl-1H-1,3-benzodiazol-2-yl]-3 - methoxybenzene-1,2-diol [00328] Step-1: To a solution of 4-bromo-1-fluoro-2-nitrobenzene (1.12 mL, 9.09 mmol) in propan-2-ol (30.0 mL), cyclobutanamine (1.17 mL, 1.5 eq., 13.6 mmol) and N,N-Diisopropylethylamine (4.76 mL, 3 eq., 27.3 mmol) was added to the reaction mixture and stirred and heated at 90 °C for 2-16 h .After completion of the reaction , the reaction mixture was concentrated under reduced pressure to get the crude and water was added to the reaction mixture was filtered and solid obtained. The dried solid afforded 4-bromo-N-cyclobutyl-2-nitroaniline (2.00 g, 7.23 mmol) as off yellow solid. Yield: 2.000 g, (79.52%) [00329] Step-2: To a stirred solution 4-bromo-N-cyclobutyl-2-nitroaniline (1.00 g, 3.69 mmol) of in toluene (30.0 mL), azetidine (496 µL, 2 eq., 7.38 mmol) was added at room temperature. The reaction mixture was degassed with argon for 5 min. dicyclohexyl[2',4',6'-tris(propan-2-yl)-[1,1'-biphenyl]-2- yl]phosphane (176 mg, 0.1 eq., 369 µmol) and Tris(dibenzylideneacetone)dipalladium(0) (169 mg, 0.05 eq., 184 µmol) were added to the above suspension, degassed for 5 min. The reaction mixture stirred and heated at 110°C for 16 h. After completion, the reaction mixture cooled to room temperature and passed through celite bed. The filtrate diluted with ethyl acetate and washed with water. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to give crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 4-(azetidin-1-yl)-N- cyclobutyl-2-nitroaniline (700 mg, 2.12 mmol) as off violet color solid. Yield: 700 mg.57.56% [00330] Step-3: To a solution of 4-(azetidin-1-yl)-N-cyclobutyl-2-nitroaniline (700 mg, 2.83 mmol) in methanol (30.0 mL) was added 10% Palladium on Carbon (50 % wet) (1.00 g, 9.40 mmol) at room temperature and the reaction mixture stirred for 2h under hydrogen atmosphere. After completion, the reaction mixture passed through celite bed. Filtrate was concentrated to get as 4-(azetidin-1-yl)-N1- cyclobutylbenzene-1,2-diamine (1.00 g, 1.01 mmol) as violet color solid. Yield: 1.00 g, 35.76% [00331] Step-4: To a stirred solution 4-(azetidin-1-yl)-N1-cyclobutylbenzene-1,2-diamine (180 mg, 1.2 eq., 828 µmol) and 3,4-bis(benzyloxy)-5-methoxy-2-methylbenzaldehyde (250 mg, 690 µmol) in methanesulfinylmethane (5.00 mL) and disodium sulfinatosulfonate (157 mg, 1.2 eq., 828 µmol) was added at room temperature. The resulting mixture stirred and heated at 85°C for 16 hr. After completion of reaction, the reaction mixture diluted with ice cold water and extracted with ethyl acetate. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to give crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 5-(azetidin-1-yl)-2-[3,4- bis(benzyloxy)-5-methoxy-2-methylphenyl]-1-cyclobutyl-1H-1,3 -benzodiazole (150 mg, 131 µmol) as off violet color solid. Yield: 0.15 g, 19.04% [00332] Step-5: To a solution of 5-(azetidin-1-yl)-2-[3,4-bis(benzyloxy)-5-methoxyphenyl]-1-c yclobutyl- 1H-1,3-benzodiazole (150 mg, 275 µmol) in Tetrahydrofuran (15.0 mL) and Palladium hydroxide on carbon 20%w/w (233 mg, 1.4 eq., 381 µmol) was added at room temperature and the reaction mixture stirred for 2h under hydrogen atmosphere. After completion, the reaction mixture passed through celite bed. Filtrate was concentrated to get crude. The crude was purified using reverse phase prep HPLC and desired fraction were lyophilized to get 5-[5-(azetidin-1-yl)-1-cyclobutyl-1H-1,3-benzodiazol-2-yl]-3 - methoxybenzene-1,2-diol (14.0 mg, 37.8 µmol) as white color solid. Yield: 0.014 g, 13.77% [00333] LCMS and NMR Data: ES MS M/Z = 380.20(M + 1); UPLC: 98.77%; 1H NMR (400 MHz, DMSO-d6) δ 7.63 (d, J = 8.8 Hz, 1H), 6.60 (d, J = 2Hz, 1H), 7.83 (dd, J = 8.4, 2.0 Hz,1H), 6.37 (s, 1H), 4.62-4.57 (m, 1H), 3.78 (t, J =7.2 Hz, 4H), 3.74(s, 3H), 2.68 (t, J = 10.0 Hz, 2H), 2.32-2.22 (m, 2H), 1.87 (t, J =7.2 Hz, 4H). Example 194: Synthesis of 3-fluoro-6-methoxy-4-(1-(3-methyloxetan-3-yl)-6-(1H-pyrazol- 4-yl)-1H- benzo[d]imidazol-2-yl)benzene-1,2-diol [00334] Step-1: To a solution of 4-bromo-2-fluoro-1-nitrobenzene (500.0 mg, 2.28 mmol) in 1- methylpyrrolidin-2-one (5.00 mL) , 3-methyloxetan-3-amine (217.1 mg, 1.1 eq., 2.27 mmol) and ethylbis(propan-2-yl)amine (1.18 mL, 3 eq., 6.81 mmol) was added to the reaction mixture and heated at 100 °C for 16 h. After completion of the reaction, the reaction mixture was diluted with water solid obtained was filtered and dried to afford N-(5-bromo-2-nitrophenyl)-3-methyloxetan-3-amine (200.0 mg, 6.96 mmol) as yellow solid. Yield: 200 mg, 32.3% [00335] Step-2: To a stirred solution of N-(5-bromo-2-nitrophenyl)-3-methyloxetan-3-amine (200 mg, 697 µmol) in ethanol (4.00 mL), toluene (4.00 mL) and water (1.00 mL), 4-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-pyrazole (149 mg, 1.1 eq., 766 µmol) and disodium carbonate (221 mg, 3 eq., 2.09 mmol) were added and reaction mixture was purged with argon for 5 min, then tetrakis(triphenylphosphine)palladium(0) (161 mg, 0.2 eq., 139 µmol) was added and again purged with argon. The reaction mixture was heated to 90 °C for 2 h. After completion of reaction, reaction mixture filtered through celite. Filtrate was washed with water and extracted with ethyl acetate. The combined organic layers dried over anhydrous sodium sulphate, filtered and concentrated to obtain crude. The crude purified by flash chromatography. The desired fraction were concentrated to afford 3-methyl-N-[2- nitro-5-(1H-pyrazol-4-yl)phenyl]oxetan-3-amine (150 mg, 301 µmol) as yellow solid. Yield: 150 mg, 43.18% and 130 mg, 40% (From two batches) [00336] Step-3: To a stirred solution 3-methyl-N-[2-nitro-5-(1H-pyrazol-4-yl)phenyl]oxetan-3-amine (280 mg, 510 µmol) in methanol (2.00 mL), zinc (167 mg, 5 eq., 2.55 mmol) and ammonium chloride (137 mg, 5 eq., 2.55 mmol) was added at 0 °C and reaction mixture was stirred at room temperature for 30 min. After completion, the reaction mixture passed through celite bed. The filtrate was concentrated under reduced pressure and washed with water. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to afford N1-(3-methyloxetan-3-yl)-5-(1H-pyrazol-4-yl)benzene-1,2-diam ine (160 mg, 118 µmol) as brown solid. Yield: 160 mg, Crude [00337] Step-4: To a stirred solution N1-(3-methyloxetan-3-yl)-5-(1H-pyrazol-4-yl)benzene-1,2-diam ine (80.0 mg, 327 µmol) and 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (120 mg, 327 µmol) in methanesulfinylmethane (5.00 mL) was added disodium sulfinatosulfonate (93.4 mg, 1.5 eq., 491 µmol) at room temperature. The resulting mixture stirred for 16 h at 85 °C. After completion, reaction mixture diluted with water solid obtained was filtered and dried to get 2-[3,4-bis(benzyloxy)-2-fluoro-5- methoxyphenyl]-1-(3-methyloxetan-3-yl)-6-(1H-pyrazol-4-yl)-1 H-1,3-benzodiazole (130 mg, 220 µmol) as brown solid. Yield: 130 mg, 75.46% [00338] Step5: To a solution of 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methylo xetan-3- yl)-6-(1H-pyrazol-4-yl)-1H-1,3-benzodiazole (130 mg, 220 µmol) in trifluroacetic acid (1.00 mL), was added at room temperature and the reaction mixture stirred at 0°C for 2h. After completion, the reaction mixture was concentrated to get crude as brown viscous liquid. Purification was done by Reverse Prep HPLC and desired fraction were lyophilized to get 2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-N- methyl-1-(3-methyloxetan-3-yl)-1H-1,3-benzodiazole-6-sulfona mide (11.0 mg, 25.1 µmol) as white solid. Yield: 11 mg, 12.08% [00339] LCMS and NMR Data: ES MS M/Z = 346.15 (M +1), 1HNMR (400 MHz, DMSO-d6): δ 9.7(bs, 1H), 8.22 (s, 2H), 7.72 (dd, J = 17.0 Hz, 8.4 Hz, 1H), 7.45 (s, 1H), 6.68 (d, J = 6.0 Hz, 1H), 4.75 (d, J = 6.0 Hz, 2H), 4.52 (d, J = 5.6 Hz, 2H), 3.80 (s, 3H), 2.13 (s, 3H). Example 195: Synthesis of 2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-N,N-dimethyl-1-(3 - methyloxetan-3-yl)-1H-1,3-benzodiazole-5-carboxamide [00340] Step-1: A stirred solution of 4-fluoro-3-nitroaniline (1.00 g, 6.41 mmol) in dichloromethane (10.0 mL), acetyl acetate (666 µL, 1.1 eq., 7.05 mmol) was added and stirred at room temperature for 16h. After completion of reaction, reaction mixture diluted with water and extracted with dichloromethane. The combined organic layers were dried over anhydrous sodium sulphate, filtered and concentrated to afford N-(4-fluoro-3-nitrophenyl)acetamide as off-white solid. Yield: 1.0 g, 57% [00341] Step-2: To a stirred solution of N-(4-fluoro-3-nitrophenyl)acetamide (500 mg, 2.52 mmol) in N,N-dimethylformamide (5.00 mL), sodium hydride (101 mg, 2.52 mmol) was added at 0°C and stirred for half an hour at room temperature. After half an hour, iodomethane (1.57 mL, 2.52 mmol) was added and reaction mixture stirred for 4 hours at room temperature. After completion, reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to get crude. The crude was purified by flash chromatography. The desired fractions concentrated to afford N-(4-fluoro-3-nitrophenyl)-N- methylacetamide (300 mg, 9.05 mmol) as yellow liquid. Yield: 0.30 g, 64% [00342] Step-3: To a stirred solution of N-(4-fluoro-3-nitrophenyl)-N-methylacetamide (180 mg, 848 µmol) in N-Methyl-2-Pyrrolidone (NMP) (2.00 ML), 3-methyloxetan-3-amine (77.8 µL, 2 eq., 1.70 mmol) and ethylbis(propan-2-yl)amine (329 mg, 2.55 µmol) was added at room temperature and stirred at 130°C for 1h.. After completion, reaction mixture quenched with ice cold water, precipitate was formed. The solid was filtered and dried to afford N-methyl-N-{4-[(3-methyloxetan-3-yl)amino]-3- nitrophenyl}acetamide (200 mg, 716 µmol) as a yellow solid. Yield: 0.20 g, 89% [00343] Step-4: To a stirred solution of N-methyl-N-{4-[(3-methyloxetan-3-yl)amino]-3- nitrophenyl}acetamide (200 mg, 716 µmol) in methanol (10.0 mL), zinc (234 mg, 5 eq., 3.58 mmol) and ammonium chloride (192 mg, 5 eq., 3.58 mmol) were added at room temperature and the reaction mixture stirred for 2h at 40°C. After completion, the reaction mixture passed through celite bed. Filtrate was extracted with dichloromethane, dried over anhydrous sodium sulfate and concentrated under reduced pressure to get as N-{3-amino-4-[(3-methyloxetan-3-yl)amino]phenyl}-N-methylace tamide (200 mg, 802 µmol) as violet color solid. Yield: 0.20 g (Crude) [00344] Step-5: To a stirred solution of 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (188 mg, 0.8 eq., 513 µmol) and N-{3-amino-4-[(3-methyloxetan-3-yl)amino]phenyl}-N-methylace tamide (200 mg, 642 µmol) in methanesulfinylmethane (5.00 mL), disodium sulfinatosulfonate (183 mg, 1.5 eq., 963 µmol) was added at room temperature. The resulting mixture stirred for 12 h at 85 °C. After completion, ice cold water was added in the reaction mixture and solid was filtered and dried to get crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford N-{2-[3,4- bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methyloxetan-3 -yl)-1H-1,3-benzodiazol-5-yl}-N- methylacetamide (250 mg, 378 µmol) as sticky solid. Yield: 0.25 g, 90% [00345] Step-6: To a stirred solution of N-{2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazol-5-yl}-N-methylacetamid e (200 mg, 336 µmol) in trifluoroacetic acid (3.00 mL), reaction mixture stirred for 4h at 65°C. After completion, reaction mixture was concentrated under reduced pressure to get the crude and further purified by reverse phase HPLC. The desired fractions were lyophilized to afford N-[2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazol-5-yl]-N-methylacetamid e (49.0 mg, 117 µmol) as off white solid. Yield: 0.049 mg, 34% [00346] LCMS and NMR data: ES MS M/Z=416 (M+1), UPLC: 99%; 1 H NMR (400 MHz, DMSO- d6) δ 9.59 (s, 1H), 7.72 (s, 1H), 7.39 (d, J = 8.4 Hz, 1H), 7.29 (d, J = 8.4 Hz, 1H), 6.62 (d, J = 6.4 Hz, 1H), 4.72 (d, J = 5.6 Hz, 2H), 4.39 (d, J = 5.6 Hz, 2H), 3.79 (s, 3H), 3.19 (s, 3H), 2.05 (s, 3H), 1.79 (s, 3H). Example 196: Synthesis of methyl 5-(5-(azetidin-1-yl)-1H-benzo[d]imidazol-2-yl)-2-hydroxy-3- methoxybenzoate [00347] Step-1: To a stirred solution of methyl 2-hydroxy-3-methoxybenzoate (5.00 g, 27.4 mmol) in trifluoroacetic acid (40.0 mL) hexamethylenetetramine (7.70 g, 2 eq., 54.9 mmol) and cuprous oxide (3.93 g, 27.4 mmol) were added at 0 °C. The resulting reaction mixture stirred at 100 °C for 16 h. After the completion of reaction, the trifluoroacetic Acid-Complex was quenched with cold 6 N Hydrochloride solution and extracted with ethyl acetate. The combined organic layers dried over anhydrous sodium sulphate, filtered and concentrated to obtain crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford methyl 5-formyl-2-hydroxy-3-methoxybenzoate (2.00 g, 9.52 mmol). Yield: 2.00 g, 34.67% [00348] Step-2: To a stirred solution of 4-(azetidin-1-yl)benzene-1,2-diamine (155 mg, 952 µmol) and methyl 5-formyl-2-hydroxy-3-methoxybenzoate (200 mg, 952 µmol) in methanesulfinylmethane (5.00 mL), Sodium metabisulfite (217 mg, 1.2 eq., 1.14 mmol) was added at room temperature. The resulting reaction mixture stirred for 16 h at 80 °C. After completion, reaction mixture quenched with ice cold water and extracted with ethyl acetate. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to give crude. The crude purified by Reverse-Phase HPLC chromatography. The desired fractions were collected and lyophilized to afford methyl 5-[5-(azetidin-1-yl)-1H-1,3- benzodiazol-2-yl]-2-hydroxy-3-methoxybenzoate (15.0 mg, 42.4 µmol) as off white solids. Yield: 15 mg, 4.46% [00349] LCMS and NMR data: ES MS M/Z = 354.12 (M + 1), UPLC: 98.82% 1H NMR (400 MHz, DMSO-d6) δ 12.58-12.48 (m, 1H), 10.67 (s, 1H), 8.17-8.12 (m, 1H), 7.92-7.90 (m, 1H), 7.43-7.30 (m, 1H),6.59-6.34 (m, 2H), 3.95 (s, 3H), 3.93 (s, 3H), 3.83-3.80 (t, 4H), 2.32-2.28 (t, 2H). Example 197: Synthesis of 1-(2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(3-methyloxe tan-3-yl)- 1H-benzo[d]imidazol-5-yl)-3-methylimidazolidin-2-one [00350] Step-1: To a stirred solution of 1-{2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazol-5-yl}imidazolidin-2-on e (190 mg, 312 µmol) in N,N- dimethylformamide (2.00 mL) was added sodium hydride (12.5 mg, 312 µmol) at 0°C and stirred for half an hour at room temperature. After half an hour, iodomethane (19.4 µL, 312 µmol) was added and the solution was stirred for 16 hours at room temperature. After completion, reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to get crude. The crude was purified by flash chromatography. The desired fractions concentrated to afford 1-{2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazol-5-yl}-3-methylimidazol idin-2-one (80.0 mg, 78.4 µmol). Yield: 0.080 g, (25%) [00351] Step-2: To a stirred solution of 1-{2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazol-5-yl}-3-methylimidazol idin-2-one (70.0 mg, 112 µmol) was added trifluoroacetic acid (2.00 mL) and the resulting mixture was stirred for 2 h at 50 °C. After completion, reaction mixture was concentrated under reduced pressure to get the crude and further purified by reverse phase HPLC. Desired fractions were lyophilized to afford 1-[2-(2-fluoro-3,4- dihydroxy-5-methoxyphenyl)-1-(3-methyloxetan-3-yl)-1H-1,3-be nzodiazol-5-yl]-3-methylimidazolidin- 2-one (8.00 mg, 17.8 µmol) as white solid. [00352] 1H NMR: ES MS M/Z=443 (M+1), NMR (400 MHz, DMSO-d6) δ 9.41 (br s, 1H), 7.70 (d, 1H), 7.64 (d, 1H), 7.21 (d, 1H), 6.57 (d, 1H), 4.70 (d, 2H), 4.37 (d, 2H), 3.84 (t, 2H), 3.78 (s, 3H), 3.45 (t, 2H), 2.78 (s, 3H), 2.00 (s, 3H), 1.23 (s, 1H). Yield: 0.008 g, 15.8% Example 198: Synthesis of 1-(2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(3-methyloxe tan-3-yl)- 1H-benzo[d]imidazol-5-yl)imidazolidin-2-one [00353] Step-1: To a stirred solution of 4-bromo-1-fluoro-2-nitrobenzene (2.00 g, 9.09 mmol) in 1- methylpyrrolidin-2-one (10.0 mL) was added 3-methyloxetan-3-amine (1.14 mL, 1.5 eq., 13.6 mmol) and ethylbis(propan-2-yl)amine (4.76 mL, 3 eq., 27.3 mmol) and heated at 100°C for 16h. After completion of reaction, reaction mixture diluted with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulphate, filtered and concentrated to afford N-(4-bromo-2-nitrophenyl)-3- methyloxetan-3-amine (2.48 g, 7.08 mmol) as orange solid. Yield: 2.48 g, 77.91% [00354] Step-2: To a stirred solution of N-(4-bromo-2-nitrophenyl)-3-methyloxetan-3-amine (500 mg, 1.74 mmol) in 1,4-dioxane (1.00 mL), imidazolidin-2-one (300 mg, 2 eq., 3.48 mmol) and Potassium carbonate (722 mg, 3 eq., 5.22 mmol) were added and reaction mixture was purged with argon for 5 min then Copper (I)Iodide (166 mg, 0.3 eq., 522 µmol) and 2-aminoacetic acid (78.4 mg, 0.6 eq., 1.04 mmol) were added and again purged with argon. The reaction mixture was heated to 130°C for 16 h. After completion of reaction, reaction mixture diluted with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to get crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 1-{4-[(3- methyloxetan-3-yl)amino]-3-nitrophenyl}imidazolidin-2-one (90.0 mg, 274 µmol) as red solid. Yield: 90 mg, 15.7% [00355] Step-3: To a stirred solution of 1-{4-[(3-methyloxetan-3-yl)amino]-3-nitrophenyl}imidazolidin - 2-one (90.0 mg, 308 µmol) in methanol (10.0 mL) , zinc (101 mg, 5 eq., 1.54 mmol) and ammonium chloride (82.4 mg, 5 eq., 1.54 mmol) were added at room temperature and stirred at 50°C for 1h. After completion of the reaction, reaction mixture was passed through celite and washed with 10% methanol in dichloromethane, filtrate was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure to get the desired product 1-{3-amino-4-[(3-methyloxetan-3- yl)amino]phenyl}imidazolidin-2-one (82.0 mg, 269 µmol) as pale green powdery solid. Yield: 82 mg, 87.31% [00356] Step-4: To a stirred solution of 1-{3-amino-4-[(3-methyloxetan-3- yl)amino]phenyl}imidazolidin-2-one (82.0 mg, 313 µmol) and 3,4-bis(benzyloxy)-2-fluoro-5- methoxybenzaldehyde (91.6 mg, 0.8 eq., 250 µmol) in methanesulfinylmethane (3.00 mL) was added disodium sulfinatosulfonate (71.3 mg, 1.2 eq., 375 µmol) at room temperature. The resulting mixture was stirred for 16 h at 80 °C. After completion, reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to get crude. The crude purified by flash chromatography. The desired fractions concentrated to afford 1-{2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-meth yloxetan-3-yl)- 1H-1,3-benzodiazol-5-yl}imidazolidin-2-one (65.0 mg, 69.0 µmol) as yellow solid. Yield: 0.065 g, 22% [00357] Step-5: To 1-{2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-meth yloxetan-3-yl)-1H- 1,3-benzodiazol-5-yl}imidazolidin-2-one (55.0 mg, 90.4 µmol) was added trifluoroacetic acid (2.00 mL) and the resulting solution was stirred for 2 h at 50 °C. After completion, the reaction mixture was concentrated under reduced pressure to get the crude and further purified by reverse phase HPLC . Desired fractions were lyophilized to afford 1-[2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazol-5-yl]imidazolidin-2-on e (8.00 mg, 18.3 µmol) (TFA Salt) as off white solid. Yield: 0.008 g, 20% [00358] 1H NMR and LCMS: ES MS M/Z=429 (M+1), NMR (400 MHz, DMSO-d6) δ 9.76 (br s, 2H), 7.87 (s, 1H), 7.70 (d, 1H), 7.40 (d, 1H), 7.04 (s, 1H), 6.67 (d, 1H), 4.73 (d, 2H), 4.44 (d, 2H), 3.95 (t, 2H), 3.81 (s, 3H), 3.44 (t, 2H), 2.09 (s, 3H). Example 199: Synthesis of 4-[5-(azetidin-1-yl)-1-(oxetan-3-yl)-1H-1,3-benzodiazol-2-yl ]-3-fluoro-6- methoxy-5-methylbenzene-1,2-diol
[00359] Step-1: To a solution of 3,4,5-trihydroxybenzaldehyde (20.0 g, 2.4 eq., 130 mmol) in Acetone (100 mL), (bromomethyl)benzene (9.75 mL, 1.5 eq., 79.8 mmol), dipotassium carbonate (13.2 g, 1.8 eq., 95.8 mmol) and potassium iodide (1.77 g, 0.2 eq., 10.6 mmol) were added to the reaction mixture and stirred and heated at 60 °C for 4 h. After completion of the reaction, the reaction mixture was filtered and the filtrate was concentrated under reduced pressure to get the crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford methyl 3,4-bis(benzyloxy)-5- hydroxybenzoate as off white solid. Yield: 7.00 g, 24.39% [00360] Step-2: To a solution of 3,4-bis(benzyloxy)-5-hydroxybenzaldehyde (2.56 g, 7.66 mmol) in Acetic acid (70.0 mL) and dibromine (393 µL, 7.66 mmol) diluted in acetic acid was added dropwise to the reaction mixture and stirred for 30 minute. After completion of the reaction, the reaction mixture was quenched with Sodium thiosulfate and stirred for 10 minute so that solid compound precipitate. After that reaction mixture filtered out and solid washed with ice cold water and dried under vacuum. The solid afford 4,5-bis(benzyloxy)-2-bromo-3-hydroxybenzaldehyde (2.00 g, 3.87 mmol) as off white solid. Yield: 2.00 g, 50.57% [00361] Step-3: To a stirred solution 4,5-bis(benzyloxy)-2-bromo-3-hydroxybenzaldehyde (2.00 g, 3.87 mmol) in N,N-dimethylformamide (3.00 mL) and dipotassium carbonate (1.07 g, 2 eq., 7.74 mmol) was added to the reaction mixture at room temperature. The resulting mixture stirred for 1 h at room temperature. After 1 hr Methyl iodide (289 µL, 1.2 eq., 4.65 mmol) was added to the reaction mixture at room temperature. After completion, reaction mixture diluted with ice cold water and extracted with ethyl acetate. The organic layer dried over anhydrous sodium sulfate and concentrated under reduced pressured to get crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 4,5-bis(benzyloxy)-2-bromo-3-methoxybenzaldehyde (1.30 g, 2.74 mmol) as White solid. Yield: 1.30 g, 70.72% [00362] Step-4: To a solution of 4,5-bis(benzyloxy)-2-bromo-3-methoxybenzaldehyde (600 mg, 1.40 mmol) and methylboronic acid (126 mg, 1.5 eq., 2.11 mmol) in 1,4-dioxane (2.50 mL) and water (500 µL). cesium carbonate (915 mg, 2 eq., 2.81 mmol) was added at room temperature and the reaction mixture was degassed with argon for 5 min.1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium (II) (205 mg, 0.2 eq., 281 µmol) was added to the reaction, continued degassing for 5 min and heated the reaction mixture at 90°C for 4 h. After completion, the reaction was cooled to room temperature and passed through celite bed. Filtrate was diluted with ethyl acetate and washed with water. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to give crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 4,5-bis(benzyloxy)- 2-bromo-3-methoxybenzaldehyde (1.30 g, 2.74 mmol) as White solid. Yield: 0.320 g, 41% [00363] Step-5: To a stirred solution of 4,5-bis(benzyloxy)-3-methoxy-2-methylbenzaldehyde (320 mg, 883 µmol) in acetonitrile (10.0 mL) was added 4-fluoro-1-methyl-1,4-diazabicyclo[2.2.2]octane-1,4- diium; bis(tetrafluoroboranuide) (424 mg, 1.5 eq., 1.32 mmol) room temperature. The resulting mixture stirred for 2 h at 45 °C for 16h. After completion, reaction mixture concentrated under reduced pressure to get the crude. Crude was purified by flash chromatography. Desired fractions were concentrated to get 3,4-bis(benzyloxy)-2-fluoro-5-methoxy-6-methylbenzaldehyde (60.0 mg, 142 µmol) as yellow color viscous liquid. Yield: 0.100 g, (16.61%) [00364] Step-5a: To a solution of N-[4-(azetidin-1-yl)-2-nitrophenyl]oxetan-3-amine (700 mg, 2.81 mmol) in methanol (15.0 mL) was added Palladium on carbon (500 mg) at room temperature and the reaction mixture stirred for 3h under hydrogen atmosphere. After completion, the reaction mixture passed through celite bed. The filtrate was concentrated to get 4-(azetidin-1-yl)-N1-(oxetan-3-yl)benzene-1,2- diamine (600 mg, 2.74 mmol) as brown semisolid. Yield: 0.60 g, (70%) [00365] Step-6: To a stirred solution N-[4-(azetidin-1-yl)-2-nitrophenyl]oxetan-3-amine (100 mg, 401 µmol) and 3,4-bis(benzyloxy)-2-fluoro-5-methoxy-6-methylbenzaldehyde (76.3 mg, 0.5 eq., 201 µmol) in methanesulfinylmethane (5.00 mL) and disodium sulfinatosulfonate (91.5 mg, 1.2 eq., 481 µmol) was added at room temperature. The resulting mixture stirred and heated at 85°C for 16 hr. After completion of reaction, the reaction mixture diluted with ice cold water and extracted with ethyl acetate. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to give 5-(azetidin-1-yl)-2-[3,4- bis(benzyloxy)-2-fluoro-5-methoxy-6-methylphenyl]-1-(oxetan- 3-yl)-1H-1,3-benzodiazole (70.0 mg, 99.3 µmol) as brown color solid. Yield: 0.07 g, (24.76%) [00366] Step-7: To a solution of 5-(azetidin-1-yl)-2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxy-6 - methylphenyl]-1-(oxetan-3-yl)-1H-1,3-benzodiazole (75.0 mg, 106 µmol) in Tetrahydrofuran (10.0 mL) and Palladium hydroxide on carbon (150 mg, 12 eq., 1.23 mmol) was added at room temperature and the reaction mixture stirred for 2h under hydrogen atmosphere. After completion, the reaction mixture passed through celite bed. Filtrate was concentrated to get crude. The crude was purified using reverse phase prep HPLC to get 4-[5-(azetidin-1-yl)-1-(oxetan-3-yl)-1H-1,3-benzodiazol-2-yl ]-3-fluoro-6-methoxy-5- methylbenzene-1,2-diol (4.00 mg, 9.52 µmol) as white solid. Yield: 0.004 g, 8.98% [00367] LCMS and NMR Data: ES MS M/Z = 400.101 (M + 1), UPLC: 95.11%.1HNMR (400 MHz, DMSO-d6): δ 9.45 (s,1H), 9.35 (s, 1H), 7.86 (d, J = 8.6 Hz, 1H), 6.68 s,1H),6.57 (d, J = 8.6 Hz, 1H), 5.20-5.03 (m, 1H), 5.01-4.95 (m, 4H), 3.81(t, J = 6.8 Hz, 4H), 3.80 (s, 3H), 2.49 (t, J = 1.68 Hz, 2H), 2.31 (s, 3H). Example 200: Synthesis of 4-[5-(azetidin-1-yl)-1-cyclobutyl-1H-1,3-benzodiazol-2-yl]-3 -fluoro-6- methoxy-5-methylbenzene-1,2-diol [00368] Step-1: To a stirred solution of 4,5-bis(benzyloxy)-3-methoxy-2-methylbenzaldehyde (520 mg, 1.43 mmol) in acetonitrile (10.0 mL) was added 4-fluoro-1-methyl-1,4-diazabicyclo[2.2.2]octane-1,4- diium; bis(tetrafluoroboranuide) (688 mg, 1.5 eq., 2.15 mmol) room temperature. The resulting mixture stirred for 2 h at 45 °C for 16h. After completion, reaction mixture concentrated under reduced pressure to get the crude. Crude was purified by flash chromatography. Desired fractions were concentrated to get 3,4-bis(benzyloxy)-2-fluoro-5-methoxy-6-methylbenzaldehyde (120 mg, 284 µmol) as yellow color viscous liquid. Yield: 0.120 g, 19.79% [00369] Step-2: To a stirred solution 4-(azetidin-1-yl)-N1-cyclobutylbenzene-1,2-diamine (68.6 mg, 1.2 eq., 315 µmol) and 3,4-bis(benzyloxy)-2-fluoro-5-methoxy-6-methylbenzaldehyde (100 mg, 263 µmol) in Dimethyl sulfoxide (3.00 mL) and disodium sulfinatosulfonate (60.0 mg, 1.2 eq., 315 µmol) was added at room temperature. The resulting mixture stirred and heated at 85°C for 16 hr. After completion of reaction, the reaction mixture diluted with ice cold water and extracted with ethyl acetate. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to give crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 5-(azetidin-1-yl)-2-[3,4- bis(benzyloxy)-2-fluoro-5-methoxy-6-methylphenyl]-1-cyclobut yl-1H-1,3-benzodiazole (150 mg, 77.9 µmol) as white color viscous liquid. Yield:0.15 g, 29.63% [00370] Step-3: To a solution of 5-(azetidin-1-yl)-2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxy-6 - methylphenyl]-1-cyclobutyl-1H-1,3-benzodiazole (75.0 mg, 130 µmol) in methanol (30.0 mL) and Palladium hydroxide was added at room temperature and the reaction mixture stirred for 2h under hydrogen atmosphere. After completion, the reaction mixture passed through celite bed. Filtrate was concentrated to get Crude. The crude was purified using reverse phase prep HPLC to get 4-[5-(azetidin- 1-yl)-1-cyclobutyl-1H-1,3-benzodiazol-2-yl]-3-fluoro-6-metho xy-5-methylbenzene-1,2-diol (4.00 mg, 9.64 µmol) as a white solid. Yield: 0.004 g, 7.42% [00371] LCMS and NMR Data: ES MS M/Z = 398.06 (M + 1) + , UPLC: 95.78%.1HNMR (400 MHz, DMSO-d6): δ 9.43 (s, 1H), 9.3 (s, 1H), 7.65 (d, J = 8.4 Hz,1H), 6.61 (s, 1H), 6.49 (d, J = 8.4 Hz, 1H), 4.53 (t, J = 8.4 Hz, 1H), 3.76 (t, 4H), 3.65 (s, 3H), 2.67-2.50 (m, 2H), 2.25 (t, J = 6.8 Hz, 2H), 2.15 (m, 2H), 1.89 (s, 3H). Example 201: Synthesis of 5-(1-cyclobutyl-1H-1,3-benzodiazol-2-yl)-3-ethoxybenzene-1,2 -diol [00372] Step-1: To a solution of 3-methyl-N-(2-nitrophenyl)oxetan-3-amine (200 mg, 961 µmol) in methanol (30.0 mL) was added Palladium on Carbon (400 mg, 3.76 mmol) at room temperature and the reaction mixture stirred for 2h under hydrogen atmosphere. After completion, the reaction mixture passed through celite bed. Filtrate was concentrated to get as N1-(3-methyloxetan-3-yl)benzene-1,2-diamine (150 mg, 808 µmol) red color semi solid. Yield: 0.15 g, 84.11% [00373] Step-2: To a stirred solution N1-(3-methyloxetan-3-yl)benzene-1,2-diamine (61.5 mg, 345 µmol) and 4,5-bis(benzyloxy)-3-methoxy-2-methylbenzaldehyde (100 mg, 0.8 eq., 276 µmol) in Dimethyl sulfoxide (3.00 mL) and disodium sulfinatosulfonate (78.7 mg, 1.2 eq., 414 µmol) was added at room temperature. The resulting mixture stirred and heated at 85°C for 16 hr. After completion of reaction, the reaction mixture diluted with ice cold water and extracted with ethyl acetate . The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to give crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 2-[4,5-bis(benzyloxy)-3-methoxy-2- methylphenyl]-1-(3-methyloxetan-3-yl)-1H-1,3-benzodiazole (150 mg, 254 µmol) as white color liquid. Yield: 0.150 g, 73.51% [00374] Step-3: To a solution of 2-[4,5-bis(benzyloxy)-3-methoxy-2-methylphenyl]-1-(3-methylo xetan- 3-yl)-1H-1,3-benzodiazole (110 mg, 211 µmol) in Tetrahydrofuran (15.0 mL) and Palladium hydroxide on carbon 20%w/w (300 mg, 2.3 eq., 490 µmol) was added at room temperature and the reaction mixture stirred for 2h under hydrogen atmosphere. After completion, the reaction mixture passed through celite bed. Filtrate was concentrated low temperature to get crude. The crude was purified using reverse phase prep HPLC and desired fractions were lyophilized to get 3-methoxy-4-methyl-5-[1-(3-methyloxetan-3- -1,3-benzodiazol-2-yl]benzene-1,2-diol (39.0 mg, 114 µmol) as white color solid. Yield: 0.039 g, (53.73%) [00375] LCMS and NMR Data: ES MS M/Z = 341.12 (M + 1); UPLC: 99.08%; 1H NMR (400 MHz, DMSO-d6) δ 9.01 (bs,1H), 7.67-7.65 (m, 1H), 7.25-7.22 (m,3H), 6.51 (s, 1H), 4.60 (s, 4H), 3.72(s, 3H), 2.01 (d, J =12.4 Hz, 6H) Example 202: Synthesis of 4-(6,7-dichloro-1H-benzo[d]imidazol-2-yl)-3-fluoro-6-methoxy benzene- 1,2-diol [00376] Step-1: To a stirred solution of 2,3-dichloro-6-nitroaniline (500 mg, 2.42 mmol) and iron (405 mg, 3 eq., 7.25 mmol) and acetic acid (2.00 mL) was added at room temperature. The resulting mixture stirred and heated for 16 h at 65 °C. After completion, reaction mixture diluted with water and extracted wit ethyl acetate. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to give crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 3,4-dichlorobenzene-1,2-diamine (300 mg, 1.69 mmol) as off yellow color solid. Yield: 0.30 g, 70.16% [00377] Step-2: To a stirred solution 3,4-dichlorobenzene-1,2-diamine (96.6 mg, 546 µmol) and 3,4- bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (200 mg, 546 µmol) in methanol (3.00 mL) and catalytic amount of acetic acid was added to the reaction mixture at room temperature. The resulting mixture stirred for 16 h at 80 °C. After completion, reaction mixture concentrated under reduced pressure to get 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-6,7-dichloro -1H-1,3-benzodiazole white solid. Yield: 210 mg.40.43% [00378] Step-3: To a stirred solution 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-6,7-dichloro -1H- 1,3-benzodiazole (200 mg, 382 µmol) in trifluoroacetic acid (3.00 mL) and the resulting mixture stirred and heated for 16 h at 65°C. After completion, reaction mixture concentrated under reduced pressure to get crude. The crude was purified using prep HPLC to get2-[3,4-bis(benzyloxy)-2-fluoro-5- methoxyphenyl]-6,7-dichloro-1H-1,3-benzodiazole white solid. Yield: 29 mg, 21.32% [00379] LCMS and NMR Data: ES MS M/Z = 343.01 (M + 1); UPLC: 96.41%; 1H NMR (400 MHz, DMSO-d6) δ 7.52 (d, J = 8.4 Hz, 1H), 7.38 (d, J = 8.8 Hz, 1H), 7.18 (d, J = 4.3 Hz,1H), 3.86 (s, J = 7.0 Hz, 3H). Example 203: Synthesis of N-[2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(3-methyloxe tan-3- yl)-1H-1,3-benzodiazol-5-yl]pyridine-2-carboxamide
[00380] Step-1: To a stirred solution of 4-fluoro-3-nitroaniline (500 mg, 3.20 mmol) in N,N- dimethylformamide (2.00 mL) was added pyridine-2-carboxylic acid (394 mg, 3.20 mmol) , hexafluoro- λ⁵-phosphanuide 1-[bis(dimethylamino)methylidene]-1H-1λ⁵-[1,2,3]triazolo[ 4,5-b]pyridin-3-ium-1- ylium-3-olate (1.83 g, 1.5 eq., 4.80 mmol) and ethylbis(propan-2-yl)amine (1.67 mL, 3 eq., 9.61 mmol) and the solution was stirred for 16 hours. After completion of reaction, the reaction mixture diluted with water and extracted with ethyl acetate. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to obtain crude. The crude was purified by flash chromatography. The desired fractions concentrated to afford N-(4-fluoro-3-nitrophenyl)pyridine-2-carboxamide (650 mg, 2.49 mmol) as yellow solid. Yield: 650 mg, 77.7% [00381] Step-2: To a stirred solution of N-(4-fluoro-3-nitrophenyl)pyridine-2-carboxamide (400 mg, 1.53 mmol) and N, N-Diisopropylethylamine (802 µL, 3 eq., 4.59 mmol) in N-Methyl-2-Pyrrolidone (NMP) (5.00 mL), 3-methyloxetan-3-amine (138 µL, 2 eq., 3.06 mmol) was added at room temperature and stirred at 100°C for 16h. After completion, reaction mixture quenched with ice cold water, precipitate was formed. The solid was filtered and dried to afford N-{4-[(3-methyloxetan-3-yl)amino]-3- nitrophenyl}pyridine-2-carboxamide (500 mg, 1.52 mmol) as a yellow solid. Yield: 500 mg, 99% [00382] Step-3: To a solution of N-{4-[(3-methyloxetan-3-yl)amino]-3-nitrophenyl}pyridine-2- carboxamide (300 mg, 914 µmol) in methanol (20.0 mL) was added zinc (299 mg, 5 eq., 4.57 mmol) at room temperature and the reaction mixture stirred for 3h under hydrogen atmosphere. After completion, the reaction mixture passed through celite bed. The filtrate was concentrated at room temperature to get as N-{3-amino-4-[(3-methyloxetan-3-yl)amino]phenyl}pyridine-2-c arboxamide (270 mg, 905 µmol) brown color solid. Yield: 270 mg, 99% [00383] Step-4: To a stirred solution of N-{3-amino-4-[(3-methyloxetan-3-yl)amino]phenyl}pyridine-2- carboxamide (203 mg, 681 µmol) and 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (200 mg, 0.8 eq., 545 µmol) in methanesulfinylmethane (3.00 mL), disodium sulfinatosulfonate (194 mg, 1.5 eq., 1.02 mmol) was added at room temperature. The resulting mixture stirred for 16h at 80 °C. After completion, water and ethyl acetate was added to reaction mixture. The organic fractions were collected, dried over anhydrous sodium sulfate, filtered and concentrated to get crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford N-{2-[3,4-bis(benzyloxy)-2-fluoro-5- methoxyphenyl]-1-(3-methyloxetan-3-yl)-1H-1,3-benzodiazol-5- yl}pyridine-2-carboxamide (240 mg, 372 µmol) as sticky solid. Yield: 240 mg, 54.65% [00384] Step-5: To N-{2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-meth yloxetan-3-yl)-1H- 1,3-benzodiazol-5-yl}pyridine-2-carboxamide (150 mg, 233 µmol) trifluoroacetic acid (2.00 mL) added at room temperature. The resulting reaction mixture stirred at 60 °C for 4 h. After the complete consumption of starting material, reaction mixture was concentrated to obtain the crude. The crude purified in reverse-phase HPLC and desired fraction were collected, lyophilized to obtain N-[2-(2-fluoro- 3,4-dihydroxy-5-methoxyphenyl)-1-(3-methyloxetan-3-yl)-1H-1, 3-benzodiazol-5-yl]pyridine-2- carboxamide (15.0 mg, 32.3 µmol) as off white solid. Yield: 15 mg, 13.88% [00385] LCMS and NMR Data: ES MS M/Z = 464.96 (M + 1); UPLC: 97.40%; 1 H NMR (400 MHz, DMSO-d6) δ 10.71(s, 1H), 9.49 (s, 1H), 9.39 (s, 1H), 8.76 (d, J = 4.8 Hz,1H), 8.32 (d, J = 1.6 Hz, 1H), 8.19 (d, J = 8.0 Hz, 1H), 8.17-8.06 (m, 1H), 7.77 (dd, J = 6.8, 2.0, 1H), 7.70-7.67 (m, 1H), 7.26 (d, J = 8.8 Hz, 1H), 6.61 (d, J = 6.0 Hz, 1H), 4.73 (d, J = 6.0 Hz, 2H) 4.39 (d, J = 6.0 Hz, 2H), 3.80 (s, 3H), 2.02 (s, 3H) Example 204: Synthesis of N-[2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(3-methyloxe tan-3- yl)-1H-1,3-benzodiazol-5-yl]cyclopropanecarboxamide [00386] Step-1: To a stirred solution of 4-fluoro-3-nitroaniline (800 mg, 5.12 mmol) in N,N- dimethylformamide (5.00 mL) was added cyclopropanecarboxylic acid (441 mg, 5.12 mmol) , hexafluoro-λ⁵-phosphanuide 1-[bis(dimethylamino)methylidene]-1H-1λ⁵-[1,2,3]triazolo[ 4,5-b]pyridin-3- ium-1-ylium-3-olate (2.92 g, 1.5 eq., 7.69 mmol) and ethylbis(propan-2-yl)amine (2.68 mL, 3 eq., 15.4 mmol) and the solution was stirred for 16 hours. After completion of reaction, the reaction mixture diluted with water and extracted with ethyl acetate. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to obtain crude. The crude was purified by flash chromatography. The desired fractions concentrated to afford N-(4-fluoro-3-nitrophenyl)cyclopropanecarboxamide (700 mg, 3.12 mmol) as yellow solid. Yield: 700 mg, 60.93% [00387] Step-2: To a stirred solution of N-(4-fluoro-3-nitrophenyl)cyclopropanecarboxamide (500 mg, 2.23 mmol) in N, N-Diisopropylethylamine (1.17 mL, 3 eq., 6.69 mmol) in N-Methyl-2-Pyrrolidone (NMP) (5.00 mL), 3-methyloxetan-3-amine (201 µL, 2 eq., 4.46 mmol) was added at room temperature and stirred at 80°C for 16 h. After completion, reaction mixture quenched with ice cold water, precipitate was formed. solid was filtered and dried to afford N-{4-[(3-methyloxetan-3-yl)amino]-3- nitrophenyl}cyclopropanecarboxamide (575 mg, 1.97 mmol) as a yellow solid. Yield: 510 mg, 69% [00388] Step-3: To a solution of N-{4-[(3-methyloxetan-3-yl)amino]-3- nitrophenyl}cyclopropanecarboxamide (350 mg, 1.20 mmol) in methanol (20.0 mL) was added zinc (393 mg, 5 eq., 6.01 mmol) and ammonium chloride (321 mg, 5 eq., 6.01 mmol) at room temperature and the reaction mixture stirred for 3h under hydrogen atmosphere. After completion, the reaction mixture passed through celite bed. Filtrate was concentrated at room temperature to get as N-{3-amino-4-[(3- methyloxetan-3-yl)amino]phenyl}cyclopropanecarboxamide (250 mg, 957 µmol) yellow color solid. Yield: 250 mg, 79.62% [00389] Step-4: To a stirred solution of N-{3-amino-4-[(3-methyloxetan-3 yl)amino]phenyl}cyclopropanecarboxamide (178 mg, 681 µmol) and 3,4-bis(benzyloxy)-2-fluoro-5- methoxybenzaldehyde (200 mg, 0.8 eq., 545 µmol) in methanesulfinylmethane (3.00 mL), disodium sulfinatosulfonate (194 mg, 1.5 eq., 1.02 mmol) was added at room temperature. The resulting mixture stirred for 16h at 80 °C. After completion, water and ethyl acetate was added to reaction mixture. The organic fractions were collected, dried over anhydrous sodium sulfate, filtered and concentrated to get crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford N- {2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methyl oxetan-3-yl)-1H-1,3-benzodiazol-5- yl}cyclopropanecarboxamide (180 mg, 296 µmol) as yellow solid. Yield: 180 mg, 43.49% [00390] Step-5: To N-{2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-meth yloxetan-3-yl)-1H- 1,3-benzodiazol-5-yl}cyclopropanecarboxamide (170 mg, 280 µmol), trifluoroacetic acid (2.00 mL) added at room temperature. The resulting reaction mixture stirred at 60 °C for 4 h. After the complete consumption of starting material, reaction mixture was concentrated to obtain the crude. The crude purified in reverse-phase HPLC and desired fraction were collected, lyophilized to obtain N-[2-(2-fluoro- 3,4-dihydroxy-5-methoxyphenyl)-1-(3-methyloxetan-3-yl)-1H-1, 3-benzodiazol-5- yl]cyclopropanecarboxamide (19.0 mg, 44.5 µmol) as off white solid. Yield: 19 mg, 15.89% [00391] LCMS and NMR Data: ES MS M/Z = 428.21 (M + 1); UPLC: 99.77%; 1H NMR (400 MHz, DMSO-d6) δ 10.20 (s, 1H), 9.43 (bs, 2H), 8.01 (s, 1H), 7.41 (d, J = 9.2 Hz, 1H), 7.19 (d, J = 8.8 Hz, 1H), 6.58 (d, J = 6.4 Hz, 1H), 4.70 (d, J = 5.6 Hz, 2H), 4.35 (d, J = 5.2 Hz, 2H), 3.78 (s, 3H), 1.99 (s, 3H), 1.78-1.75 (m, 1H), 0.81-0.78 (m, 4H) Example 205: Synthesis of N-(3,3-difluorocyclobutyl)-2-(2-fluoro-3,4-dihydroxy-5-metho xyphenyl)- 1-(3-methyloxetan-3-yl)-1H-benzo[d]imidazole-6-carboxamide
[00392] Step:1 To a stirred solution of methyl 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazole-6-carboxylate (150 mg, 257 µmol) in oxolane (1.20 mL) and water (400 µL) was added lithium hydroxide (30.8 mg, 5 eq., 1.29 mmol). The reaction mixture was heated at 40°C for 16 h. After completion of reaction, reaction mixture was acidified with 2N HCl and extracted with ethyl acetate. The organic layer was separated, dried over sodium sulphate, filtered and concentrated under reduced pressure to get the crude. The crude was purified by flash chromatography. The desired fractions concentrated to get 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazole-6-carboxylic acid (135 mg, 230 µmol) as pale yellow crystalline solid. Yield: 0.135 g, 89% [00393] Step:2 To a stirred solution of 3,3-difluorocyclobutan-1-amine hydrochloride (32.8 mg, 229 µmol) and 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methylo xetan-3-yl)-1H-1,3- benzodiazole-6-carboxylic acid (130 mg, 229 µmol) in N,N-dimethylformamide (2.00 mL) was added hexafluoro-λ⁵-phosphanuide 1-[bis(dimethylamino)methylidene]-1H-1λ⁵-[1,2,3]triazolo[ 4,5-b]pyridin-3- ium-1-ylium-3-olate (130 mg, 1.5 eq., 343 µmol) and ethylbis(propan-2-yl)amine (119 µL, 3 eq., 686 µmol) and the solution was stirred at room temperature for 16 hours. After completion of reaction, the reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to obtain crude. The crude was purified by flash chromatography. The desired fractions concentrated to afford 2-[3,4-bis(benzyloxy)-2-fluoro-5- methoxyphenyl]-N-(3,3-difluorocyclobutyl)-1-(3-methyloxetan- 3-yl)-1H-1,3-benzodiazole-6- carboxamide (75.0 mg, 106 µmol) as yellow sticky solid. Yield: 0.075 g, (46%) [00394] Step:3 To 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-N-(3,3-diflu orocyclobutyl)-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazole-6-carboxamide (75.0 mg, 114 µmol) was added trifluoroacetic acid (1.00 mL) and the resulting solution was stirred for 3 h at 50 °C. After completion, reaction mixture was concentrated under reduced pressure to get the crude and further purified by reverse phase HPLC. Desired fractions were lyophilized to afford N-(3,3-difluorocyclobutyl)-2-(2-fluoro-3,4-dihydroxy-5- methoxyphenyl)-1-(3-methyloxetan-3-yl)-1H-1,3-benzodiazole-6 -carboxamide as white solid. Yield: 0.02 g, 36% [00395] 1H NMR: ES MS M/Z=443 (M+1), NMR (400 MHz, DMSO-d6) δ 9.41 (br s, 1H), 7.70 (d, 1H), 7.64 (d, 1H), 7.21 (d, 1H), 6.57 (d, 1H), 4.70 (d, 2H), 4.37 (d, 2H), 3.84 (t, 2H), 3.78 (s, 3H), 3.45 (t, 2H), 2.78 (s, 3H), 2.00 (s, 3H), 1.23 (s, 1H). Example 206: Synthesis of N-(2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(3-methyloxe tan-3- yl)-1H-benzo[d]imidazol-5-yl)isoxazole-4-carboxamide [00396] Step-1: To a stirred solution of tert-butyl N-(4-fluoro-3-nitrophenyl)carbamate (500 mg, 1.95 mmol) and 3-methyloxetan-3-amine (131 µL, 1.5 eq., 2.93 mmol) in 1-methylpyrrolidin-2-one (5.00 mL) was added ethylbis(propan-2-yl)amine (1.02 mL, 3 eq., 5.85 mmol) and the solution was stirred for 16 hours at 110 °C. After completion of reaction, the reaction mixture diluted with water and extracted with ethyl acetate. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to obtain tert-butyl N-{4-[(3-methyloxetan-3-yl)amino]-3-nitrophenyl}carbamate (600 mg, 816 µmol) (crude) as yellow liquid. Yield: 0.60 g, Crude [00397] Step-2: To a stirred solution of tert-butyl N-{4-[(3-methyloxetan-3-yl)amino]-3- nitrophenyl}carbamate (300 mg, 928 µmol) in methanol (5.00 mL) was added zinc (303 mg, 5 eq., 4.64 mmol) and ammonium chloride (248 mg, 5 eq., 4.64 mmol) were added at room temperature and stirred at 50°C for 1h. After completion of the reaction, reaction mixture was passed through celite and washed with 10% methanol in dichloromethane, filtrate was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure to get tert-butyl N-{3-amino-4-[(3-methyloxetan-3- yl)amino]phenyl}carbamate (250 mg, 648 µmol) (crude) as brown solid. Yield: 0.25 g, Crude [00398] Step-3: To a stirred solution of disodium sulfinatosulfonate (144 mg, 1.2 eq., 757 µmol) and 3,4- bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (185 mg, 0.8 eq., 504 µmol) in methanesulfinylmethane (5.00 mL) was added disodium sulfinatosulfonate (144 mg, 1.2 eq., 757 µmol) at room temperature. The resulting mixture stirred for 16 h at 85 °C. After completion, reaction mixture cooled to room temperature and diluted with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to get crude. The crude purified by flash chromatography. The desired fractions concentrated to afford tert-butyl N-{2- [3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methyloxe tan-3-yl)-1H-1,3-benzodiazol-5- yl}carbamate (240 mg, 315 µmol) as off white solid. Yield: 0.24 g, 49.97% [00399] Step-4: To a stirred solution of tert-butyl N-{2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]- 1-(3-methyloxetan-3-yl)-1H-1,3-benzodiazol-5-yl}carbamate (240 mg, 375 µmol) in dichloromethane (5.00 mL), 4 M hydrochloride in 1,4-Dioxane (5.00 mL) was added and stirred at room temperature for 3h. After completion of reaction, reaction mixture was concentrated to get 2-[3,4-bis(benzyloxy)-2- fluoro-5-methoxyphenyl]-1-(3-methyloxetan-3-yl)-1H-1,3-benzo diazol-5-amine hydrochloride (200 mg, 316 µmol) as off-white solid. Yield: 0.20 g, 84.22% [00400] Step-5: To a stirred solution of 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazol-5-amine (200 mg, 347 µmol) and 1,2-oxazole-4-carboxylic acid (47.1 mg, 1.2 eq., 417 µmol) in dichloromethane (5.00 mL) was added triethylamine (109 mg, 3.1 eq., 1.08 mmol) and tripropyl-1,3,5,2λ⁵,4λ⁵,6λ⁵-trioxatriphosphinane-2, 4,6-trione (707 µL, 3.2 eq., 1.11 mmol) and the solution was stirred for 16 hours at room temperature. After completion of reaction, the reaction mixture diluted with water and extracted with dichloromethane. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to obtain crude. Crude was purified by flash chromatography. Desired fractions were concentrated to get N-{2-[3,4-bis(benzyloxy)-2-fluoro-5- methoxyphenyl]-1-(3-methyloxetan-3-yl)-1H-1,3-benzodiazol-5- yl}-1,2-oxazole-4-carboxamide (140 mg, 207 µmol) as light brown oil. Yield: 0.14 g, 59.72% [00401] Step-6: To a solution of N-{2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazol-5-yl}-1,2-oxazole-4-ca rboxamide (80.0 mg, 126 µmol) in trifluoroacetic acid (1.50 mL) was stirred for 3h at 55 °C. After completion, the reaction mixture was concentrated to get crude. Crude was purified by reverse phase HPLC and pure fractions were lyophilized to get N-[2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(3-methyloxe tan-3-yl)-1H-1,3- benzodiazol-5-yl]-1,2-oxazole-4-carboxamide (26.0 mg, 53.8 µmol) as off white solid. Yield: 0.026 g, 42.67% [00402] ES MS M/Z = 455.28 (M +1), 1H NMR (400 MHz, DMSO-d6) δ 10.33 (s, 1H), 9.60 (s, 1H), 9.54-9.47 (m, 2H), 8.13 (d, 1H), 7.54 (m, 1H), 7324 (m, 1H), 6.62 (d, 1H), 4.74 (d, 2H), 4.39 (d, 2H), 3.79 (s, 3H), 2.03 (s, 3H). Example 207: Synthesis of N-[2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(3-methyloxe tan-3- yl)-1H-1,3-benzodiazol-6-yl]acetamide [00403] Step-1: To a stirred solution of 3-fluoro-4-nitroaniline (1.00 g, 6.41 mmol) in dichloromethane (10.0 mL), acetyl acetate (666 µL, 1.1 eq., 7.05 mmol) was added and stirred at room temperature for 16h. After completion of reaction, reaction mixture diluted with water and extracted with dichloromethane. The combined organic layers were dried over anhydrous sodium sulphate, filtered and concentrated to afford N-(3-fluoro-4-nitrophenyl)acetamide (840 mg, 4.24 mmol) as off-white solid. Yield: 840 mg, 66.18% [00404] Step-2: To a stirred solution of N-(3-fluoro-4-nitrophenyl)acetamide (345 mg, 1.74 mmol) and N, N-Diisopropylethylamine (912 µL, 3 eq., 5.22 mmol) in N-Methyl-2-Pyrrolidone (NMP) (5.00 mL), 3- methyloxetan-3-amine (157 µL, 2 eq., 3.48 mmol) was added at room temperature and stirred at 100°C for 16h. After completion, reaction mixture quenched with ice cold water, precipitate was formed. The solid was filtered and dried to afford N-{3-[(3-methyloxetan-3-yl)amino]-4-nitrophenyl}acetamide (395 mg, 1.49 mmol) as a yellow solid. Yield: 395 mg, 85.52% [00405] Step-3: To a solution of N-{3-[(3-methyloxetan-3-yl)amino]-4-nitrophenyl}acetamide (250 mg, 942 µmol) in methanol (20.0 mL) was added zinc (308 mg, 5 eq., 4.71 mmol) followed by addition of ammonium chloride (252 mg, 5 eq., 4.71 mmol) at room temperature and the reaction mixture stirred for 3h under hydrogen atmosphere. After completion, the reaction mixture diluted with dichloromethane and passed through celite bed. water was added to filtrate and extracted with 10% methanol in dichloromethane solution. The organic fraction collected, dried over anhydrous sodium sulphate, concentrated to obtain N-{4-amino-3-[(3-methyloxetan-3-yl)amino]phenyl}acetamide (130 mg, 553 µmol) as brown liquid. Yield: 130 mg, 58.63% [00406] Step-4: To a stirred solution of N-{4-amino-3-[(3-methyloxetan-3-yl)amino]phenyl}acetamide (125 mg, 531 µmol) and 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (156 mg, 0.8 eq., 425 µmol) in methanesulfinylmethane (3.00 mL), disodium sulfinatosulfonate (151 mg, 1.5 eq., 797 µmol) was added at room temperature. The resulting mixture stirred for 16h at 80 °C. After completion, water and ethyl acetate was added to reaction mixture. The organic fractions were collected, dried over anhydrous sodium sulfate, filtered and concentrated to get crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford N-{2-[3,4-bis(benzyloxy)-2-fluoro-5- methoxyphenyl]-1-(3-methyloxetan-3-yl)-1H-1,3-benzodiazol-6- yl}acetamide (150 mg, 224 µmol) as yellow solid. Yield: 150 mg, 42.23% [00407] Step-5: A dried round bottom flask was charged with N-{2-[3,4-bis(benzyloxy)-2-fluoro-5- methoxyphenyl]-1-(3-methyloxetan-3-yl)-1H-1,3-benzodiazol-6- yl}acetamide (150 mg, 258 µmol) and trifluoroacetic acid (1.00 mL) at room temperature. The resulting reaction mixture stirred at 60 °C for 4 h. After the complete consumption of starting material, reaction mixture was concentrated to obtain the crude. The crude purified by reverse-phase High performance liquid chromatography. The desired fractions were collected and lyophilized to obtain N-[2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazol-6-yl]acetamide (71.0 mg, 177 µmol) as off white solid. Yield: 71 mg, 68.59% [00408] 1H NMR and LCMS data: ES MS M/Z = 402.07 [M+H] + ; UPLC: 99.19%; 1H NMR (400 MHz, DMSO-d6) δ 10.05 (s, 1H), 9.43 (Bs, 2H), 7.71 (s, 1H), 7.59 (d, J = 8.8 Hz, 1H), 7.31-7.29 (m, 1H), 6.58 (d, J = 6.0 Hz, 1H), 4.73 (d, J = 6.0 Hz, 2H), 4.29 (d, J = 6.0 Hz, 2H), 3.78 (s, 3H), 2.06 (s, 1H), 2.00 (s, 3H). Example 208: Synthesis of N-[2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(3-methyloxe tan-3- yl)-1H-1,3-benzodiazol-6-yl]acetamide [00409] Step-1: To a stirred solution of 3-fluoro-4-nitroaniline (1.00 g, 6.41 mmol) in dichloromethane (10.0 mL), acetyl acetate (666 µL, 1.1 eq., 7.05 mmol) was added and stirred at room temperature for 16h. After completion of reaction, reaction mixture diluted with water and extracted with dichloromethane. The combined organic layers were dried over anhydrous sodium sulphate, filtered and concentrated to afford N-(3-fluoro-4-nitrophenyl)acetamide (840 mg, 4.24 mmol) as off-white solid. Yield: 840 mg, 66.18% [00410] Step-2: To a stirred solution of N-(3-fluoro-4-nitrophenyl)acetamide (345 mg, 1.74 mmol) and N, N-Diisopropylethylamine (912 µL, 3 eq., 5.22 mmol) in N-Methyl-2-Pyrrolidone (NMP) (5.00 mL), 3- methyloxetan-3-amine (157 µL, 2 eq., 3.48 mmol) was added at room temperature and stirred at 100°C for 16h. After completion, reaction mixture quenched with ice cold water, precipitate was formed. The solid was filtered and dried to afford N-{3-[(3-methyloxetan-3-yl)amino]-4-nitrophenyl}acetamide (395 mg, 1.49 mmol) as a yellow solid. Yield: 395 mg, 85.52% [00411] Step-3: To a solution of N-{3-[(3-methyloxetan-3-yl)amino]-4-nitrophenyl}acetamide (250 mg, 942 µmol) in methanol (20.0 mL) was added zinc (308 mg, 5 eq., 4.71 mmol) followed by addition of ammonium chloride (252 mg, 5 eq., 4.71 mmol) at room temperature and the reaction mixture stirred for 3h under hydrogen atmosphere. After completion, the reaction mixture diluted with dichloromethane and passed through celite bed. water was added to filtrate and extracted with 10% methanol in dichloromethane solution. The organic fraction collected, dried over anhydrous sodium sulphate, concentrated to obtain N-{4-amino-3-[(3-methyloxetan-3-yl)amino]phenyl}acetamide (130 mg, 553 µmol) as brown liquid. Yield: 130 mg, 58.63% [00412] Step-4: To a stirred solution of N-{4-amino-3-[(3-methyloxetan-3-yl)amino]phenyl}acetamide (125 mg, 531 µmol) and 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (156 mg, 0.8 eq., 425 µmol) in methanesulfinylmethane (3.00 mL), disodium sulfinatosulfonate (151 mg, 1.5 eq., 797 µmol) was added at room temperature. The resulting mixture stirred for 16h at 80 °C. After completion, water and ethyl acetate was added to reaction mixture. The organic fractions were collected, dried over anhydrous sodium sulfate, filtered and concentrated to get crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford N-{2-[3,4-bis(benzyloxy)-2-fluoro-5- methoxyphenyl]-1-(3-methyloxetan-3-yl)-1H-1,3-benzodiazol-6- yl}acetamide (150 mg, 224 µmol) as yellow solid. Yield: 150 mg, 42.23% [00413] Step-5: A dried round bottom flask was charged with N-{2-[3,4-bis(benzyloxy)-2-fluoro-5- methoxyphenyl]-1-(3-methyloxetan-3-yl)-1H-1,3-benzodiazol-6- yl}acetamide (150 mg, 258 µmol) and trifluoroacetic acid (1.00 mL) at room temperature. The resulting reaction mixture stirred at 60 °C for 4 h. After the complete consumption of starting material, reaction mixture was concentrated to obtain the crude. The crude purified by reverse-phase High performance liquid chromatography. The desired fractions were collected and lyophilized to obtain N-[2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazol-6-yl]acetamide (71.0 mg, 177 µmol) as off white solid. Yield: 71 mg, 68.59% [00414] 1H NMR and LCMS data: ES MS M/Z = 402.07 [M+H] + ; UPLC: 99.19%; 1H NMR (400 MHz, DMSO-d6) δ 10.05 (s, 1H), 9.43 (Bs, 2H), 7.71 (s, 1H), 7.59 (d, J = 8.8 Hz, 1H), 7.31-7.29 (m, 1H), 6.58 (d, J = 6.0 Hz, 1H), 4.73 (d, J = 6 Hz, 2H), 4.29 (d, J = 6 Hz, 2H), 3.78 (s, 3H), 2.06 (s, 1H), 2.00 (s, 3H). Example 209: Synthesis of N-[2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(3-methyloxe tan-3- yl)-1H-1,3-benzodiazol-4-yl]acetamide [00415] Step-1: To a stirred solution of 3-fluoro-2-nitroaniline (1.00 g, 6.41 mmol) in dichloromethane (10.0 mL), acetyl acetate (666 µL, 1.1 eq., 7.05 mmol) was added and stirred at room temperature for 16h. After completion of reaction, reaction mixture diluted with water and extracted with dichloromethane. The combined organic layers were dried over anhydrous sodium sulphate, filtered and concentrated to afford N-(3-fluoro-2-nitrophenyl)acetamide (888 mg, 4.48 mmol) as off-white solid. Yield: 0.888 g, 69.96% [00416] Step-2: To a stirred solution of N-(3-fluoro-2-nitrophenyl)acetamide (345 mg, 1.74 mmol) and N, N-Diisopropylethylamine (912 µL, 3 eq., 5.22 mmol) in N-Methyl-2-Pyrrolidone (NMP) (5.00 mL), 3- methyloxetan-3-amine (157 µL, 2 eq., 3.48 mmol) was added at room temperature and stirred at 100°C for 16h. After completion, reaction mixture quenched with ice cold water, precipitate was formed. solid was filtered and dried to afford N-{3-[(3-methyloxetan-3-yl)amino]-2-nitrophenyl}acetamide (370 mg, 1.39 mmol) as a yellow solid. Yield: 370 mg, 80% [00417] Step-3: To a solution of N-{3-[(3-methyloxetan-3-yl)amino]-2-nitrophenyl}acetamide (300 mg, 1.13 mmol) in methanol (20.0 mL) was added zinc (370 mg, 5 eq., 5.65 mmol) followed by addition of ammonium chloride (302 mg, 5 eq., 5.65 mmol) at room temperature and the reaction mixture stirred for 3h under hydrogen atmosphere. After completion, the reaction mixture diluted with dichloromethane and passed through celite bed. Then water was added to filtrate and extracted with 10% methanol in dichloromethane solution. The organic fraction collected, dried over anhydrous sodium sulfate, concentrated to obtain N-{2-amino-3-[(3-methyloxetan-3-yl)amino]phenyl}acetamide (230 mg, 978 µmol) as brown liquid. Yield: 230 mg, 86.44% [00418] Step-4: To a stirred solution of N-{2-amino-3-[(3-methyloxetan-3-yl)amino]phenyl}acetamide (120 mg, 510 µmol) and 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (149 mg, 0.8 eq., 408 µmol) in methanesulfinylmethane (3.00 mL), disodium sulfinatosulfonate (145 mg, 1.5 eq., 765 µmol) was added at room temperature. The resulting mixture stirred for 16h at 80 °C. After completion, water and ethyl acetate was added to reaction mixture. The organic fractions were collected, dried over anhydrous sodium sulfate, filtered and concentrated to get crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford N-{2-[3,4-bis(benzyloxy)-2-fluoro-5- methoxyphenyl]-1-(3-methyloxetan-3-yl)-1H-1,3-benzodiazol-4- yl}acetamide (100 mg, 167 µmol) as yellow solid. Yield: 100 mg, 32.70% [00419] Step-5: To N-{2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-meth yloxetan-3-yl)-1H- 1,3-benzodiazol-4-yl}acetamide (90.0 mg, 155 µmol), trifluoroacetic acid (2.00 mL) was added at room temperature. The resulting reaction mixture stirred at 60 °C for 4 h. After the complete consumption of starting material, reaction mixture was concentrated to obtain the crude. The crude purified by reverse- phase High performance liquid chromatography. The desired fractions were collected and lyophilized to obtain N-[2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(3-methyloxe tan-3-yl)-1H-1,3-benzodiazol-4- yl]acetamide (25.0 mg, 62.3 µmol) as off white solid. Yield: 25 mg, 40.25% [00420] 1H NMR and LCMS data: ES MS M/Z = 402.07 [M+H] + ; UPLC: 98.09% ; 1 H NMR (400 MHz, DMSO-d6) δ 9.91 (s, 1H), 9.41 (bs, 2H), 8.00 (d, J = 7.6 Hz, 1H), 7.18 (t, J = 9.04 Hz, 1H), 6.94 (d, J = 8.0 Hz, 1H), 6.62 (d, J = 6.0 Hz, 1H), 4.77 (d, J = 6.0 Hz, 2H), 4.35 (d, J = 6.0 Hz, 2H), 3.77 (s, 3H), 2.16 (s, 1H), 1.98 (s, 3H) Example 210: Synthesis of N-[2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(3-methyloxe tan-3- yl)-1H-1,3-benzodiazol-7-yl]acetamide
[00421] Step-1: To a stirred solution of 2-fluoro-3-nitroaniline (1.00 g, 6.41 mmol), acetyl acetate (666 µL, 1.1 eq., 7.05 mmol) was added and stirred at room temperature for 16h. After completion of reaction, reaction mixture diluted with water and extracted with dichloromethane. The combined organic layers were dried over anhydrous sodium sulphate, filtered and concentrated to afford N-(2-fluoro-3- nitrophenyl)acetamide (890 mg, 4.49 mmol) as off-white solid. Yield: 890 mg g, 70.12% [00422] Step-2: To a stirred solution of N-(2-fluoro-3-nitrophenyl)acetamide (345 mg, 1.74 mmol) and N, N-Diisopropylethylamine (912 µL, 3 eq., 5.22 mmol) in N-Methyl-2-Pyrrolidone (NMP) (5.00 mL), 3-methyloxetan-3-amine (157 µL, 2 eq., 3.48 mmol) was added at room temperature and stirred at 100°C for 16h. After completion, reaction mixture quenched with ice cold water, precipitate was formed. The solid was filtered and dried to afford N-{2-[(3-methyloxetan-3-yl)amino]-3-nitrophenyl}acetamide (170 mg, 641 µmol) as orange solid. Yield: 170 mg, 36.81% [00423] Step-3: To a solution of N-{2-[(3-methyloxetan-3-yl)amino]-3-nitrophenyl}acetamide (170 mg, 641 µmol) in methanol (20.0 mL) was added zinc (209 mg, 5 eq., 3.20 mmol) followed by addition of ammonium chloride (171 mg, 5 eq., 3.20 mmol) at room temperature and the reaction mixture stirred for 3h under hydrogen atmosphere. After completion, the reaction mixture diluted with dichloromethane and passed through celite bed. Then water was added to filtrate and extracted with 10% methanol in dichloromethane solution. The organic fraction collected, dried over anhydrous sodium sulphate, concentrated to obtain N-{3-amino-2-[(3-methyloxetan-3-yl)amino]phenyl}acetamide (140 mg, 518 µmol) as brown liquid. Yield: 140 mg, 80.78% [00424] Step-4: To a stirred solution of N-{3-amino-2-[(3-methyloxetan-3-yl)amino]phenyl}acetamide (140 mg, 595 µmol) and 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (174 mg, 0.8 eq., 476 µmol) in methanesulfinylmethane (3.00 mL), disodium sulfinatosulfonate (170 mg, 1.5 eq., 893 µmol) was added at room temperature. The resulting mixture stirred for 16h at 80 °C. After completion, water and ethyl acetate was added to reaction mixture. The organic fractions were collected, dried over anhydrous sodium sulfate, filtered and concentrated to get crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford N-{2-[3,4-bis(benzyloxy)-2-fluoro-5- methoxyphenyl]-1-(3-methyloxetan-3-yl)-1H-1,3-benzodiazol-7- yl}acetamide (155 mg, 245 µmol) as off white solid. Yield: 180 mg, 43.49% [00425] Step-5: To N-{2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-meth yloxetan-3-yl)-1H- 1,3-benzodiazol-7-yl}acetamide (150 mg, 258 µmol) trifluoroacetic acid (1.00 mL) added at room temperature. The resulting reaction mixture stirred at 60 °C for 4 h. After the complete consumption of starting material, reaction mixture was concentrated to obtain the crude. The crude was purified by reverse phase HPLC and desired fractions were collected and lyophilized to obtain N-[2-(2-fluoro-3,4- dihydroxy-5-methoxyphenyl)-1-(3-methyloxetan-3-yl)-1H-1,3-be nzodiazol-7-yl]acetamide (13.0 mg, 32.4 µmol) as off white solid. Yield: 13 mg, 12.56% [00426] LCMS and NMR Data: ES MS M/Z = 402.28 (M +1) + , UPLC: 99.49% 1H NMR (400 MHz, DMSO-d6) δ 9.24 (bs, 1H), 7.19-7.15 (m, 1 H), 6.97 (d, J = 8.4 Hz,1H), 6.76 (d, J = 6.0 Hz, 1H), 6.61 (d, J = 7.6 Hz, 1H), 4.18 (d, J = 11.6 Hz,1H), 4.09 (d, J = 11.6 Hz,1H), 3.79 (s, 3H), 3.52 (d, J = 12.4 Hz,1H), 3.32 (d, J = 12.8 Hz,1H), 1.91 (s, 3H), 1.31 (s, 3H) Example 211: Synthesis of methyl 2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(3-methyloxetan - 3-yl)-1H-benzo[d]imidazole-6-carboxylate [00427] Step-1: To a stirred solution of 3-methyloxetan-3-amine (691 µL, 1.5 eq., 15.1 mmol) in N- Methyl-2-Pyrrolidone (NMP) (5.00 mL), 3-methyloxetan-3-amine (691 µL, 1.5 eq., 15.1 mmol) and N, N-Diisopropylethylamine (5.26 mL, 3 eq., 30.1 mmol) was added at room temperature and stirred at 130°C for 1h. After completion, reaction mixture quenched with ice cold water , precipitate was formed . solid was filtered and dried to afford methyl 4-[(3-methyloxetan-3-yl)amino]-3-nitrobenzoate (600 mg, 2.25 mmol) as a yellow solid. Yield: 0.60 g, 89% [00428] Step-2: To a stirred solution of methyl 3-[(3-methyloxetan-3-yl)amino]-4-nitrobenzoate (700 mg, 2.63 mmol) in methanol (10.0 mL) , zinc (859 mg, 5 eq., 13.1 mmol) and ammonium chloride (703 mg, 5 eq., 13.1 mmol) were added at room temperature and stirred at 50°C for 1h. After completion of the reaction, reaction mixture was passed through celite and washed with dichloromethane, filtrate was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure to get crude. Yield: 0.600 g, 59% [00429] Step-3: To a stirred solution of 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (595 mg, 0.8 eq., 1.63 mmol) and methyl 4-amino-3-[(3-methyloxetan-3-yl)amino]benzoate (600 mg, 2.03 mmol) in methanesulfinylmethane (6.00 mL), disodium sulfinatosulfonate (579 mg, 1.5 eq., 3.05 mmol) was added at room temperature. The resulting mixture stirred for 16 h at 80 °C. After completion, ice cold water was added in the reaction mixture and solid was filtered and dried to get crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford methyl 2-[3,4- bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methyloxetan-3 -yl)-1H-1,3-benzodiazole-6-carboxylate (700 mg, 1.14 mmol) as sticky solid. Yield: 0.700 g, 56% [00430] Step-4: To a solution of methyl 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazole-6-carboxylate (100 mg, 172 µmol) in trifluoroacetic acid (2.00 mL) was stirred for 3h under. After completion, the reaction mixture was concentrated to get crude. Crude was purified by reverse phase HPLC and desired fractions were lyophilized to get methyl 2-(2- fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(3-methyloxetan-3-yl )-1H-1,3-benzodiazole-6-carboxylate (45.0 mg, 111 µmol) as white solid. Yield: 0.045 g, 64.51% [00431] ES MS M/Z = 403.29 (M +1), 1H NMR (400 MHz, DMSO-d6) δ 9.52 (brs, 2H), 7.92 (dd, J = 8.4,1.2 Hz, 1H), 7.81-7.79 (m, 1H), 7.75 (s, 1H), 6.642 (d, J = 6.4 Hz, 1H), 4.77 (d, J = 5.6 Hz, 2H), 4.42 (d, J = 6 Hz, 2H), 3.89 (s, 3H), 3.79 (s, 3H), 2.05 (s, 3H). Example 212: Synthesis of 2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-N-methyl-1-(3- methyloxetan-3-yl)-1H-benzo[d]imidazole-6-carboxamide [00432] Step-1: To a stirred solution of 3-methyloxetan-3-amine (437 mg, 2 eq., 5.02 mmol) in N- Methyl-2-Pyrrolidone (NMP) (5.00 mL), methyl 4-[(3-methyloxetan-3-yl)amino]-3-nitrobenzoate (600 mg, 2.25 mmol) and N, N-Diisopropylethylamine (1.32 mL, 3 eq., 7.53 mmol) was added at room temperature and stirred at 130°C for 1h.. After completion, reaction mixture quenched with ice cold water, precipitate was formed. solid was filtered and dried to afford methyl 4-[(3-methyloxetan-3- yl)amino]-3-nitrobenzoate (600 mg, 2.25 mmol) as a yellow solid. Yield: 0.60 g, 89% [00433] Step-2: To a stirred solution of methyl 4-[(3-methyloxetan-3-yl)amino]-3-nitrobenzoate (500 mg, 1.88 mmol) in methanol (10.0 mL) , zinc (614 mg, 5 eq., 9.39 mmol) and ammonium chloride (502 mg, 5 eq., 9.39 mmol) were added at room temperature and stirred at 40°C for 1h. After completion of the reaction, reaction mixture was passed through celite, filtrate was extracted with dichloromethane and concentrated under reduced pressure to get the crude methyl 4-amino-3-((3-methyloxetan-3- yl)amino)benzoate (400 mg, 1.13 mmol). Yield: 0.40 g, Crude [00434] Step-3: To a stirred solution of methyl 4-amino-3-[(3-methyloxetan-3-yl)amino]benzoate (220 mg, 931 µmol) and 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (273 mg, 0.8 eq., 745 µmol) in methanesulfinylmethane (5.00 mL) , disodium sulfinatosulfonate (266 mg, 1.5 eq., 1.40 mmol) was added at room temperature. The resulting mixture stirred for 16h at room temperature. After completion, reaction mixture was concentrated to get crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford methyl 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazole-6-carboxylate (350 mg, 601 µmol) as sticky solid. Yield: 0.35 g, 64% [00435] Step-4: To a stirred solution of methyl 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazole-6-carboxylate (300 mg, 515 µmol) in Methyl amine (40% in ethanol) (30.0 mL, 515 µmol), reaction mixture was stirred at 60 °C for 16 h. After completion, reaction mixture was concentrated to afford the Crude 2-(3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl)-N- methyl-1-(3-methyloxetan-3-yl)-1H-benzo[d]imidazole-6-carbox amide (300 mg, 0.418 mmol). Yield: 0.30 g, 81% [00436] Step-5: To a stirred solution of 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-N-methyl-1- (3-methyloxetan-3-yl)-1H-1,3-benzodiazole-6-carboxamide (200 mg, 344 µmol) in trifluoroacetic acid (5.00 mL), reaction mixture stirred for 4h at 65°C. After completion, reaction mixture was concentrated under reduced pressure to get the crude and further purified by reverse phase HPLC. Desired fractions were lyophilized to afford 2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-N-methyl-1-(3-met hyloxetan-3- yl)-1H-1,3-benzodiazole-6-carboxamide (66.0 mg, 163 µmol) (TFA Salt) as an off white solid. Yield: 0.066 g, 47% [00437] LCMS and NMR Data: ES MS M/Z=402 (M+1), NMR (400 MHz, DMSO-d6) δ 9.60 (s, 1H), 8.54 (d, J = 4.56 Hz, 1H), 7.86 (d, J = 7.44 Hz, 1H), 7.77 (d, J = 8.48 Hz, 1H), 7.68 (s, 1H), 6.65 (d, J = 4.56 Hz, 1H), 4.76 (d, J = 5.84 Hz, 2H), 4.43 (d, J = 6.08 Hz, 2H), 3.80 (s, 3H), 2.84 (s, 3H), 2.09 (s, 3H). Example 213: Synthesis of 2-(3,4-dihydroxy-5-methoxy-2-methylphenyl)-N-methyl-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazole-6-carboxamide [00438] Step-1: To a stirred solution of methyl 4-amino-3-[(3-methyloxetan-3-yl)amino]benzoate (400 mg, 1.3 eq., 914 µmol) and 3,4-bis(benzyloxy)-5-methoxy-2-methylbenzaldehyde (250 mg, 690 µmol) in Dimethyl sulfoxide (3.00 mL) and disodium sulfinatosulfonate (157 mg, 1.2 eq., 828 µmol) was added at room temperature. The resulting mixture was stirred in microwave at 140°C for 1 hr. After completion of reaction, the reaction mixture diluted with water and extracted with ethyl acetate. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to give crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford methyl 2-[3,4-bis(benzyloxy)-5- methoxy-2-methylphenyl]-1-(3-methyloxetan-3-yl)-1H-1,3-benzo diazole-6-carboxylate (150 L, 238 µmol). Yield: 0.150 g, (34.57%) [00439] Step-2: A stirred solution of methyl 2-[3,4-bis(benzyloxy)-5-methoxy-2-methylphenyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazole-6-carboxylate (150 mg, 259 µmol) and methanamine (12.1 mg, 1.5 eq., 389 µmol) in ethanol at 0 °C and stirred at room temperature for 16 h. After completion of the reaction, the reaction mixture was concentrated under reduced pressure to get the crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 2-[3,4- bis(benzyloxy)-5-methoxy-2-methylphenyl]-N-methyl-1-(3-methy loxetan-3-yl)-1H-1,3-benzodiazole-6- carboxamide (160 mg, 193 µmol) as off white color solid. Yield: 0.160 g, 74.53% [00440] Step-3: To 2-[3,4-bis(benzyloxy)-5-methoxy-2-methylphenyl]-N-methyl-1-( 3-methyloxetan-3- yl)-1H-1,3-benzodiazole-6-carboxamide (160 mg, 277 µmol), trifluoroacetic acid (3.00 mL) added at room temperature. The resulting reaction mixture stirred at 60 °C for 4 h. After the complete consumption of starting material, reaction mixture was concentrated to obtain the crude. The crude was purified by reverse phase HPLC, the desired fractions were collected and lyophilized to obtain 2-(3,4- dihydroxy-5-methoxy-2-methylphenyl)-N-methyl-1-(3-methyloxet an-3-yl)-1H-1,3-benzodiazole-6- carboxamide (36.0 mg, 90.6 µmol) as off white solid. Yield: 36 mg, 32.7% [00441] LCMS and NMR Data: ES MS M/Z = 398.34(M + 1) + , 1 H NMR (400 MHz, DMSO-d6) δ 9.08 (s, 1H), 8.75 (s, 1H), 7.81 (d, 1H), 7.73 (d, 1H), 7.65 (s, 1H), 6.50 (s, 1H), 4.92 (s, 1H), 4.67 (s, 1H), 4.43 (s, 1H), 3.77 (s, 3H), 2.83 (d, 3H), 2.08 (s, 3H), 3.01 (s, 3H). Example 214: Synthesis of 2-(3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl)-N-methyl-1-( 3- methyloxetan-3-yl)-1H-benzo[d]imidazole-4-carboxamide [00442] Step-1: To a stirred solution of Methanamine hydrochloride (320 mg, 4.74 mmol) in N,N- dimethylformamide (2.00 mL) was added 3-fluoro-2-nitrobenzoic acid (1.05 g, 1.2 eq., 5.69 mmol) , hexafluoro-λ⁵-phosphanuide 1-[bis(dimethylamino)methylidene]-1H-1λ⁵-[1,2,3]triazolo[ 4,5-b]pyridin-3- ium-1-ylium-3-olate (2.70 g, 1.5 eq., 7.11 mmol) and ethylbis(propan-2-yl)amine (2.48 mL, 3 eq., 14.2 mmol) and the solution was stirred for 16 hours at room temperature. After completion of reaction, the reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to obtain crude. The crude was purified by flash chromatography. The desired fractions concentrated to afford 3-fluoro-N-methyl-2-nitrobenzamide (900 mg, 3.27 mmol) as off-white solid. Yield: 0.900 g, (69%) [00443] Step-2: To a stirred solution of 3-fluoro-N-methyl-2-nitrobenzamide (300 mg, 1.51 mmol) in 1- methylpyrrolidin-2-one (2.50 mL) was added 3-methyloxetan-3-amine (198 mg, 1.5 eq., 2.27 mmol) and ethylbis(propan-2-yl)amine (529 µL, 2 eq., 3.03 mmol) and heated at 120°C for 16h. After completion of reaction, reaction mixture diluted with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulphate, filtered and concentrated to get crude. Yield: 0.360 g, crude. [00444] Step-3: To a stirred solution of N-methyl-3-[(3-methyloxetan-3-yl)amino]-2-nitrobenzamide (360 mg, 1.36 mmol) in methanol (5.00 mL) , zinc (444 mg, 5 eq., 6.79 mmol) and ammonium chloride (363 mg, 5 eq., 6.79 mmol) were added at room temperature and stirred at 50°C for 2h. After completion of the reaction, reaction mixture was passed through celite and washed with dichloromethane, filtrate was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure to get 2-amino-N-methyl-3-[(3-methyloxetan-3-yl)amino]benzamide (270 mg, 367 µmol). Yield: 0.270 g, crude [00445] Step-4: To a stirred solution of 2-amino-N-methyl-3-[(3-methyloxetan-3-yl)amino]benzamide (270 mg, 803 µmol) and 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (235 mg, 0.8 eq., 643 µmol) was added disodium sulfinatosulfonate (183 mg, 1.2 eq., 964 µmol) at room temperature. The resulting mixture stirred for 16 h at 85 °C. After completion, ice cold water was added in the reaction mixture and solid was filtered and dried to get crude. The crude was purified by flash chromatography. The desired fractions were concentrated to afford 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-N- methyl-1-(3-methyloxetan-3-yl)-1H-1,3-benzodiazole-4-carboxa mide (90.0 mg, 144 µmol) as pale yellow liquid. Yield: 0.090 g, 17.9% [00446] Step:5 To 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-N-methyl-1-( 3-methyloxetan-3-yl)- 1H-1,3-benzodiazole-4-carboxamide (90.0 mg, 155 µmol) was added trifluoroacetic acid (1.50 mL) and the resulting solution was stirred for 3 h at 50 °C. After completion, the reaction mixture was concentrated under reduced pressure to get the crude and further purified by reverse phase HPLC . Desired fractions were lyophilized to afford 2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-N-methyl-1- (3-methyloxetan-3-yl)-1H-1,3-benzodiazole-4-carboxamide (30.0 mg, 74.7 µmol) as white solid. Yield: 0.030 g, 48% [00447] 1H NMR: ES MS M/Z=443 (M+1), NMR (400 MHz, DMSO-d6) δ 9.41 (br s, 1H), 7.70 (d, 1H), 7.64 (d, 1H), 7.21 (d, 1H), 6.57 (d, 1H), 4.70 (d, 2H), 4.37 (d, 2H), 3.84 (t, 2H), 3.78 (s, 3H), 3.45 (t, 2H), 2.78 (s, 3H), 2.00 (s, 3H), 1.23 (s, 1H). Example 215: Synthesis of N-(2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(3-methyloxe tan-3- yl)-1H-benzo[d]imidazol-5-yl)butyramide
[00448] Step-1: To a stirred solution of 4-fluoro-3-nitroaniline hydrochloride (500 mg, 2.60 mmol) in N,N-dimethylformamide (5.00 mL) was added butanoic acid (287 µL, 1.2 eq., 3.12 mmol) , hexafluoro- λ⁵-phosphanuide 1-[bis(dimethylamino)methylidene]-1H-1λ⁵-[1,2,3]triazolo[ 4,5-b]pyridin-3-ium-1- ylium-3-olate (1.48 g, 1.5 eq., 3.90 mmol) and ethylbis(propan-2-yl)amine (1.36 mL, 3 eq., 7.81 mmol) and the solution was stirred for 16 hours. After completion, reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to get crude. The crude was purified by flash chromatography. The desired fractions concentrated to afford N-(4-fluoro-3-nitrophenyl)butanamide (510 mg, 2.23 mmol) as off white solid. Yield: 0.510 g, (85.59%) [00449] Step-2: To a stirred solution of N-(4-fluoro-3-nitrophenyl)butanamide (300 mg, 1.33 mmol) in 1- methylpyrrolidin-2-one (2.00 mL) was added 3-methyloxetan-3-amine (167 µL, 1.5 eq., 1.99 mmol) and ethylbis(propan-2-yl)amine (463 µL, 2 eq., 2.65 mmol) and heated at 100°C for 16h. After completion of reaction, reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulphate, filtered and concentrated to afford N-{4-[(3-methyloxetan-3- yl)amino]-3-nitrophenyl}butanamide (364 mg, 980 µmol) as orange solid. Yield: 364 mg (73.92%) [00450] Step-3: To a stirred solution of N-{4-[(3-methyloxetan-3-yl)amino]-3-nitrophenyl}butanamide (364 mg, 1.24 mmol) in methanol (10.0 mL) , zinc (406 mg, 5 eq., 6.20 mmol) and ammonium chloride (332 mg, 5 eq., 6.20 mmol) were added at room temperature and stirred at 50°C for 1h. After completion of the reaction, reaction mixture was passed through celite and washed with 10% methanol in dichloromethane, filtrate was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure to get the desired product N-{3-amino-4-[(3-methyloxetan-3- yl)amino]phenyl}butanamide (263 mg, 829 µmol). Yield: 0.263 g, (66.8%) [00451] Step-4: To a stirred solution of N-{3-amino-4-[(3-methyloxetan-3-yl)amino]phenyl}butanamide (263 mg, 999 µmol) and 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (293 mg, 0.8 eq., 799 µmol) in methanesulfinylmethane (3.00 mL) was added disodium sulfinatosulfonate (228 mg, 1.2 eq., 1.20 mmol) at room temperature. The resulting mixture was stirred for 16 h at 80 °C. After completion, reaction mixture was diluted with ice cold water and filtered. The filtered solid was dissolved in dichloromethane, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to get crude. The crude purified by flash chromatography. The desired fractions concentrated to afford N- {2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methyl oxetan-3-yl)-1H-1,3-benzodiazol-5- yl}butanamide (288 mg, 449 µmol) as yellow solid. Yield: 0.288 g, (44.93%) [00452] Step-5: To a stirred solution of N-{2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazol-5-yl}butanamide (288 mg, 472 µmol) was added trifluoroacetic acid (2.00 mL) . The resulting mixture was stirred for 2 h at 50 °C. After completion, the reaction mixture was concentrated under reduced pressure to get the crude and further purified by reverse phase HPLC . Desired fractions were lyophilized to afford N-[2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-1- (3-methyloxetan-3-yl)-1H-1,3-benzodiazol-5-yl]butanamide (120 mg, 274 µmol) as white solid. Yield: 0.120 g, 58% [00453] 1H NMR: ES MS M/Z=430 (M+1),NMR (400 MHz, DMSO-d6) δ 10.13 (s,1H), 9.77 (br s, 2H), 8.24 (s, 1H), 7.51-7.48 (m, 1H), 7.42 (d, J = 8.80 Hz, 1H), 6.68 (d, J =6.00 Hz, 1H), 4.74 (d, J = 5.60 Hz, 2H), 4.43 (d, J = 6.00 Hz, 2H), 3.81 (s, 3H), 2.33 (t, J = 7.20 Hz, 2H), 2.09 (s, 3H), 1.68-1.59 (m, 2H), 0.93 (t, J = 7.20 Hz, 3H). Example 216: Synthesis of 2,3-dihydroxy-4-methoxy-6-[1-(3-methyloxetan-3-yl)-1H-1,3- benzodiazol-2-yl]benzonitrile [00454] Step-1: To a stirred solution of 1-fluoro-2-nitrobenzene (1.49 mL, 14.2 mmol) in 1- methylpyrrolidin-2-one (10.0 mL) was added 3-methyloxetan-3-amine (1.28 mL, 2 eq., 28.3 mmol) and ethylbis(propan-2-yl)amine (4.95 mL, 2 eq., 28.3 mmol) and heated at 100°C for 16h. After completion of reaction, reaction mixture diluted with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulphate, filtered and concentrated to afford 3-methyl-N-(2- nitrophenyl)oxetan-3-amine (2.30 g, 10.8 mmol) as orange solid. Yield: 2.30 g (76.54%) [00455] Step-2: To a stirred solution of 3-methyl-N-(2-nitrophenyl)oxetan-3-amine (300 mg, 1.44 mmol) in methanol (5.00 mL) was added zinc (471 mg, 5 eq., 7.20 mmol) and ammonium chloride (385 mg, 5 eq., 7.20 mmol) were added at room temperature and stirred at 50°C for 1h. After completion of the reaction, reaction mixture was passed through celite and washed with 10% methanol in dichloromethane, filtrate was washed with water, dried over anhydrous sodium sulphate and concentrated under reduced pressure to get N1-(3-methyloxetan-3-yl)benzene-1,2-diamine (350 mg, 1.04 mmol) (crude) as brown solid. Yield: 0.350 g, Crude [00456] Step-3: To a stirred solution of N1-(3-methyloxetan-3-yl)benzene-1,2-diamine (250 mg, 1.40 mmol) and 3,4-bis(benzyloxy)-2-bromo-5-methoxybenzaldehyde (479 mg, 0.8 eq., 1.12 mmol) in methanesulfinylmethane (3.00 mL), disodium sulfinatosulfonate (400 mg, 1.5 eq., 2.10 mmol) was added at room temperature. The resulting mixture stirred for 16h at 80 °C. After completion, water and ethyl acetate was added to reaction mixture. The organic fractions were collected, dried over anhydrous sodium sulphate, filtered and concentrated to get crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 2-[3,4-bis(benzyloxy)-2-bromo-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazole (230 mg, 393 µmol) as off white solid. Yield: 230 mg, 26.28% [00457] Step-4: To a stirred solution of 2-[3,4-bis(benzyloxy)-2-bromo-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazole (240 mg, 410 µmol) in N,N-dimethylformamide (5.00 mL), λ¹- copper iminomethanide (CuCN) (55.1 mg, 1.5 eq., 615 µmol) added at room temperature. The reaction mixture was degassed with argon for 5 min and reaction mixture stirred was heated at 150°C for 16 h. After completion, the reaction mixture cooled to room temperature, filtered through celite, the filtrate was diluted with water and extracted ethyl acetate. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to give crude. The crude purified by flash chromatography. The desired fractions concentrated to afford 2,3-bis(benzyloxy)-4-methoxy-6-[1-(3-methyloxetan-3-yl)-1H- 1,3-benzodiazol-2-yl]benzonitrile (190 mg, 357 µmol) as off white solid. Yield: 190 mg, 87.19% [00458] Step-5: To 2,3-bis(benzyloxy)-4-methoxy-6-[1-(3-methyloxetan-3-yl)-1H-1 ,3-benzodiazol-2- yl]benzonitrile (180 mg, 339 µmol) in oxolane (5.00 mL) added palladium(2+) hydroxide (209 mg, 5 eq., 1.69 mmol) at room temperature. The resulting reaction mixture stirred under hydrogen atmosphere for 4 h at room temperature. After the complete consumption of starting material, reaction mixture was concentrated to obtain the crude. The crude purified by reverse-phase High performance liquid chromatography. The desired fractions were collected and lyophilized to obtain 2,3-dihydroxy-4- methoxy-6-[1-(3-methyloxetan-3-yl)-1H-1,3-benzodiazol-2-yl]b enzonitrile (46.0 mg, 131 µmol) as off white solids. Yield: 46 mg, 38.67% [00459] 1 H NMR and LCMS data: ES MS M/Z = 352.25 [M + 1]+; UPLC: 99.28%; 1 H NMR (400 MHz, DMSO-d6) 10.53 (s, 1H), δ 9.68 (s, 1H), 7.75-7.72 (m, 1H), 7.30-7.28 (m, 1H), 7.69 (S, 1H), 4.67 (d, J = 6.0 Hz, 2H), 4.42 (d, J = 6.0 Hz, 2H), 3.90 (s, 3H), 2.08 (s, 3H). Example 217: Synthesis of 3-(difluoromethoxy)-6-methoxy-4-(1-(3-methyloxetan-3-yl)-1H- benzo[d]imidazol-2-yl)benzene-1,2-diol
[00460] Step:1 To a stirred solution of 3,4-bis(benzyloxy)-2-bromo-5-methoxybenzaldehyde (1.00 g, 2.34 mmol) in 1,4-dioxane (7.50 mL) and water (2.50 mL) was added potassium hydroxide (394 mg, 3 eq., 7.02 mmol) at room temperature and the reaction mixture was degassed with argon for 5 min. tris(1,5-diphenylpenta-1,4-dien-3-one) dipalladium (107 mg, 0.05 eq., 117 µmol) and di-tert- butyl[2',4',6'-tris(propan-2-yl)-[1,1'-biphenyl]-2-yl]phosph ane (99.4 mg, 0.1 eq., 234 µmol) were added to the reaction, continued degassing for 5 min and heated the reaction mixture at 100°C for 16 h. After completion, the reaction was cooled to room temperature and passed through celite. The filtrate was diluted with 1N hydrochloric acid and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to give crude. The crude was purified by flash chromatography. Desired fractions were concentrated to get 3,4-bis(benzyloxy)-2-hydroxy-5- methoxybenzaldehyde (900 mg, 1.72 mmol) as thick yellow liquid. Yield: 0.900 g, 73% [00461] Step:2 To a stirred solution of 3,4-bis(benzyloxy)-2-hydroxy-5-methoxybenzaldehyde (800 mg, 2.20 mmol) in acetonitrile (8.00 mL), sodium 2,2-difluoroethanecarboperoxoyl chloride (1.00 g, 3 eq., 6.59 mmol) and cesium carbonate (1.79 g, 2.5 eq., 5.49 mmol) were added and stirred at 80 °C for 16 h. After the completion of reaction, water was added and extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtered and concentrated to obtain crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 3,4-bis(benzyloxy)-2-(difluoromethoxy)-5- methoxybenzaldehyde (120 mg, 246 µmol) as thick greenish liquid. Yield: 0.120 g, 11% [00462] Step:3 To a stirred solution of N1-(3-methyloxetan-3-yl)benzene-1,2-diamine (110 mg, 617 µmol) and 3,4-bis(benzyloxy)-2-(difluoromethoxy)-5-methoxybenzaldehyde (205 mg, 0.8 eq., 494 µmol) in methanesulfinylmethane (1.20 mL), disodium sulfinatosulfonate (176 mg, 1.5 eq., 926 µmol) was added at room temperature. The resulting mixture stirred for 16h at 80 °C. After completion, chilled water was added to reaction mixture and filtered. The solid filtrate was dissolved in dichloromethane, dried over anhydrous sodium sulfate, filtered and concentrated to get crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 2-[3,4-bis(benzyloxy)-2- (difluoromethoxy)-5-methoxyphenyl]-1-(3-methyloxetan-3-yl)-1 H-1,3-benzodiazole (108 mg, 166 µmol). Yield: 108 mg, 27% [00463] Step-4: To 2-[3,4-bis(benzyloxy)-2-(difluoromethoxy)-5-methoxyphenyl]-1 -(3-methyloxetan-3- yl)-1H-1,3-benzodiazole (100 mg, 175 µmol) was added trifluoroacetic acid (2.00 mL) and the resulting solution was stirred for 2 h at 60 °C. After completion, the reaction mixture was concentrated under reduced pressure to get crude and further purified by reverse phase HPLC . Desired fractions were lyophilized to afford 3-(difluoromethoxy)-6-methoxy-4-[1-(3-methyloxetan-3-yl)-1H- 1,3-benzodiazol-2- yl]benzene-1,2-diol (27.0 mg, 66.4 µmol) as the product. Yield: 0.027 g, 38% [00464] 1H NMR: ES MS M/Z=374 (M+1), NMR (400 MHz, DMSO-d6) δ 9.43 (s,1H), 9.33 (s, 1H), 8.13 (s, 1H), 6.96 (d, 1H), 6.68 (s, 1H), 6.62 (d, 1H), 6.53 (d, 1H), 4.67 (d, 2H), 4.33 (d, 2H), 3.78 (s, 3H), 2.69 (s ,3H), 1.97 (s, 3H). Example 218: Synthesis of 4-[6-ethyl-3-(3-methyloxetan-3-yl)-3H-imidazo[4,5-c]pyridin- 2-yl]-3- fluoro-6-methoxybenzene-1,2-diol [00465] Step-1: To a stirred solution of 6-bromo-N-(3-methyloxetan-3-yl)-4-nitropyridin-3-amine (800 mg, 2.78 mmol) in methanol (5.00 mL), Zinc dust (902 mg, 5 eq., 13.9 mmol) and ammonium chloride (743 mg, 5 eq., 13.9 mmol) were added at room temperature and the reaction mixture stirred for 2h at 30 °C. After completion, the reaction mixture passed through celite bed. Filtrate was extracted with ethyl acetate, organic layer dried over anhydrous sodium sulfate, filtered and concentrated to get as 6-bromo- N3-(3-methyloxetan-3-yl)pyridine-3,4-diamine (450 mg, 1.74 mmol) as a sticky liquid. Yield: 450 mg, 62.78% [00466] Step-2: To a stirred solution of 6-bromo-N3-(3-methyloxetan-3-yl)pyridine-3,4-diamine (450 mg, 1.55 mmol) and 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (455 mg, 0.8 eq., 1.24 mmol) in methanesulfinylmethane (3.00 mL), disodium sulfinatosulfonate (442 mg, 1.5 eq., 2.33 mmol) was added at room temperature. The resulting mixture stirred for 16h at 80 °C. After completion, water and ethyl acetate was added to reaction mixture. The organic fractions were collected, dried over anhydrous sodium sulphate, filtered and concentrated to get crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-6- bromo-3-(3-methyloxetan-3-yl)-3H-imidazo[4,5-c]pyridine (410 mg, 631 µmol) as pink solid. Yield: 410 mg, 40.65% [00467] Step-3: To a stirred solution of 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-6-bromo-3-(3 - methyloxetan-3-yl)-3H-imidazo[4,5-c]pyridine (200 mg, 331 µmol) and ethylboronic acid (196 mg, 8 eq., 2.65 mmol) in toluene (1.50 mL) and water (500 µL)was added dipotassium carbonate (137 mg, 3 eq., 993 µmol) at room temperature. The reaction mixture was degassed with argon for 5 min. Then [1,1′- Bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (24.3 mg, 0.09 eq., 29.8 µmol) added to the above suspension, degassed for 5 minutes and reaction mixture stirred was heated at 120°C for 16 h. After completion, the reaction mixture cooled to room temperature, diluted with water and extracted ethyl acetate. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to give crude. The crude purified by flash chromatography. The desired fractions concentrated to afford 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-6-ethyl-3-(3 -methyloxetan-3- yl)-3H-imidazo[4,5-c]pyridine (50.0 mg, 90.3 µmol). Yield: 50 mg, 27.3% [00468] Step-4: To 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-6-ethyl-3-(3 -methyloxetan-3-yl)- 3H-imidazo[4,5-c]pyridine (85.0 mg, 154 µmol) trifluoroacetic acid (1.00 mL) added at room temperature. The resulting reaction mixture stirred at 60 °C for 4 h. After the complete consumption of starting material, reaction mixture was concentrated to obtain the crude. The crude was purified by reverse phase HPLC, the desired fractions were collected and lyophilized to obtain 4-[6-ethyl-3-(3- methyloxetan-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl]-3-fluoro-6 -methoxybenzene-1,2-diol (16.0 mg, 42.4 µmol) as off-white solid. Yield: 16 mg, 27.63% [00469] LCMS and NMR Data: ES MS M/Z = 374.32 (M + 1) + , UPLC: 99.68%; 1H NMR (400 MHz, DMSO-d6) δ 9.69 (s, 2H), 8.93 (s, 1H), 8.01 (s, 1H), 6.66 (d, J = 6.0 Hz, 1H), 4.75 (d, J = 6.0 Hz , 2H), 4.46 (d, J = 6.0 Hz, 1H ), 3.81 (s, 3H), 2.02 (m, 2H), 2.11 (s, 3H), 1.33 (t, J = 7.6 Hz, 3H). Example 219: Synthesis of 2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-3-(3-methyloxetan -3-yl)- 3H-imidazo[4,5-c]pyridine-6-carboxamide [00470] Step-1: A stirred solution of 3-fluoro-4-nitropyridine (7.00 g, 49.3 mmol) and 3-methyloxetan-3- amine (3.34 mL, 1.5 eq., 73.9 mmol) in 1-methylpyrrolidin-2-one (5.00 mL) and N,N- Diispropylethylamine (25.8 mL, 3 eq., 148 mmol) was added and stirred and heated at 110 °C for 16h. After completion of reaction, reaction mixture diluted with water and extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulphate, filtered and concentrated to get crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford N- (3-methyloxetan-3-yl)-4-nitropyridin-3-amine (5.40 g, 25.6 mmol) as orange color solid. Yield: 5.400 g, 51.87% [00471] Step-2: A stirred solution of N-(3-methyloxetan-3-yl)-4-nitropyridin-3-amine (2.00 g, 9.56 mmol) in N,N-dimethylformamide (5.00 mL) and N-Bromosuccinamide (2.24 g, 1.2 eq., 11.5 mmol) was added at 0 °C and stirred for 16 h. After completion of the reaction, the reaction mixture was diluted with water and extracted ethyl acetate and dried and concentrated under reduced pressure to get the crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 6- bromo-N-(3-methyloxetan-3-yl)-4-nitropyridin-3-amine (2.50 g, 7.46 mmol) as orange color solid. Yield: 2.500 g, 78.06% [00472] Step-3: A stirred solution of 6-bromo-N-(3-methyloxetan-3-yl)-4-nitropyridin-3-amine (1.00 g, 3.47 mmol) in methanol (10.0 mL), zinc (1.13 g, 5 eq., 17.4 mmol) and ammonium chloride (928 mg, 5 eq., 17.4 mmol) were added and stirred at room temperature for 3h. After completion of reaction, reaction mixture filtered through celite and filtrate was diluted with water and extracted with dichloromethane. The combined organic layers were dried over anhydrous sodium sulphate, filtered and concentrated to afford 6-bromo-N3-(3-methyloxetan-3-yl)pyridine-3,4-diamine (800 mg, 2.76 mmol) as brown sticky solid. Yield: 0.800 g, 79.47% [00473] Step-4: To a stirred solution 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (650 mg, 1.77 mmol) and 6-bromo-N3-(3-methyloxetan-3-yl)pyridine-3,4-diamine (458 mg, 1.77 mmol) in Dimethyl sulfoxide (5.00 mL) and 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-6-bromo-1-(3 -methyloxetan- 3-yl)-1H-imidazo[4,5-c]pyridine (500 mg, 678 µmol) was added at room temperature. The resulting mixture stirred and heated at 85°C for 16 hr. After completion of reaction, the reaction mixture diluted with ice cold water and extracted with ethyl acetate . The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to give crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-6- bromo-1-(3-methyloxetan-3-yl)-1H-imidazo[4,5-c]pyridine (500 mg, 678 µmol) as brown color solid. Yield: 0.50 g, 38.23% [00474] Step-5: To a stirred solution of 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-3-(3- methyloxetan-3-yl)-3H-imidazo[4,5-c]pyridine-6-carbonitrile (150 mg, 272 µmol) in N,N- dimethylformamide (4.00 mL) and peroxol (92.7 mg, 3 eq., 817 µmol) and dipotassium carbonate (113 mg, 3 eq., 817 µmol) were added and heated at 140 °C for 16 hours. Reaction monitored by LCMS Reaction mixture concentrated under reduced pressure to get crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 2-[3,4-bis(benzyloxy)-2-fluoro-5- methoxyphenyl]-3-(3-methyloxetan-3-yl)-3H-imidazo[4,5-c]pyri dine-6-carboxamide (90.0 mg, 95.0 µmol) as brown color solid. Yield: 0.090g, 34.86% [00475] Step-6: To a solution of 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-3-(3-methylo xetan-3- yl)-3H-imidazo[4,5-c]pyridine-6-carboxamide (90.0 mg, 158 µmol) in trifluoroacetic acid was at 60 °C temperature and the reaction mixture stirred for 2h . After completion, the reaction mixture concentrated under reduced pressure to get crude. The crude was purified on reverse phase prep HPLC to get 2-(2- fluoro-3,4-dihydroxy-5-methoxyphenyl)-3-(3-methyloxetan-3-yl )-3H-imidazo[4,5-c]pyridine-6- carboxamide (5.00 mg, 12.9 µmol) as white solid. Yield: 0.005 g (8.13%) [00476] LCMS and NMR Data: ES MS M/Z = 389.32 (M + 1), 1H NMR (400 MHz, DMSO-d6) δ 9.56 (d, J =17.2 Hz, 2H), 8.70 (s, 1H), 8.31 (s, 1H), 8.05 (s, 1H), 7.63 (s, 1H), 6.67 (d, J =8.4 Hz, 1H), 4.78 (d, J = 6.0 Hz, 2H), 4.44 (d, J = 6.0 Hz, 2H), 3.80 (s, 3H), 2.09 (s, 3H) Example 220: Synthesis of 6-methoxy-3-methyl-4-(1-(1-methylcyclobutyl)-1H-benzo[d]imid azol-2- yl)benzene-1,2-diol [00477] Step-1: To a solution of 3,4-dihydroxy-5-methoxybenzaldehyde (15.0 g, 89.2 mmol) in acetic acid (100 mL) and bromine (1.08 mL, 20.9 mmol) diluted in acetic acid was added dropwise to the reaction mixture and stirred for 16 hr. After completion of the reaction, the reaction mixture was quenched with Sodium thiosulfate and stirred for 10 minute so that solid compound precipitate. After that reaction mixture filtered out and solid washed with ice cold water and dried under vacuum. The solid afford 2-bromo-3,4-dihydroxy-5-methoxybenzaldehyde (22.0 g, 80.1 mmol) as off white solid. Yield: 22.00 g, 89.83% Step-2: To a solution of 2-bromo-3,4-dihydroxy-5-methoxybenzaldehyde (22.0 g, 89.1 mmol) in N,N- dimethylformamide (200 mL) , (bromomethyl)benzene (31.7 mL, 3 eq., 267 mmol), dipotassium carbonate (36.9 g, 3 eq., 267 mmol) and potassium iodide (2.96 g, 0.2 eq., 17.8 mmol) were added to the reaction mixture and stirred and heated at 60 °C for 4 h . After completion of the reaction, the reaction mixture was filtered and the filtrate was concentrated under reduced pressure to get the crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 3,4-bis(benzyloxy)- 2-bromo-5-methoxybenzaldehyde (23.0 g, 45.8 mmol) as off white solid. Yield: 23.0 g, 74.46% [00478] Step-3: To a solution of 3,4-bis(benzyloxy)-2-bromo-5-methoxybenzaldehyde (4.00 g, 9.36 mmol) and methylboronic acid (672 mg, 1.2 eq., 11.2 mmol) in 1,4-dioxane (30.0 mL) and water (2.00 mL). Cesium carbonate (6.10 g, 2 eq., 18.7 mmol) added at room temperature and the reaction mixture was degassed with argon for 5 min. was added to the reaction, continued degassing for 5 min and heated the reaction mixture at 90°C for 4 h. After completion, the reaction was cooled to room temperature and passed through celite bed. Filtrate was diluted with ethyl acetate and washed with water. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to give crude. The crude purified in flash chromatography. The desired fractions were concentrated to afford 3,4-bis(benzyloxy)- 5-methoxy-2-methylbenzaldehyde (2.50 g, 6.48 mmol) as pale yellow oil. Yield: 2.5 g, 69.21% [00479] Step-4: A solution of N-(2-bromophenyl)-3-methyloxetan-3-amine (500 mg, 2.07 mmol) and 2,3-bis(benzyloxy)-5-ethynyl-1-methoxy-4-methylbenzene (740 mg, 2.07 mmol) in N,N- dimethylformamide (5.00 mL), triethylamine (746 µL, 2.6 eq., 5.37 mmol) was added, and reaction mixture was purged with argon for 5 min, then Bis(triphenylphosphine)palladium(II) dichloride (58.0 mg, 0.04 eq., 82.6 µmol) and diiodocopper (45.9 mg, 0.07 eq., 145 µmol) and again purged with argon for 5 min and heated to 100 °C for 24 h. After completion of reaction, the reaction mixture diluted with water and extracted with dichloromethane. The combined organic layers dried over anhydrous sodium sulphate, filtered and concentrated to obtain crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 2-[3,4-bis(benzyloxy)-5-methoxy-2-methylphenyl]-1-(3- methyloxetan-3-yl)-1H-indole (180 mg, 149 µmol) as brown mass. Yield: 180.0 mg, 43% [00480] Step-5: To a solution of 1,2-dibromobenzene (1.00 g, 4.24 mmol) and N-(2-bromophenyl)-3- methyloxetan-3-amine (500 mg, 2.03 mmol) in toluene (5.00 mL) sodium 2-methylpropan-2-olate (823 mg, 2 eq., 8.48 mmol) added at room temperature and the reaction mixture was degassed with argon for 5 min. tris((1E,4E)-1,5-diphenylpenta-1,4-dien-3-one) dipalladium (77.6 mg, 0.02 eq., 84.8 µmol) and [2'- (diphenylphosphanyl)-[1,1'-binaphthalen]-2-yl]diphenylphosph ane (52.8 mg, 0.02 eq., 84.8 µmol) was added to the reaction, continued degassing for 5 min and heated the reaction mixture at 90°C for 6 h. After completion, the reaction was cooled to room temperature and passed through celite bed. Filtrate was diluted with ethyl acetate and washed with water. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to give crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford N-(2-bromophenyl)-3-methyloxetan-3-amine as pale yellow oil. Yield: 0.45 g, 45.96% [00481] Step-6: A solution of N-(2-bromophenyl)-3-methyloxetan-3-amine (500 mg, 2.07 mmol) and 2,3-bis(benzyloxy)-5-ethynyl-1-methoxy-4-methylbenzene (740 mg, 2.07 mmol) in N,N- dimethylformamide (5.00 mL), triethylamine (746 µL, 2.6 eq., 5.37 mmol) was added, and reaction mixture was purged with argon for 5 min, then Bis(triphenylphosphine)palladium(II) dichloride (58.0 mg, 0.04 eq., 82.6 µmol) and diiodocopper (45.9 mg, 0.07 eq., 145 µmol) and again purged with argon for 5 min and heated to 100 °C for 24 h. After completion of reaction, the reaction mixture diluted with water and extracted with dichloromethane. The combined organic layers dried over anhydrous sodium sulphate, filtered and concentrated to obtain crude. Purification was done by Reverse Prep HPLC to afford 2-[3,4-bis(benzyloxy)-5-methoxy-2-methylphenyl]-1-(3-methylo xetan-3-yl)-1H-indole (180 mg, 149 µmol) as brown mass. Yield: 72.0 mg, 18% [00482] Step-7: To a stirred solution of 2-[3,4-bis(benzyloxy)-5-methoxy-2-methylphenyl]-1-(3- methyloxetan-3-yl)-1H-indole (70.0 mg, 135 µmol) in Tetrahydrofuran (5.00 mL), Palladium hydroxide (16.5 mg, 135 µmol) was charged and stirred under hydrogen atmosphere at room temperature for 2 h. After completion of reaction, reaction mixture filtered through celite. Filtrate was distilled below 30 °C to obtain crude. Purification was done by Reverse Prep HPLC to get 6-methoxy-3-methyl-4-[1-(3- methyloxetan-3-yl)-1H-indol-2-yl]benzene-1,2-diol (5.40 mg, 15.9 µmol) as off white solid. Yield: 5.40 mg, 11.78% [00483] ES MS M/Z = 338.03 (M - 1), UPLC: 99.74%. 1 HNMR (400 MHz, DMSO-d6): δ 7.55 (J = 7.52 Hz, 1H), 7.12-6.99 (m, 3H), 6.37 (s, 1H), 6.27 (s, 1H), 4.89 (J = 5.4 Hz, 1H), 4.59 (J = 4.5 Hz, 1H), 4.89 (J = 5.8 Hz, 1H)), 3.82 (4.89 (J = 5.4 Hz, 1H)), 3.74 (s, 3H), 2.00 (s, 3H), 1.97 (s, 3H), 1.77 (s, 3H), 1.70- 1.63 (m, 1H), 1.56 (bs, 1H). Example 221: Synthesis of 4-(5-(azetidin-1-yl)-1-methyl-1H-benzo[d]imidazol-2-yl)-6-me thoxy-3- (trifluoromethyl)benzene-1,2-diol [00484] Step-1: To a solution of 3,4-bis(benzyloxy)-2-bromo-5-methoxybenzaldehyde (2.00 g, 4.68 mmol) in dry toluene (20.0 mL), ethane-1,2-diol (785 µL, 3 eq., 14.0 mmol) and dry 4-methylbenzene-1- sulfonic acid (80.6 mg, 0.1 eq., 468 µmol) were added to the reaction mixture and stirred and heated at 130 °C for 8h. After completion of the reaction, the reaction mixture was concentrated under reduced pressure to get the crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 2-[3,4-bis(benzyloxy)-2-bromo-5-methoxyphenyl]-1,3-dioxolane (1.00 g, 2.10 mmol) as off white solid. Yield: 1.0 g, 44.87% [00485] Step-2: To a stirred solution of 2-[3,4-bis(benzyloxy)-2-bromo-5-methoxyphenyl]-1,3-dioxolane (1.00 g, 2.12 mmol) in Tetrahydrofuran (10.0 mL) under inert atmosphere. The solution was cooled at - 78 °C and lithium butyl (1.27 mL, 1.5 eq., 3.18 mmol) was added dropwise. The reaction mixture stirred for 20 minutes at -78 °C. Iodine (535 mg, 2 eq., 4.24 mmol) in tetrahydrofuran (5 ml) was added dropwise at -78 °C and stirred for 1 h and allowed to come at room temperature. After completion, the reaction mixture quenched with 6N hydrochloric acid solution at 0 °C and extracted with ethyl acetate. The combined organic layers dried over anhydrous sodium sulphate, filtered and concentrated to obtain crude. The crude was purified by flash chromatography. Pure fractions were concentrated to get 3,4- bis(benzyloxy)-2-iodo-5-methoxybenzaldehyde (480 mg, 972 µmol) as off white solid. Yield: 0.48 g, 45.79% [00486] Step-3: To a stirred solution of 3,4-bis(benzyloxy)-2-iodo-5-methoxybenzaldehyde (575 mg, 1.21 mmol) in N,N-dimethylformamide (5.00 mL), [bis(dimethylamino)phosphoryl]dimethylamine (844 µL, 4 eq., 4.85 mmol) and Copper(I) iodide (277 mg, 1.2 eq., 1.45 mmol) and methyl 2,2-difluoro-2- (fluorosulfonyl)acetate (1.23 mL, 8 eq., 9.70 mmol) were added at room temperature in presence of nitrogen atmosphere. The resulting mixture stirred for 16 h at 85 °C. After completion, reaction mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate and concentrated under reduced pressure to get crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 3,4-bis(benzyloxy)-5-methoxy-2-(trifluoromethyl)benzaldehyde (300 mg, 576 µmol) as sticky solid. Yield: 0.30 g, 53% [00487] Step-4: To a stirred solution of 4-(azetidin-1-yl)-N1-methylbenzene-1,2-diamine (240 mg, 1.08 mmol) and 3,4-bis(benzyloxy)-5-methoxy-2-(trifluoromethyl)benzaldehyde (361 mg, 0.8 eq., 867 µmol) in methanesulfinylmethane (10.0 mL) was added disodium sulfinatosulfonate (247 mg, 1.2 eq., 1.30 mmol) at room temperature. The resulting mixture stirred for 16 h at 85 °C. After completion, reaction mixture cooled to room temperature and diluted with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to get crude. The crude purified by flash chromatography. The desired fractions concentrated to afford 5-(azetidin-1-yl)-2- [3,4-bis(benzyloxy)-5-methoxy-2-(trifluoromethyl)phenyl]-1-m ethyl-1H-1,3-benzodiazole (230 mg, 317 µmol)as off white solid. Yield: 0.23 g, 29.24% [00488] Step-5: To a solution of 5-(azetidin-1-yl)-2-[3,4-bis(benzyloxy)-5-methoxy-2- (trifluoromethyl)phenyl]-1-methyl-1H-1,3-benzodiazole (200 mg, 275 µmol) in Tetrahydrofuran (10.0 mL) was added 20% Palladium hydroxide (250 mg, 1.3 eq., 357 µmol) at room temperature and the reaction mixture stirred for 3h under hydrogen atmosphere. After completion, the reaction mixture passed through celite bed. Filtrate was concentrated to get crude. Crude was purified by reverse phase HPLC and desired fractions were lyophilized to get 4-[5-(azetidin-1-yl)-1-methyl-1H-1,3-benzodiazol-2-yl]-6- methoxy-3-(trifluoromethyl)benzene-1,2-diol (29.0 mg, 70.0 µmol) as off white solid. Yield: 0.029 g, 25.43% [00489] ES MS M/Z = 394.00 (M +1), 1H NMR (400 MHz, DMSO-d6) δ 9.71 (brs, 1H), 7.36 (d, J = 8.8 Hz, 1H), 6.57-6.56 (m, 2H), 6.48 (dd, J = 2, 8.4 Hz, 1H), 3.8 (s, 3H), 3.80 (t, J = 7.2 Hz, 4H), 3.45 (s, 3H), 2.32-2.25 (m, 2H). Example 222: Synthesis of 4-(5-(benzylamino)-1-(3-methyloxetan-3-yl)-1H-benzo[d]imidaz ol-2-yl)- 3-fluoro-6-methoxybenzene-1,2-diol [00490] Step:1 To a stirred solution of 4-fluoro-3-nitroaniline (3.00 g, 19.2 mmol) in Tetrahydrofuran (30.0 mL) was added di-tert-butyl dicarbonate (5.56 mL, 1.3 eq., 25.0 mmol). The reaction mixture was heated at 70°C for 16 h. After completion of reaction, reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was separated, dried over sodium sulphate, filtered and concentrated under reduced pressure to get the crude. The crude purified by flash chromatography. The desired fractions concentrated to get tert-butyl N-(4-fluoro-3-nitrophenyl)carbamate (2.00 g, 7.79 mmol) as pale yellow solid. Yield: 2.0 g, 40.5% [00491] Step:2 To a stirred solution of tert-butyl N-(4-fluoro-3-nitrophenyl)carbamate (350 mg, 1.37 mmol) in 1-methylpyrrolidin-2-one (3.00 mL) was added 3-methyloxetan-3-amine (179 mg, 1.5 eq., 2.05 mmol) and ethylbis(propan-2-yl)amine (477 µL, 2 eq., 2.73 mmol) and heated at 120°C for 16h. After completion of reaction, reaction mixture diluted with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulphate, filtered and concentrated to get crude. Crude was purified by flash chromatography. Desired fractions were collected and concentrated to get tert-butyl N- {4-[(3-methyloxetan-3-yl)amino]-3-nitrophenyl}carbamate (200 mg, 579 µmol) as orange solid. Yield: 0.200 g (42.4%) [00492] Step-3: To a stirred solution of tert-butyl N-{4-[(3-methyloxetan-3-yl)amino]-3- nitrophenyl}carbamate (200 mg, 619 µmol) in methanol (5.00 mL), zinc (202 mg, 5 eq., 3.09 mmol) and ammonium chloride (165 mg, 5 eq., 3.09 mmol) were added at room temperature and stirred at 50°C for 1h. After completion of the reaction, reaction mixture was passed through celite and washed with dichloromethane, filtrate was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure to get the desired product tert-butyl N-{3-amino-4-[(3-methyloxetan-3- yl)amino]phenyl}carbamate (170 mg, 539 µmol). Yield: 0.170 g, 87% [00493] Step-4: To a stirred solution of tert-butyl N-{3-amino-4-[(3-methyloxetan-3- yl)amino]phenyl}carbamate (170 mg, 579 µmol) and 3,4-bis(benzyloxy)-2-fluoro-5- methoxybenzaldehyde (170 mg, 0.8 eq., 464 µmol) in methanesulfinylmethane (2.00 mL) was added disodium sulfinatosulfonate (132 mg, 1.2 eq., 695 µmol) at room temperature. The resulting mixture was stirred for 16 h at 80 °C. After completion, ice cold water was added in the reaction mixture and solid was dissolved in dichloromethane and concentrated under reduced pressure to get crude. The crude was purified by flash chromatography. The desired fractions were concentrated to afford tert-butyl N-{2-[3,4- bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methyloxetan-3 -yl)-1H-1,3-benzodiazol-5-yl}carbamate (190 mg, 275 µmol) as shiny yellow crystalline solid. Yield: 0.190 g, 47% [00494] Step-5: To a stirred solution of tert-butyl N-{2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]- 1-(3-methyloxetan-3-yl)-1H-1,3-benzodiazol-5-yl}carbamate (50.0 mg, 78.2 µmol) in dichloromethane (50.0 µL) was added 4M HCl in 1,4-Dioxane (2.00 mL) and the reaction mixture was stirred at room temperature for 3 h. After completion of the reaction , the reaction mixture was concentrated under reduced pressure to get the desired product 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazol-5-amine (60.0 mg, 74.1 µmol) as hydrochloride salt. Yield: 0.060 g, 94.7% [00495] Step-6: To a stirred solution of 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazol-5-amine hydrochloride (60.0 mg, 104 µmol) in N,N- dimethylformamide (600 µL) was added benzoic acid (14.0 mg, 1.1 eq., 114 µmol), hexafluoro-λ⁵- phosphanuide 1-[bis(dimethylamino)methylidene]-1H-1λ⁵-[1,2,3]triazolo[ 4,5-b]pyridin-3-ium-1-ylium- 3-olate (59.3 mg, 1.5 eq., 156 µmol) and ethylbis(propan-2-yl)amine (54.4 µL, 3 eq., 312 µmol) and the solution was stirred at room temperature for 16 hours. After completion of reaction, the reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to obtain crude. The crude was purified by flash chromatography. Desired fractions were concentrated to get N-{2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazol-5-yl}benzamide (28.0 mg, 41.3 µmol) as pale yellow solid. Yield: 0.028 g, 39.7% [00496] Step-7: To N-{2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-meth yloxetan-3-yl)-1H- 1,3-benzodiazol-5-yl}benzamide (25.0 mg, 38.8 µmol) was added trifluoroacetic acid (1.00 mL) and the resulting solution was stirred for 2 h at 60 °C. After completion, the reaction mixture was concentrated under reduced pressure to get N-[2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(3-methyloxe tan-3-yl)- 1H-1,3-benzodiazol-5-yl]benzamide (22.0 mg, 33.2 µmol) as the desired product. Yield: 0.022 g, 85% [00497] Step-8: To a stirred solution of N-[2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazol-5-yl]benzamide (75.0 mg, 162 µmol) in Tetrahydrofuran (1.00 mL), Borane dimethylsulfide (46.1 µL, 3 eq., 485 µmol) was added at 0°C and stirred for 3 hr at 60°C. After 3 hr methanol was added to reaction mixture and stirred for 1 hr at RT. After completion, reaction mixture was evaporated under reduced pressured to give crude and further purified by reverse phase HPLC. Desired fractions were lyophilized to afford 4-[5-(benzylamino)-1-(3-methyloxetan-3-yl)-1H-1,3- benzodiazol-2-yl]-3-fluoro-6-methoxybenzene-1,2-diol (8.00 mg, 17.8 µmol) as white solid. Yield: 8 mg, 77.76% [00498] 1H NMR and LCMS: ES MS M/Z=443 (M+1), NMR (400 MHz, DMSO-d6) δ 9.41 (br s, 1H), 7.70 (d, 1H), 7.64 (d, 1H), 7.21 (d, 1H), 6.57 (d, 1H), 4.70 (d, 2H), 4.37 (d, 2H), 3.84 (t, 2H), 3.78 (s, 3H), 3.45 (t, 2H), 2.78 (s, 3H), 2.00 (s, 3H), 1.23 (s, 1H). Example 223: Synthesis of 4-(5-(ethylamino)-1-(3-methyloxetan-3-yl)-1H-benzo[d]imidazo l-2-yl)-3- fluoro-6-methoxybenzene-1,2-diol [00499] Step-1: To a stirred solution of tert-butyl N-(4-fluoro-3-nitrophenyl)carbamate (500 mg, 1.95 mmol) in N,N-dimethylformamide (7.00 mL) was added sodium hydride (93.7 mg, 1.2 eq., 2.34 mmol) at 0°C and stirred for half an hour at room temperature. After half an hour, iodoethane (240 µL, 1.5 eq., 2.93 mmol) was added and the solution was stirred for 2 hours at room temperature. After completion, reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to get crude. The crude was purified by flash chromatography. The desired fractions concentrated to afford tert-butyl N-ethyl-N-(4- fluoro-3-nitrophenyl)carbamate (418 mg, 1.40 mmol) as yellow liquid. Yield: 0.418 g, 71.58% [00500] Step-2: To a stirred solution of tert-butyl N-ethyl-N-(4-fluoro-3-nitrophenyl)carbamate (418 mg, 1.47 mmol) in 1-methylpyrrolidin-2-one (2.00 mL) was added 3-methyloxetan-3-amine (185 µL, 1.5 eq., 2.21 mmol) and ethylbis(propan-2-yl)amine (514 µL, 2 eq., 2.94 mmol) and heated at 100°C for 16h. After completion of reaction, reaction mixture diluted with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulphate, filtered and concentrated to afford tert-butyl N- ethyl-N-{4-[(3-methyloxetan-3-yl)amino]-3-nitrophenyl}carbam ate (483 mg, 1.22 mmol) as yellow solid. Yield: 0.483 g (83.2%) [00501] Step-3: To a stirred solution of tert-butyl N-ethyl-N-{4-[(3-methyloxetan-3-yl)amino]-3- nitrophenyl}carbamate (300 mg, 854 µmol) in methanol (10.0 mL), zinc (279 mg, 5 eq., 4.27 mmol) and ammonium chloride (228 mg, 5 eq., 4.27 mmol) were added at room temperature and stirred at 50°C for 1h. After completion of the reaction, reaction mixture was passed through celite and washed with 10% methanol in dichloromethane, filtrate was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure to get the desired product. Yield: 0.256 g, (78.37%) [00502] Step-4: To a stirred solution of tert-butyl N-{3-amino-4-[(3-methyloxetan-3-yl)amino]phenyl}- N-ethylcarbamate (250 mg, 778 µmol) and 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (285 mg, 778 µmol) in methanesulfinylmethane (5.00 mL) was added disodium sulfinatosulfonate (177 mg, 1.2 eq., 933 µmol) at room temperature. The resulting mixture stirred for 2 h at 85 °C. After completion, reaction mixture cooled to room temperature and diluted with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to get crude. The crude purified by flash chromatography. The desired fractions concentrated to afford tert- butyl N-{2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-meth yloxetan-3-yl)-1H-1,3- benzodiazol-5-yl}-N-ethylcarbamate (240 mg, 349 µmol) as off white solid. Yield: 0.24 g, 44.82% [00503] Step-5: To a stirred solution of tert-butyl N-{2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]- 1-(3-methyloxetan-3-yl)-1H-1,3-benzodiazol-5-yl}-N-ethylcarb amate (140 mg, 210 µmol) was added trifluoroacetic acid (2.00 mL) and the resulting mixture was stirred for 2 h at 50 °C. After completion, the reaction mixture was concentrated under reduced pressure to get the crude and further purified by reverse phase HPLC. Desired fractions were lyophilized to afford 4-[5-(ethylamino)-1-(3-methyloxetan-3-yl)- 1H-1,3-benzodiazol-2-yl]-3-fluoro-6-methoxybenzene-1,2-diol (53.0 mg, 136 µmol) as white solid. Yield: 0.053g, 65% [00504] 1H NMR and LCMS: ES MS M/Z=388 (M+1),1H NMR (400 MHz, DMSO-d6) δ 14.65 (s,1H), 9.90 (br s, 2H), 7.37 (d, 1H), 7.02 (s, 1H), 6.84 (s, 1H), 6.73 (d, 1H), 4.73 (d, 2H), 4.44 (d, 2H), 3.81 (s, 3H), 3.16 (d, 2H), 2.11 (s, 3H), 1.21 (t, 3H). Example 224: Synthesis of N-(2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-1-(3-methyloxe tan-3- yl)-1H-benzo[d]imidazol-5-yl)-3-hydroxypropanamide [00505] Step-1: To a stirred solution of phenylmethanol (962 µL, 9.25 mmol) in oxolane (20.0 mL) was added sodium hydride (444 mg, 1.2 eq., 11.1 mmol) at 0 °C and stirred for 20 minutes at room temperature. methyl 3-bromopropanoate (1.11 mL, 1.1 eq., 10.2 mmol) was added at 0 °C and stirred for 16h at room temperature. After completion, reaction mixture quenched with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to get crude. as off white solid. Crude was purified by flash chromatography. Desired fractions were concentrated to get methyl 3-(benzyloxy)propanoate (500 mg, 1.18 mmol) as transparent oil. Yield: 0.50 g, 12.81% [00506] Step-2: To a stirred solution of methyl 3-(benzyloxy)propanoate (500 mg, 2.57 mmol) in methanol (5.00 mL) and water (5.00 mL) was added sodium hydroxide (515 mg, 5 eq., 12.9 mmol) at 0 °C and stirred for 2h at 50 °C. After completion, reaction mixture organic layer was concentrated and crude was acidified with 6N hydrochloric acid and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to get 3-(benzyloxy)propanoic acid (270 mg, 1.12 mmol) as transparent oil. Yield: 0.27 g, 43.65% [00507] Step-3: To a stirred solution of 4-fluoro-3-nitroaniline (200 mg, 1.04 mmol) and 3- (benzyloxy)propanoic acid (238 mg, 1.04 mmol) in N,N-dimethylformamide (10.0 mL) was added hexafluoro-λ⁵-phosphanuide 1-[bis(dimethylamino)methylidene]-1H-1λ⁵-[1,2,3]triazolo[ 4,5-b]pyridin-3- ium-1-ylium-3-olate (594 mg, 1.5 eq., 1.56 mmol) and ethylbis(propan-2-yl)amine (544 µL, 3 eq., 3.13 mmol) and the solution was stirred for 6 hours at room temperature. After completion of reaction, the reaction mixture diluted with water and extracted with ethyl acetate. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to obtain crude. The crude was purified by flash chromatography. The desired fractions concentrated to afford 3-(benzyloxy)-N-(4-fluoro-3- nitrophenyl)propanamide (230 mg, 715 µmol) as yellow liquid. Yield: 0.23 g, 68.67% [00508] Step-4: To a stirred solution of 3-(benzyloxy)-N-(4-fluoro-3-nitrophenyl)propanamide (230 mg, 723 µmol) and 3-methyloxetan-3-amine (64.9 µL, 2 eq., 1.45 mmol) in 1-methylpyrrolidin-2-one (5.00 mL) was added ethylbis(propan-2-yl)amine (378 µL, 3 eq., 2.17 mmol) and the solution was stirred for 6 hours at 110 °C. After completion of reaction, the reaction mixture diluted with water and extracted with ethyl acetate. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to obtain 3-(benzyloxy)-N-{4-[(3-methyloxetan-3-yl)amino]-3-nitropheny l}propanamide (240 mg, 455 µmol) crude. Yield: 0.24 g, 62.91% [00509] Step-5: To a stirred solution of 3-(benzyloxy)-N-{4-[(3-methyloxetan-3-yl)amino]-3- nitrophenyl}propanamide (230 mg, 597 µmol) in methanol (5.00 mL) was added zinc (195 mg, 5 eq., 2.98 mmol) and ammonium chloride (160 mg, 5 eq., 2.98 mmol) were added at room temperature and stirred at 50°C for 1h. After completion of the reaction, reaction mixture was passed through celite and washed with dichloromethane, filtrate was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure to get N-{3-amino-4-[(3-methyloxetan-3-yl)amino]phenyl}-3- (benzyloxy)propanamide (200 mg, 501 µmol) (crude) as brown solid. Yield: 0.20 g, 83.92% [00510] Step-6: To a stirred solution of N-{3-amino-4-[(3-methyloxetan-3-yl)amino]phenyl}-3- (benzyloxy)propanamide (190 mg, 476 µmol) and 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (139 mg, 0.8 eq., 381 µmol) in methanesulfinylmethane (5.00 mL) was added disodium sulfinatosulfonate (109 mg, 1.2 eq., 571 µmol) at room temperature. The resulting mixture stirred for 16 h at 85 °C. After completion, reaction mixture cooled to room temperature and diluted with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to get crude. The crude purified by flash chromatography. The desired fractions concentrated to afford 3-(benzyloxy)-N-{2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphe nyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazol-5-yl}propanamide (150 mg, 203 µmol) as off white solid. Yield: 0.15 g, 42.68% [00511] Step-7: To a stirred solution of 3-(benzyloxy)-N-{2-[3,4-bis(benzyloxy)-2-fluoro-5- methoxyphenyl]-1-(3-methyloxetan-3-yl)-1H-1,3-benzodiazol-5- yl}propanamide (120 mg, 171 µmol) in Tetrahydrofuran (10.0 mL) was added 20% Palladium hydroxide (155 mg, 1.3 eq., 222 µmol) at room temperature and the reaction mixture stirred for 3h under hydrogen atmosphere. After completion, the reaction mixture passed through celite bed. Filtrate was concentrated to get crude. Crude was purified by reverse phase HPLC and desired fractions were lyophilized to get N-[2-(2-fluoro-3,4-dihydroxy-5- methoxyphenyl)-1-(3-methyloxetan-3-yl)-1H-1,3-benzodiazol-5- yl]-3-hydroxypropanamide (30.0 mg, 68.8 µmol) as off white solid. Yield: 0.030 g, 40.26% [00512] ES MS M/Z = 432.08 (M +1), 1H NMR (400 MHz, DMSO-d6) δ 9.92 (s, 1H), 9.36 (brs, 1H), 8.05 (d, 1H), 7.42-7.40 (dd, 1H), 7.19 (d, 1H), 6.58 (d, 1H), 4.71 (d, 2H), 4.37 (d, 2H), 3.78 (s, 3H), 3.74 (t, 2H), 2.49 (s, 2H), 1.99 (s,3H). Example 225: Synthesis of 6-methoxy-3-methyl-4-(1-(1-methylcyclobutyl)-1H-benzo[d]imid azol-2- yl)benzene-1,2-diol
[00513] Step-1: To a stirred solution of 1-fluoro-2-nitrobenzene (800 mg, 5.67 mmol) in 1- methylpyrrolidin-2-one (4.00 mL) cyclobutanamine (484 mg, 1.2 eq., 6.80 mmol) and N-cyclobutyl-2- nitroaniline (800 mg, 3.07 mmol) were added and reaction mixture was heated to 90 °C for 16 h. After completion, the reaction mixture diluted with water and extracted with dichloromethane. The combined organic layers dried over anhydrous sodium sulphate, filtered and concentrated to obtain crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford N-cyclobutyl- 2-nitroaniline (800 mg, 3.07 mmol) as yellow oil. Yield: 800 mg, 54.12% [00514] Step-2: To a stirred solution of N-cyclobutyl-2-nitroaniline (800 mg, 4.16 mmol) in methanol zinc (1.63 g, 6 eq., 25.0 mmol) and Ammonium chloride (1.34 g, 6 eq., 25.0 mmol) were added and reaction mixture was stirred at room temperature for 2 h. After completion, the reaction mixture was filtered through celite bed and solvent was removed under reduced pressure. The crude diluted with water and extracted with dichloromethane. The combined organic layers dried over anhydrous sodium sulphate, filtered and concentrated to obtain N1-cyclobutylbenzene-1,2-diamine (700 mg, 2.09 mmol) as yellow oil. Yield: 700 mg, 50.31% [00515] Step-3: To a stirred solution N1-(1-methylcyclobutyl)benzene-1,2-diamine (200 mg, 1.13 mmol) and 3,4-bis(benzyloxy)-5-methoxy-2-methylbenzaldehyde (288 mg, 0.7 eq., 794 µmol) in Methanol (2.00 mL) was added Acetic acid (200 mL) at 80 °C for 6 h. After completion, reaction mixture concentrated under reduced pressure to get crude 2-[3,4-bis(benzyloxy)-5-methoxy-2-methylphenyl]-1- (1-methylcyclobutyl)-1H-1,3-benzodiazole (150 mg, 217 µmol) as brown mass. Yield: 150 mg, 19.12% [00516] Step-4: To a stirred solution of 2-[3,4-bis(benzyloxy)-5-methoxy-2-methylphenyl]-1-(1- methylcyclobutyl)-1H-1,3-benzodiazole (150 mg, 289 µmol) in Tetrahydrofuran (5.00 mL), Palladium hydroxide (35.4 mg, 289 µmol) was charged and stirred under hydrogen atmosphere at room temperature for 2 h. After completion of reaction, reaction mixture filtered through celite. Filtrate was distilled below 30 °C to obtain 6-methoxy-3-methyl-4-[1-(1-methylcyclobutyl)-1H-1,3-benzodia zol-2-yl]benzene-1,2- diol (34.0 mg, 100 µmol) as pale green solid. Crude was submitted for Prep purification which afforded 6-methoxy-3-methyl-4-[1-(1-methylcyclobutyl)-1H-1,3-benzodia zol-2-yl]benzene-1,2-diol (34.0 mg, 100 µmol). Yield: 34 mg, 34.66% [00517] ES MS M/Z = 339.13 (M + 1), UPLC: 99.78%. 1 HNMR (400 MHz, DMSO-d6): δ 8.86 (bs, 1H), 8.57 (bs, 1H), 7.62 (dd, J = 5.2 Hz, 2 Hz, 1H), 7.44 (dd, J = 7.2 Hz, 4.0 Hz, 1H), 7.20-7.18 (m, 2H), 6.42 (s, 1H), 3.74 (s, 3H), 2.44-2.41 (m, 2H), 2.11 (d, J = 10.0 Hz, 1H), 1.93 (s, 3H), 1.89-1.82 (m, 2H), 1.77 (s, 3H), 1.70-1.63 (m, 1H), 1.56 (bs, 1H). Example 226: Synthesis of 4-(1-isopropyl-1H-benzo[d]imidazol-2-yl)-6-methoxy-3-methylb enzene- 1,2-diol [00518] Step-1: To a stirred solution of 1-fluoro-2-nitrobenzene (500 mg, 3.54 mmol) in Isopropyl alcohol (5.00 mL) propan-2-amine (290 µL, 3.54 mmol) was added followed by addition of ethylbis(propan-2-yl)amine (1.86 mL, 3 eq., 10.6 mmol) and reaction mixture was heated to 90 °C for 16 h. After completion solvent was removed under reduced pressure to get the crude. The crude purified by flash chromatography. The desired fraction were concentrated to afford2-nitro-N-(propan-2-yl)aniline (450 mg, 2.42 mmol) as yellow oil. Yield: 450 mg, 68.36% [00519] Step-2: To a stirred solution of 2-nitro-N-(propan-2-yl)aniline (450 mg, 2.50 mmol) in methanol (10.0 mL), Palladium on carbon (133 mg, 0.5 eq., 1.25 mmol) was charged and stirred under hydrogen atmosphere at room temperature for 1h. After completion of reaction, reaction mixture filtered through celite. Filtrate was distilled below 30 °C to obtain N1-(propan-2-yl)benzene-1,2-diamine (350 mg, 2.33 mmol) as black sticky mass. Yield: 200 mg, 93.3% [00520] Step-3: To a stirred solution N1-(propan-2-yl)benzene-1,2-diamine (200 mg, 1.50 mmol) and 3,4-bis(benzyloxy)-5-methoxy-2-methylbenzaldehyde (434 mg, 0.8 eq., 1.20 mmol) in Methanol (5.00 mL) was added Acetic acid (200 µL) at room temperature. The resulting mixture was stirred at 85 °C for 6 h. After completion, reaction mixture concentrated under reduced pressure to get crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 2-[3,4- bis(benzyloxy)-5-methoxy-2-methylphenyl]-1-(propan-2-yl)-1H- 1,3-benzodiazole (180 mg, 226 µmol) as yellow sticky mass. Yield: 180.0 mg, 15.1% [00521] Step-4: To a stirred solution of 2-[3,4-bis(benzyloxy)-5-methoxy-2-methylphenyl]-1-(propan-2- yl)-1H-1,3-benzodiazole (150 mg, 304 µmol) in Tetrahydrofuran (5.00 mL), Palladium hydroxide (37.3 mg, 304 µmol) was charged and stirred under hydrogen atmosphere at room temperature for 2 h. After completion of reaction, reaction mixture filtered through celite. Filtrate was distilled below 30 °C to obtain crude and purification of compound was purified by Reverse Prep HPLC to get 6-methoxy-3- methyl-4-[1-(propan-2-yl)-1H-1,3-benzodiazol-2-yl]benzene-1, 2-diol (34.0 mg, 109 µmol) as light pink solid. Yield: 34.0 mg, 35.71% [00522] 1 H NMR and LCMS : ES MS M/Z = 313.14 (M + 1), UPLC: 99.89%. 1 HNMR (400 MHz, DMSO-d6): δ 8.91(bs, 1H), 8.65 (bs, 1H), 7.76 (dd, J = 6.0 Hz, 2.0 Hz, 1H), 7.63 (dd, J = 6.4 Hz, 3.2 Hz, 1H), 7.23-7.18 (m, 2H), 6.45 (s, 1H), 4.35-4.28 (m, 1H), 3.75 (s, 3H), 1.86 (s, 3 H), 1.50 (s, 3H), 1.49 (s, 3 H). Example 227: Synthesis of 4-(1-(tert-butyl)-1H-benzo[d]imidazol-2-yl)-6-methoxy-3- methylbenzene-1,2-diol [00523] Step-1: To a stirred solution of 1-fluoro-2-nitrobenzene (500 mg, 3.54 mmol) in propan-2-ol, ethylbis(propan-2-yl)amine (458 mg, 3.54 mmol) was added followed by 2-methylpropan-2-amine (259 mg, 3.54 mmol) and reaction mixture was heated to 90 °C for 48 h. After completion, isopropyl alcohol was removed under reduced pressured and diluted with water and extracted with ethyl acetate. The combined organic layers dried over anhydrous sodium sulphate, filtered and concentrated to obtain crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford N-tert- butyl-2-nitroaniline (500 mg, 2.57 mmol) as yellow oil. Yield: 500 mg, 72.64% [00524] Step-2: To a stirred solution of N tert-butyl-2-nitroaniline (500 mg, 2.57 mmol) in methanol (5.00 mL) Palladium on carbon (54.8 mg, 0.2 eq., 515 µmol) was charged and stirred under hydrogen atmosphere at room temperature for 2 h. After completion of reaction, reaction mixture filtered through celite. Filtrate was distilled below 30 °C to obtain N1-tert-butylbenzene-1,2-diamine (400 mg, 2.33 mmol) as brown mass. Yield: 450 mg, 90.35% [00525] Step-3: To a stirred solution N1-tert-butylbenzene-1,2-diamine (250 mg, 1.52 mmol) and 3,4- bis(benzyloxy)-5-methoxy-2-methylbenzaldehyde (386 mg, 0.7 eq., 1.07 mmol) in Methanol (5.00 mL) was added Acetic acid (100 µL) at room temperature. The resulting mixture stirred for 6 h at 85 °C. After completion, reaction mixture concentrated under reduced pressure to get crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 2-[3,4-bis(benzyloxy)-5- methoxy-2-methylphenyl]-1-tert-butyl-1H-1,3-benzodiazole (150 mg, 224 µmol) as yellow wax. Yield: 150 mg, 14.73% [00526] Step-4: To a stirred solution of 2-[3,4-bis(benzyloxy)-5-methoxy-2-methylphenyl]-1-tert-butyl - 1H-1,3-benzodiazole (160 mg, 316 µmol) in Tetrahydrofuran (5.00 mL), Palladium hydroxide (38.7 mg, 316 µmol) was charged and stirred under hydrogen atmosphere at room temperature for 2 h. After completion of reaction, reaction mixture filtered through celite. Filtrate was distilled below 30 °C to obtain 4-(1-tert-butyl-1H-1,3-benzodiazol-2-yl)-6-methoxy-3-methylb enzene-1,2-diol (32.0 mg, 97.4 µmol) as pale green solid. Yield: 32 mg, 30.85% [00527] ES MS M/Z = 327.11 (M + 1), UPLC: 99.38%. 1 HNMR (400 MHz, DMSO-d6): δ 8.74(bs, 1H), 8.56 (bs, 1H), 7.85-7.82 (m, 1H), 7.59-7.57 (m, 1H), 7.23-7.17 (m, 2H), 6.44 (s, 1H), 3.73 (s, 3H), 1.78 (s, 3 H), 1.53 (s, 9H). Example 228: Synthesis of 2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-N,N-dimethyl-1-(3 - methyloxetan-3-yl)-1H-benzo[d]imidazole-6-sulfonamide [00528] Step-1: To a stirred solution of Dimethylamine hydrochloride (67.6 mg, 835 µmol) in dichloromethane (10.0 mL) was added triethylamine (233 µL, 2 eq., 1.67 mmol) and stirred for 5 minutes.3-fluoro-4-nitrobenzene-1-sulfonyl chloride (200 mg, 835 µmol) was added to the solution and was stirred for 1 hour at room temperature. After completion of reaction, the reaction mixture diluted with water and extracted with dichloromethane. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to obtain crude. The crude was purified by flash chromatography. The desired fractions concentrated to afford 3-fluoro-N,N-dimethyl-4-nitrobenzene-1-sulfonamide (160 mg, 625 µmol) as yellow solid. Yield: 0.16 g, 74.9% [00529] Step-2: To a stirred solution of 3-fluoro-N,N-dimethyl-4-nitrobenzene-1-sulfonamide (160 mg, 645 µmol) and 3-methyloxetan-3-amine (112 mg, 2 eq., 1.29 mmol) in 1-methylpyrrolidin-2-one (5.00 mL) was added ethylbis(propan-2-yl)amine (337 µL, 3 eq., 1.93 mmol) and the solution was stirred for 16 hours at 110 °C. After completion of reaction, the reaction mixture diluted with water and extracted with ethyl acetate. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to obtained N,N-dimethyl-3-[(3-methyloxetan-3-yl)amino]-4-nitrobenzene-1 -sulfonamide (180 mg, 537 µmol) (crude) as brown solid. Yield: 0.180 g, 83.24% [00530] Step-3: To a stirred solution of N,N-dimethyl-3-[(3-methyloxetan-3-yl)amino]-4-nitrobenzene-1 - sulfonamide (180 mg, 571 µmol) in methanol (5.00 mL) was added zinc (187 mg, 5 eq., 2.85 mmol) and ammonium chloride (153 mg, 5 eq., 2.85 mmol) were added at room temperature and stirred at 50°C for 1h. After completion of the reaction, reaction mixture was passed through celite and washed with dichloromethane, filtrate was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure to get 4-amino-N,N-dimethyl-3-[(3-methyloxetan-3-yl)amino]benzene-1 - sulfonamide (130 mg, 424 µmol) (crude) as brown solid. Yield: 0.13 g, 74.22% [00531] Step-4: To a stirred solution of disodium sulfinatosulfonate (104 mg, 1.2 eq., 547 µmol) and 3,4- bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (134 mg, 0.8 eq., 364 µmol) in methanesulfinylmethane (5.00 mL) was added disodium sulfinatosulfonate (104 mg, 1.2 eq., 547 µmol) at room temperature. The resulting mixture stirred for 16 h at 85 °C. After completion, reaction mixture cooled to room temperature and diluted with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to get crude. The crude purified by flash chromatography. The desired fractions concentrated to afford 2-[3,4- bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-N,N-dimethyl-1-(3-m ethyloxetan-3-yl)-1H-1,3-benzodiazole- 6-sulfonamide (165 mg, 248 µmol) as brown oil. Yield: 0.165 g, 54.47% [00532] Step-5: To a solution of 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-N,N-dimethyl -1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazole-6-sulfonamide (100 mg, 158 µmol) in trifluoroacetic acid (1.00 mL) was stirred for 3h at 60 °C. After completion, the reaction mixture was concentrated to get crude. Crude was purified by reverse phase HPLC and pure fractions were lyophilized to get 2-(2-fluoro-3,4- dihydroxy-5-methoxyphenyl)-N,N-dimethyl-1-(3-methyloxetan-3- yl)-1H-1,3-benzodiazole-6- sulfonamide (28.0 mg, 61.4 µmol) as off white solid. Yield: 0.028 g, 38.79% [00533] ES MS M/Z = 452.10 (M +1), 1H NMR (400 MHz, DMSO-d6) δ 9.58 (brs, 2H), 7.96 (d, 1H), 7.66-7.64 (dd, 1H), 7.49 (s, 1H), 6.65 (d, 1H), 4.7 (d, 2H), 4.45 (d, 2H), 3.79 (s, 3H), 2.61 (s, 6H), 2.07 (s, 3H). Example 229: Synthesis of 3-fluoro-6-methoxy-4-(1-(3-methyloxetan-3-yl)-1H-imidazo[4,5 - c]pyridin-2-yl)benzene-1,2-diol [00534] Step-1: To a stirred solution of 3-nitropyridin-4-ol (2.00 g, 14.3 mmol) in phosphoroyl trichloride (10.0 mL) was heated to 100 °C for 16h. After completion of reaction concentrated completely and basified with 10% sodium hydroxide solution and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered and concentrated to get 4-chloro-3- nitropyridine (1.50 g, 8.99 mmol) as brown solid. Yield: 1.50 g, 62.96% [00535] Step-2: To a stirred solution of 4-chloro-3-nitropyridine (500 mg, 3.15 mmol) in N-Methyl-2- Pyrrolidone (NMP) (5.00 mL) were added 3-methyloxetan-3-amine (285 µL, 2 eq., 6.31 mmol) and N, N- Diisopropylethylamine (1.65 mL, 3 eq., 9.46 mmol) at room temperature and stirred for 16h at 80°C. After completion, reaction mixture quenched with ice cold water and extracted with ethyl acetate and organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to get N-(3- methyloxetan-3-yl)-3-nitropyridin-4-amine (200 mg, 841 µmol) crude. Yield: 0.20 g, 26.68% [00536] Step-3: To a stirred solution of N-(3-methyloxetan-3-yl)-3-nitropyridin-4-amine (200 mg, 841 µmol) in methanol (5.00 mL) , zinc (275 mg, 5 eq., 4.21 mmol) and ammonium chloride (225 mg, 5 eq., 4.21 mmol) were added at room temperature and stirred at 50°C for 1h. After completion of the reaction, reaction mixture was passed through celite and washed with 10% methanol in dichloromethane, filtrate was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure to get N4-(3-methyloxetan-3-yl)pyridine-3,4-diamine (120 mg, 402 µmol) (crude). Yield: 0.12 g, Crude [00537] Step-4: To a stirred solution of N4-(3-methyloxetan-3-yl)pyridine-3,4-diamine (100 mg, 279 µmol) and 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (81.8 mg, 0.8 eq., 223 µmol) in toluene (1.00 mL) and N,N-dimethylformamide (1.00 mL) was added 4-methylbenzene-1-sulfonic acid (9.61 mg, 0.2 eq., 55.8 µmol) at room temperature. The resulting mixture stirred for 16 h at 100 °C. After completion, reaction mixture cooled to room temperature and diluted with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to get crude. The crude purified by flash chromatography. The desired fractions concentrated to afford 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methylo xetan-3-yl)-1H-imidazo[4,5- c]pyridine (40.0 mg, 57.1 µmol) as off white solid. Yield: 0.04 g, 20.46% [00538] Step 5: To a solution of 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methylo xetan-3- yl)-1H-imidazo[4,5-c]pyridine (40.0 mg, 76.1 µmol) in trifluoroacetic acid (1.00 mL) was stirred for 3h at 60 °C. After completion, the reaction mixture was concentrated to get crude. Crude was purified by reverse phase HPLC and pure fractions were lyophilized to get 3-fluoro-6-methoxy-4-[1-(3- methyloxetan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl]benzene-1,2 -diol (6.00 mg, 17.2 µmol) as off white solid. Yield: 0.006 g, 22.6% ES MS M/Z = 346.15 (M +1), 1H NMR (400 MHz, DMSO-d6) δ 9.56 (brs, 1H), 9.00 (s, 1H), 8.36 (d, 1H), 7.38 (d, 1H), 6.65 (d, 1H), 4.74 (d, 2H), 4.39 (d, , 1H), 3.79 (s, 3H), 2.00 (s, 3H). Example 230: Synthesis of 3-fluoro-6-methoxy-4-[3-(3-methyloxetan-3-yl)-3H-imidazo[4,5 - c]pyridin-2-yl]benzene-1,2-diol
[00539] Step-1a: To a stirred solution of 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (200 mg, 546 µmol) in oxolane (4.00 mL) and water (1.00 mL) sulfamic acid (106 mg, 2 eq., 1.09 mmol) followed by addition of sodium chlorite (74.1 mg, 1.5 eq., 819 µmol) at 0 °C. The resulting reaction mixture stirred at room temperature for 12 h. After the completion of reaction, water was added and extracted with ethyl acetate. The combined organic fractions were collected, dried over anhydrous sodium sulfate, filtered and concentrated to obtain crude. The crude purified by flash chromatography. The desired fractions were collected and concentrated to obtain 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzoic acid (110 mg, 288 µmol) as cream colored solid. Yield: 110 mg, 52.7% [00540] Step-1: To a stirred solution of N, N-Diisopropylethylamine (369 µL, 3 eq., 2.11 mmol) in N- Methyl-2-Pyrrolidone (NMP) (5.00 mL), 3-methyloxetan-3-amine (63.3 µL, 2 eq., 1.41 mmol) was added at room temperature and stirred at 130°C for 1h. After completion, reaction mixture quenched with ice cold water, precipitate was formed, solid was filtered and dried to afford N-(3-methyloxetan-3-yl)-4- nitropyridin-3-amine (200 mg, 287 µmol) as a yellow oil. Yield: 0.20 g, 40.75% [00541] Step-2: To a stirred solution of N-(3-methyloxetan-3-yl)-4-nitropyridin-3-amine (100 mg, 478 µmol) in methanol (5.00 mL), Zinc dust (155 mg, 5 eq., 2.39 mmol) and ammonium chloride (128 mg, 5 eq., 2.39 mmol) were added at room temperature and the reaction mixture stirred for 2h at 30°C. After completion, the reaction mixture passed through celite bed. The filtrate was extracted with ethyl acetate, organic layer dried over anhydrous sodium sulphate, filtered and concentrated to get as N3-(3- methyloxetan-3-yl)pyridine-3,4-diamine (75.0 mg, 418 µmol) as a sticky liquid. Yield: 75 mg, 87.55% [00542] Step-3: To a stirred solution of N3-(3-methyloxetan-3-yl)pyridine-3,4-diamine (46.9 mg, 262 µmol) in N,N-dimethylformamide (2.00 mL) was added 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzoic acid (100 mg, 262 µmol), hexafluoro-λ⁵-phosphanuide 1-[bis(dimethylamino)methylidene]-1H-1λ⁵- [1,2,3]triazolo[4,5-b]pyridin-3-ium-1-ylium-3-olate (149 mg, 1.5 eq., 392 µmol) and ethylbis(propan-2- yl)amine (137 µL, 3 eq., 785 µmol) and the solution was stirred for 16 hours. After completion of reaction, the reaction mixture diluted with water and extracted with ethyl acetate. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to obtain crude. The crude was purified by flash chromatography. The desired fractions concentrated to afford 3,4-bis(benzyloxy)-2-fluoro-5- methoxy-N-{3-[(3-methyloxetan-3-yl)amino]pyridin-4-yl}benzam ide (80.0 mg, 147 µmol) as yellow liquid. Yield: 80 mg, 56.28% [00543] Step-4: 3,4-bis(benzyloxy)-2-fluoro-5-methoxy-N-{3-[(3-methyloxetan- 3-yl)amino]pyridin-4- yl}benzamide (70.0 mg, 129 µmol) taken in acetic acid (1.00 mL) at room temperature. The resulting mixture was stirred at 80 °C for 16 h. The progress of reaction monitored by LCMS and TLC analysis. After the completion of starting material, acetic acid was concentrated to obtain the crude. The crude washed with n-pentane and diethylether to obtain 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-3- (3-methyloxetan-3-yl)-3H-imidazo[4,5-c]pyridine (65.0 mg, 124 µmol) as yellow liquid. Yield: 65 mg, 96.04% [00544] Step-5: To 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-3-(3-methylo xetan-3-yl)-3H- imidazo[4,5-c]pyridine (70.0 mg, 133 µmol), trifluoroacetic acid (2.00 mL) added at room temperature. The resulting reaction mixture stirred at 60 °C for 4 h. After the complete consumption of starting material, reaction mixture was concentrated to obtain the crude. The crude purified in reverse-phase HPLC and desired fraction were collected, lyophilized to obtain 3-fluoro-6-methoxy-4-[3-(3- methyloxetan-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl]benzene-1,2 -diol (17.0 mg, 49.2 µmol) as beige solid. Yield: 17 mg, 36.96% [00545] LCMS and NMR Data: ES MS M/Z = 345.92 (M + 1); UPLC: 99.22% 1 H NMR (400 MHz, DMSO-d6) δ 9.52 (Bs, -OH peaks), 8.71 (s, 1H), 8.41 (d, J = 5.2 Hz,1H), 7.71 (d, J = 5.2 Hz, 1H), 6.64 (d, J = 6.0 Hz, 1H), 4.75 (d, J = 6.0 Hz, 2H), 4.43 (d, J = 6.0 Hz, 2H), 3.79 (s, 3H), 2.06 (s, 3H), Example 231: Synthesis of 3-fluoro-4-(5-fluoro-1H-benzo[d]imidazol-2-yl)-6-methoxybenz ene-1,2- diol [00546] Step-1: To a solution of 5-fluoro-2-nitroaniline (300 mg, 1.92 mmol) in methanol (10.0 mL) was added 10% Palladium on Carbon (50% wet) (300 mg, 2.82 mmol) at room temperature and the reaction mixture stirred for 2h under hydrogen atmosphere. After completion, the reaction mixture passed through celite bed. The filtrate was concentrated to get 4-fluorobenzene-1,2-diamine (200 mg, 1.11 mmol) as green solid. Yield: 0.20 g, 58% [00547] Step-2: To a stirred solution 4-fluorobenzene-1,2-diamine (130 mg, 1.03 mmol) and 3,4- bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (302 mg, 0.8 eq., 825 µmol) in methanol (10.0 mL) was added acetic acid (5.89 µL, 0.1 eq., 103 µmol) at room temperature. The resulting mixture stirred for 16 h at room temperature. After completion, reaction mixture concentrated under reduced pressure to get the crude. Crude was purified by flash chromatography. Desired fractions were concentrated to get 2- [3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-5-fluoro-1H-1, 3-benzodiazole (145 mg, 301 µmol) as off white semi solid. Yield: 0.145 g, 29.18% [00548] Step-3: To a solution of 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-5-fluoro-1H- 1,3- benzodiazole (120 mg, 254 µmol) in tetrahydrofuran (5.00 mL) was added 20% Palladium hydroxide (600 mg, 3.4 eq., 857 µmol) at room temperature and the reaction mixture stirred for 3h under hydrogen atmosphere. After completion, the reaction mixture passed through celite bed. Filtrate was concentrated to get crude. Crude was purified by reverse phase HPLC and desired fractions were lyophilized to get 3- fluoro-4-(5-fluoro-1H-1,3-benzodiazol-2-yl)-6-methoxybenzene -1,2-diol (38.0 mg, 129 µmol) as white solid. Yield: 0.038 g, 50.69% [00549] ES MS M/Z = 293.04 (M +1) + , 1 H NMR (400 MHz, DMSO-d6) δ 9.83-9.71 (m, 2H), 7.70-7.67 (m, 1H), 7.50 (dd, J = 2.4, 9.2 Hz, 1H), 7.23-7.21 (m, 2H), 3.87 (s, 3H). Example 232: Synthesis of 3-fluoro-6-methoxy-4-(1-(3-methyloxetan-3-yl)-1H-benzo[d]imi dazol-2- yl)benzene-1,2-diol [00550] Step-1: To a stirred solution of 1-fluoro-2-nitrobenzene (4.00 g, 28.3 mmol) in 1- methylpyrrolidin-2-one (20.0 mL), 3-methyloxetan-3-amine (3.70 g, 1.5 eq., 42.5 mmol)and ethylbis(propan-2-yl)amine (13.9 mL, 3 eq., 85.0 mmol) were added at room temperature and stirred at 100°C for 16h. After completion, reaction mixture quenched with ice cold water and obtained precipitate was filtered and dried to afford 3-methyl-N-(2-nitrophenyl)oxetan-3-amine (4.50 g, 20.3 mmol)as a yellow solid. Yield: 4.50 g, 71.66% [00551] Step-2: To a stirred solution of 3-methyl-N-(2-nitrophenyl)oxetan-3-amine (6.50 g, 29.3 mmol) in methanol (50.0 mL) was added zinc (9.59 g, 5 eq., 147 mmol) and ammonium chloride (7.85 g, 5 eq., 147 mmol) were added at room temperature and stirred at 50°C for 1h. After completion of the reaction, reaction mixture was passed through celite and washed with 10% methanol in dichloromethane, filtrate was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure to get N1-(3-methyloxetan-3-yl)benzene-1,2-diamine (4.00 g, 20.9 mmol) (crude) as brown solid. Yield: 4.00 g, 92.4% [00552] Step-3: To a stirred solution of N1-(3-methyloxetan-3-yl)benzene-1,2-diamine (150 mg, 842 µmol) and 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (308 mg, 842 µmol) in methanesulfinylmethane (5.00 mL) , disodium sulfinatosulfonate (208 mg, 1.3 eq., 1.09 mmol) was added at room temperature. The resulting mixture stirred for 12 h at 85 °C. After completion, ice cold water was added in the reaction mixture and solid was filtered and dried to get crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 2-[3,4-bis(benzyloxy)-2- fluoro-5-methoxyphenyl]-1-(3-methyloxetan-3-yl)-1H-1,3-benzo diazole (190 mg, 359 µmol) as sticky solid. Yield: 0.19 g, 42% [00553] Step-4: To a solution of 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methylo xetan-3- yl)-1H-1,3-benzodiazole (180 mg, 343 µmol) in oxolane (10.0 mL) was added 20% Palladium hydroxide (300 mg) at room temperature and the reaction mixture stirred for 3h under hydrogen atmosphere. After completion, the reaction mixture passed through celite bed. Filtrate was concentrated to get crude. Crude was purified by reverse phase HPLC and desired fractions were lyophilized to get 3-fluoro-6-methoxy-4- [1-(3-methyloxetan-3-yl)-1H-1,3-benzodiazol-2-yl]benzene-1,2 -diol (54.0 mg, 154 µmol) as white solid. [00554] ES MS M/Z = 345.1 (M +1), 1H NMR (400 MHz, DMSO-d6) δ 9.47 (brs, 2H), 7.70-7.68 (m, 1H), 7.28-7.26 (m, 3H), 6.60 (d, J = 6.4 Hz, 1H), 4.73 (d, J = 6.0 Hz, 2H), 4.39 (d, J = 6.0 Hz, 2H), 3.78 (s, 3H), 2.01 (s, 3H). Example 233: Synthesis of 5-(1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-3- (trifluoromethoxy)benzene-1,2-diol [00555] Step-1a: To a stirred solution of 1-fluoro-2-nitrobenzene (5.00 g, 35.4 mmol) in 1- methylpyrrolidin-2-one (30.0 mL) cyclobutanamine (3.02 g, 1.2 eq., 42.5 mmol) was added and reaction mixture was heated to 90 °C for 16 h. After completion, the reaction mixture diluted with water and extracted with dichloromethane. The combined organic layers dried over anhydrous sodium sulphate, filtered and concentrated to obtain crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford N-cyclobutyl-2-nitroaniline (2.00 g, 10.4 mmol) as yellow oil. Yield: 2.00 g, 29.36% [00556] Step-2a: To a stirred solution of N-cyclobutyl-2-nitroaniline (500 mg, 2.60 mmol) in methanol (10.0 mL), zinc (1.02 g, 6 eq., 15.6 mmol) and Ammonium chloride (835 mg, 6 eq., 15.6 mmol) were added and reaction mixture was stirred at room temperature for 4h. After completion, the reaction mixture was filtered through celite bed and solvent was removed under reduced pressure. The crude diluted with water and extracted with dichloromethane. The combined organic layers dried over anhydrous sodium sulphate, filtered and concentrated to obtain N1-cyclobutylbenzene-1,2-diamine (400 mg, 2.47 mmol) as yellow oil. Yield: 400 mg, Crude [00557] Step-1: To a stirred solution 2-(trifluoromethoxy)phenol (8.00 g, 44.9 mmol) in trifluoroacetic acid (60.0 mL) was added 1,3,5,7-tetraazatricyclo[3.3.1.1³,⁷]decane (12.6 g, 2 eq., 89.8 mmol) and stirred for 16h at 70 °C. After completion, reaction mixture diluted with water and extracted with ethyl acetate. Organic layer dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to get the crude. The crude purified by flash chromatography. The desired fractions concentrated to afford 4-hydroxy-3-(trifluoromethoxy) benzaldehyde (2.30 g, 10.6 mmol) as off white solid. Yield: 2.30 g, 23.6% Step-2: To a stirred solution 4-hydroxy-3-(trifluoromethoxy)benzaldehyde (700 mg, 3.40 mmol) in dichloromethane (10.0 mL) was added 1-bromopyrrolidine-2,5-dione (635 mg, 1.1 eq., 3.57 mmol) at 0 °C and stirred for 2h at room temperature. After completion, reaction mixture diluted with water and extracted with dichloromethane. Organic layer dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to get the crude. The crude was purified by flash chromatography and pure fractions were concentrated to get 3-bromo-4-hydroxy-5-(trifluoromethoxy)benzaldehyde (800 mg, 1.68 mmol) as off white solid. Yield: 0.80 g, 49.59% [00558] Step-3: To a stirred solution 3-bromo-4-hydroxy-5-(trifluoromethoxy)benzaldehyde (800 mg, 2.81 mmol) in N,N-dimethylformamide (10.0 mL) was added dipotassium carbonate (970 mg, 2.5 eq., 7.02 mmol) followed by (bromomethyl)benzene (500 µL, 1.5 eq., 4.21 mmol) and stirred for 16h at room temperature. After completion, reaction mixture diluted with water and extracted with ethyl acetate. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to get the crude. Crude was purified by flash chromatography and pure fractions were concentrated to get 4- (benzyloxy)-3-bromo-5-(trifluoromethoxy)benzaldehyde (800 mg, 1.86 mmol) as light brown oil. Yield: 0.80 g, 66.1% [00559] Step-4: To a solution of 4-(benzyloxy)-3-bromo-5-(trifluoromethoxy)benzaldehyde (750 mg, 2.00 mmol) in 1,4-dioxane (10.0 mL) and water (2.50 mL) was added potassium hydroxide (337 mg, 3 eq., 6.00 mmol) was added at room temperature and the reaction mixture was degassed with argon for 5 min. tris(1,5-diphenylpenta-1,4-dien-3-one) dipalladium (91.5 mg, 0.05 eq., 100 µmol) and di-tert- butyl[2',4',6'-tris(propan-2-yl)-[1,1'-biphenyl]-2-yl]phosph ane (84.9 mg, 0.1 eq., 200 µmol) was added to the reaction, continued degassing for 5 min and heated the reaction mixture at 100°C for 16 h. After completion, the reaction was cooled to room temperature and diluted with 6 N hydrochloric acid and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulphate, filtered and concentrated to give crude. The crude was purified by flash chromatography. The desired fractions were concentrated to get 4-(benzyloxy)-3-hydroxy-5-(trifluoromethoxy)benzaldehyde (300 mg, 845 µmol) as off white solid. Yield: 0.30 g, 42% [00560] Step-5: To a stirred solution of 4-(benzyloxy)-3-hydroxy-5-(trifluoromethoxy)benzaldehyde (154 mg, 0.8 eq., 493 µmol) and 2-(benzyloxy)-5-(1-cyclobutyl-1H-1,3-benzodiazol-2-yl)-3- (trifluoromethoxy)phenol (150 mg, 297 µmol) in Dimethyl sulfoxide (10.0 mL) was added disodium sulfinatosulfonate (141 mg, 1.2 eq., 740 µmol) at room temperature. The resulting mixture stirred for 2 h at 85 °C. After completion, reaction mixture cooled to room temperature and diluted with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure to get crude. The crude purified by flash chromatography. The desired fractions concentrated to afford 2-(benzyloxy)-5-(1-cyclobutyl-1H-1,3-benzodiazol-2-yl)-3- (trifluoromethoxy)phenol (150 mg, 297 µmol) as off white solid. Yield: 0.150 g, 48.19% [00561] Step-6: To a solution of 2-(benzyloxy)-5-(1-cyclobutyl-1H-1,3-benzodiazol-2-yl)-3- (trifluoromethoxy)phenol (150 mg, 330 µmol) in Tetrahydrofuran (10.0 mL) was added 20% Palladium hydroxide (200 mg, 0.87 eq., 286 µmol) at room temperature and the reaction mixture stirred for 3h under hydrogen atmosphere. After completion, the reaction mixture passed through celite bed. The filtrate was concentrated to get crude. The crude was purified by reverse phase HPLC and desired fractions were lyophilized to get 5-(1-cyclobutyl-1H-1,3-benzodiazol-2-yl)-3-(trifluoromethoxy )benzene- 1,2-diol (51.0 mg, 139 µmol) as white solid. Yield: 0.051 g, 41.99% [00562] ES MS M/Z = 365.05 (M +1), 1H NMR (400 MHz, DMSO-d6) δ 7.83-7.81 (m, 1H), 7.66-7.64 (m, 1H), 7.28-7.21 (m, 2H), 7.08 (d, 2H), 7.02 (s, 1H), 5.14-5.05 (m, 1H), 2.75-2.65 (m, 1H), 2.42-2.32 (m, 2H), 1.92-1.87 (m, 1H), 1.84-1.77 (m, 1H). Example 234: Synthesis of 5-(1-cyclobutyl-1H-1,3-benzodiazol-2-yl)-3-ethoxybenzene-1,2 -diol [00563] Step-1: To a solution of methyl 7-hydroxy-2,2-dimethyl-2H-1,3-benzodioxole-5-carboxylate (100 mg, 446 µmol) in N,N-Dimethylformamide (10.0 mL), methyl 7-ethoxy-2,2-dimethyl-2H-1,3- benzodioxole-5-carboxylate (100 mg, 309 µmol) , dipotassium carbonate (123 mg, 2 eq., 892 µmol) were added to the reaction mixture and stirred at room temperature for 12. After completion of the reaction, the reaction mixture was quenched with ice cold water to get the precipitate which were filtered to get the crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford methyl 7-ethoxy-2,2-dimethyl-2H-1,3-benzodioxole-5-carboxylate as off white solid. Yield: 100 mg. 69.33% [00564] Step-2: To a solution of methyl 7-hydroxy-2,2-dimethyl-2H-1,3-benzodioxole-5-carboxylate (1.00 g, 4.46 mmol) in dry oxolane (7.00 mL), lithium aluminum hydride (4.16 mL, 1.5 eq., 4.16 mmol) added at 0 °C under inert atmosphere. The resulting reaction mixture stirred at room temperate. After completion of the reaction, the reaction mixture was quenched with aqueous ammonium chloride to get the precipitate which were filtered, and washed with ethyl acetate. The organic fractions were collected, dried over anhydrous sodium sulphate, filtered and concentrated to obtain (7-ethoxy-2,2-dimethyl-2H- 1,3-benzodioxol-5-yl)methanol (460 mg, 2.05 mmol) as sticky brown liquid. Yield: 460 mg, 73.92% [00565] Step-3: To a solution of (7-ethoxy-2,2-dimethyl-2H-1,3-benzodioxol-5-yl)methanol (460 mg, 2.05 mmol) in 1,2-dichloromethane (10.0 mL), Dess Martin (1.28 g, 1.5 eq., 3.01 mmol) added at 0 °C. The resulting reaction mixture stirred at room temperature. After completion of the reaction, the reaction mixture was quenched with saturated solution of sodium thiosulfate and sodium bicarbonate, extracted with ethyl acetate. The combined organic fractions collected, dried over anhydrous sodium sulphate, filtered and concentrated to get the crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 7-ethoxy-2,2-dimethyl-2H-1,3-benzodioxole-5-carbaldehyde (550 mg, 1.09 mmol ) as off white solid. Yield: 550 mg, 54.27% [00566] Step-4: To a stirred solution of N1-cyclobutylbenzene-1,2-diamine (219 mg, 1.35 mmol) and 7- ethoxy-2,2-dimethyl-2H-1,3-benzodioxole-5-carbaldehyde (300 mg, 1.35 mmol) in methanesulfinylmethane (10.0 mL), disodium sulfinatosulfonate (385 mg, 1.5 eq., 2.02 mmol) was added at room temperature. The resulting mixture stirred for 16 h at 85 °C. After completion, ice cold water was added in the reaction mixture and solid was filtered and dried to get crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 1-cyclobutyl-2-(7-ethoxy-2,2- dimethyl-2H-1,3-benzodioxol-5-yl)-1H-1,3-benzodiazole (185 mg, 340 µmol) as sticky solid. Yield: 185 mg, 25.2% [00567] Step-5: A mixture of 1-cyclobutyl-2-(7-ethoxy-2,2-dimethyl-2H-1,3-benzodioxol-5-y l)-1H-1,3- benzodiazole (180 mg, 494 µmol) in trifluoroacetic acid (2.00 mL) heated at 100 °C for 4 h. After the completion of reaction, reaction mixture was concentrated to obtain crude. The crude purified in reverse phase HPLC chromatography. The desired fractions were collected and lyophilized to obtain 5-(1- cyclobutyl-1H-1,3-benzodiazol-2-yl)-3-ethoxybenzene-1,2-diol (45.0 mg, 139 µmol) as off white solid. Yield: 45 mg, 28.09% [00568] LCMS and NMR Data: ES MS M/Z = 325.08 [M+1] +: UPLC: 99.47%; 1H NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 7.6 Hz, 1H), 8.61 (d, J = 3.6 Hz, 1H), 7.83 (d, J = 7.1 Hz,1H), 7.62 (t, J = 7.0 Hz, 1H), 7.26-7.19 (m, 2H), 6.69 (s, 2H), 5.13 (quin, J = 8.8 Hz, 1H), 4.11 (q, J = 13.6 Hz, 2H), 2.77- 2.71 (m, 2H), 2.44-2.37 (m, 2H), 1.96-1.76 (m, 2H), 1.35 (t, J = 13.8 Hz, 3H). Example 235: Synthesis of 4-(5-amino-1-cyclobutyl-1H-benzo[d]imidazol-2-yl)-6-methoxy- 3- methylbenzene-1,2-diol
[00569] Step-1: A stirred solution of 4-fluoro-3-nitroaniline (1.00 g, 6.41 mmol) in dichloromethane (10.0 mL), di-tert-butyl dicarbonate (1.68 g, 1.2 eq., 7.69 mmol) and diethyl(propan-2-yl)amine (1.11 g, 1.5 eq., 9.61 mmol) were added and stirred at room temperature for 3h. After completion of reaction, reaction mixture diluted with water and extracted with dichloromethane. The combined organic layers were dried over anhydrous sodium sulphate, filtered and concentrated to obtained crude. The crude purified in flash chromatography. The desired fractions were concentrated to afford tert-butyl (4-fluoro- 3-nitrophenyl)carbamate as off-white solid. Yield: 1.50 g, 91% [00570] Step-2: A stirred solution of tert-butyl N-(4-fluoro-3-nitrophenyl)carbamate (1.50 g, 5.85 mmol) and cyclobutanamine (625 mg, 1.5 eq., 8.78 mmol) in 1-methylpyrrolidin-2-one (3.00 mL), diethyl(propan-2-yl)amine (2.73 mL, 3 eq., 17.6 mmol) was added and heated at 100 °C for 8h. After completion of reaction, reaction mixture poured on crushed ice and obtained solid was filtered and dried to afford tert-butyl (4-(cyclobutylamino)-3-nitrophenyl)carbamate as orange solid. Yield: 1.50 g, 72% [00571] Step-3: To a stirred solution of tert-butyl N-[4-(cyclobutylamino)-3-nitrophenyl]carbamate (500 mg, 1.63 mmol) in methanol (5.00 mL),zinc (532 mg, 5 eq., 8.13 mmol) and ammonium chloride (435 mg, 5 eq., 8.13 mmol) were added and reaction mixture was heated to 90 °C for 16 h. After completion, the reaction mixture filtered through celite bed was concentrated. Then diluted with water and extracted with dichloromethane. The combined organic layers dried over anhydrous sodium sulphate, filtered and concentrated to obtain tert-butyl N-[3-amino-4-(cyclobutylamino)phenyl]carbamate (300 mg, 898 µmol)as yellow oil. Yield: 300 mg, 55.18% [00572] Step-4: To a stirred solution tert-butyl N-[3-amino-4-(cyclobutylamino)phenyl]carbamate (276 mg, 1.2 eq., 993 µmol) and 3,4-bis(benzyloxy)-5-methoxy-2-methylbenzaldehyde (300 mg, 828 µmol) in Methanol (3.00 mL) was added Acetic acid (100 µL) (catalytic amount) at room temperature for 16 h. After completion, reaction mixture concentrated under reduced pressure to get crude. The crude was purified in flash chromatography to afford tert-butyl N-{2-[3,4-bis(benzyloxy)-5-methoxy-2- methylphenyl]-1-cyclobutyl-1H-1,3-benzodiazol-5-yl}carbamate (200 mg, 242 µmol) as light yellow solid. Yield:200mg, 29%. [00573] Step-5: To a solution of tert-butyl N-{2-[3,4-bis(benzyloxy)-5-methoxy-2-methylphenyl]-1- cyclobutyl-1H-1,3-benzodiazol-5-yl}carbamate (180 mg, 290 µmol) in trifluoroacetic acid (2.00 mL) was reflux at 60 °C for 3 h .After completion of reaction, the reaction mixture concentrated to obtained crude. The crude was purified by prep HPLC to afford 4-(5-amino-1-cyclobutyl-1H-1,3-benzodiazol-2- yl)-6-methoxy-3-methylbenzene-1,2-diol (19.0 mg, 52.2 µmol) as pink solid. Yield: 19 mg, 17.97% [00574] LCMS and NMR Data: LCMS and NMR Data: ES MS M/Z 340.14 (M +1), 1H NMR (400 MHz, DMSO-d6) δ 7.49 (d, J = 8.8 Hz, 1H), 7.78 (d, J =1.6 Hz, 1H), 6.60 (dd, J = 2,8.8 Hz, 1H), 6.38 (s,1H),4.75 (bs, 1H), 4.57 (t, J = 8.8 Hz, 1H), 3.76 (d, J =14 Hz, 3H), 2.68 (t, J=9.6 Hz, 2H), 2.19 (bs, 2H), 1.83 (s, 4H), 1.80-1.66 (m, 1H). Example 236: Synthesis of 3-fluoro-6-methoxy-4-(1-(3-methyloxetan-3-yl)-6- ((phenylamino)methyl)-1H-benzo[d]imidazol-2-yl)benzene-1,2-d iol [00575] Step:1 To a solution of methyl 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazole-6-carboxylate (430 mg, 738 µmol) in dry oxolane (5.00 mL), lithium alumanuide (1.11 mL, 1.5 eq., 1.11 mmol) added at 0 °C under inert atmosphere. The resulting reaction mixture stirred at room temperature till the complete consumption of starting material. After completion of the reaction, the reaction mixture was quenched with aqueous ammonium chloride to get the precipitate which were filtered, and ethyl acetate was added to filtrate. The organic fractions were collected, dried over anhydrous sodium sulphate, filtered and concentred to obtain {2-[3,4- bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methyloxetan-3 -yl)-1H-1,3-benzodiazol-6-yl}methanol (380 mg, 651 µmol) as sticky brown liquid. Yield: 380 mg, 88.19% [00576] Step:2 To a solution of {2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methyl oxetan- 3-yl)-1H-1,3-benzodiazol-6-yl}methanol (460 mg, 829 µmol) in 1,2-dichloromethane (10.0 mL), 1,1- bis(acetyloxy)-3-oxo-3H-1λ⁵,2-benziodaoxol-1-yl acetate (528 mg, 1.5 eq., 1.24 mmol) added at 0 °C. The resulting reaction mixture stirred at room temperature for 2 h. After completion of the reaction, the reaction mixture was quenched with saturated solution of sodium thiosulfate and sodium bicarbonate, extracted with ethyl acetate. The combined organic fractions collected, dried over anhydrous sodium sulphate, filtered and concentrated to get the crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazole-6-carbaldehyde (350 mg, 602 µmol) as yellow liquid. Yield: 0.320 g, 72% [00577] Step:3 To a stirred solution of 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazole-6-carbaldehyde (120 mg, 217 µmol) in methanol (10.0 mL), aniline (27.8 mg, 1.1 eq., 299 µmol) was added at room temperature. The reaction mixture was stirred at room temperature for 2 h, and then sodium boranuide (38.9 mg, 5 eq., 1.09 mmol) was added in batches and the mixture was further stirred for another period of 16 h. The reaction was concentrated and extracted with Dichloromethane. The combined organic phases were dried over sodium sulphate and reduced under pressure to get N-({2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-met hyloxetan- 3-yl)-1H-1,3-benzodiazol-6-yl}methyl)aniline (140 mg, 160 µmol) as white solid. Yield: 0.14 g, 58% [00578] Step:4 To a stirred solution of N-({2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazol-6-yl}methyl)aniline (150 mg, 238 µmol) in trifluoroacetic acid (1.00 mL) . The resulting mixture stirred for 2 h at 60°C. After completion, reaction mixture was concentrated under reduced pressure to get the crude and further purified by reverse phase HPLC. The desired fractions were lyophilized to afford 3-fluoro-6-methoxy-4-(1-(3-methyloxetan-3-yl)-6- ((phenylamino)methyl)-1H-benzo[d]imidazol-2-yl)benzene-1,2-d iol (0.024 g, 52.9 µmol) as off white solid. Yield: 0.024 g, 22.19% [00579] 1H NMR: ES MS M/Z=456.46 (M+1), 1 HNMR (400 MHz, DMSO-d6) δ 9.41 (brs, 2H), 7.62 (d, J = 8.4 Hz, 1H), 7.28 (d, J = 8.4 Hz, 1H), 7.20 (s, 1H), 7.04 (t, J = 8.0 Hz, 1H), 6.62 (d, J = 7.6 Hz, 2H), 6.57 (d, J = 6.4 Hz, 1H), 6.51 (t, J = 7.2 Hz, 1H), 6.25 (t, J = 6.0 Hz, 1H), 4.66 (d, J = 6.0 Hz, 2H), 4.39 (d, J = 6.0 Hz, 2H), 4.32 (d, J = 6.0 Hz, 2H), 3.77 (s, 3H), 1.97 (s, 3H). Example 237: Synthesis of N-(2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-3-(3-methyloxe tan-3- yl)-3H-imidazo[4,5-c]pyridin-6-yl)acetamide [00580] Step-1: To a stirred solution of 6-bromo-N-(3-methyloxetan-3-yl)-4-nitropyridin-3-amine (300 mg, 1.04 mmol) in 1,4-dioxane (5.00 mL), tert-butyl N-{5-[(3-methyloxetan-3-yl)amino]-4-nitropyridin- 2-yl}carbamate (220 mg, 651 µmol) and cesium carbonate (679 mg, 2 eq., 2.08 mmol) were added and reaction mixture was purged with argon and then tris((1E,4E)-1,5-diphenylpenta-1,4-dien-3-one) dipalladium (47.7 mg, 0.05 eq., 52.1 µmol) and [5-(diphenylphosphanyl)-9,9-dimethyl-9H-xanthen-4- yl]diphenylphosphane (30.1 mg, 0.05 eq., 52.1 µmol) was added and again purged with argon. The reaction mixture was heated to 80 °C for 6 h. After completion, the reaction cooled to room temperature and passed through celite bed. The filtrate diluted with ethyl acetate and washed with water. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to give crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford tert-butyl N-{5-[(3- methyloxetan-3-yl)amino]-4-nitropyridin-2-yl}carbamate (220 mg, 651 µmol) as off white solid. Yield: 220 mg, 62.5% [00581] Step-2: To a stirred solution of tert-butyl N-{5-[(3-methyloxetan-3-yl)amino]-4-nitropyridin-2- yl}carbamate (220 mg, 678 µmol) in dichloromethane (2.00 mL), trifluoroacetic acid (1.00 mL) was added and reaction mixture was stirred at room temperature for 2 h. After completion, solvent was removed under reduced pressured to get the N5-(3-methyloxetan-3-yl)-4-nitropyridine-2,5-diamine (170 mg, 732 µmol) as brown solid. Yield: 170 mg, Crude [00582] Step-3: To a stirred solution N5-(3-methyloxetan-3-yl)-4-nitropyridine-2,5-diamine TFA salt (170 mg, 758 µmol) in acetic acid (5.00 mL), acetyl acetate (232 mg, 3 eq., 2.27 mmol) was added and reaction mixture was heated to 60 °C for 16 h. After completion, reaction mixture concentrated under reduced pressure to get crude. The crude purified in flash chromatography. Combined fractions were concentrated under reduced pressure to get N-{5-[(3-methyloxetan-3-yl)amino]-4-nitropyridin-2- yl}acetamide (160 mg, 577 µmol) as white solid. Yield: 160 mg, 76.09% [00583] Step-4: To a stirred solution N-{5-[(3-methyloxetan-3-yl)amino]-4-nitropyridin-2-yl}acetam ide (170 mg, 638 µmol) in methanol (2.00 mL), zinc (209 mg, 5 eq., 3.19 mmol) and ammonium chloride (171 mg, 5 eq., 3.19 mmol) was added at 0 °C and reaction mixture was stirred at room temperature for 30 min. After completion, the reaction mixture passed through celite bed. The filtrate was concentrated under reduced pressure and washed with water. The organic layer dried over anhydrous sodium sulphate, filtered and concentrated to afford N-{4-amino-5-[(3-methyloxetan-3-yl)amino]pyridin-2-yl}acetam ide (150 mg, 216 µmol) as brown solid. Yield: 150 mg, Crude [00584] Step-5: To a stirred solution N-{4-amino-5-[(3-methyloxetan-3-yl)amino]pyridin-2-yl}acetam ide (140 mg, 593 µmol) and 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (174 mg, 0.8 eq., 474 µmol) in methanesulfinylmethane (5.00 mL) was added disodium sulfinatosulfonate (169 mg, 1.5 eq., 889 µmol) at room temperature. The resulting mixture stirred for 1 h at 85 °C. After completion, reaction mixture diluted with water solid obtained was filtered and dried to get N-{2-[3,4-bis(benzyloxy)-2- fluoro-5-methoxyphenyl]-3-(3-methyloxetan-3-yl)-3H-imidazo[4 ,5-c]pyridin-6-yl}acetamide (140 mg, 42.1 µmol) as brown solid. Yield: 140 mg, Crude [00585] Step-6: A stirred solution of N-{2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-3-(3- methyloxetan-3-yl)-3H-imidazo[4,5-c]pyridin-6-yl}acetamide (100 mg, 172 µmol) in trifluoroacetic acid (1.00 mL) was heated to 60 °C for 2 h. After completion of reaction, reaction mixture was distilled below 30 °C to obtain crude as pale green mass. Crude was submitted for prep purification to get pure compound N-[2-(2-fluoro-3,4-dihydroxy-5-methoxyphenyl)-3-(3-methyloxe tan-3-yl)-3H-imidazo[4,5- c]pyridin-6-yl]acetamide (6.00 mg, 14.9 µmol) as off white solid. Yield: 6 mg, 6.77% [00586] LCMS and NMR Data: ES MS M/Z = 403.35 (M + 1), 1HNMR (400 MHz, DMSO-d6): δ 10.45 (s, 1H), 9.5 (bs, 2H), 8.43 (s, 1H), 8.32 (s, 1H), 6.64 (d, J = 6.4 Hz, 1H), 4.74 (d, J = 6.4 Hz, 2H), 4.41 (d, J = 6.4 Hz, 2H), 3.79 (s, 3H), 2.11 (s, 3H), 2.02 (s, 3H). Example 238: Synthesis of 3-fluoro-6-methoxy-4-[1-(3-methyloxetan-3-yl)-6-(1, 3, 4-oxadiazol-2-yl)- 1H-1, 3-benzodiazol-2-yl] benzene-1, 2-diol [00587] Step-1: To a stirred solution of methyl 3-fluoro-4-nitrobenzoate (500 mg, 2.51 mmol) in N- Methyl-2-Pyrrolidone (NMP) (5 ml), 3-methyloxetan-3-amine (230 µL, 2 eq., 5.02 mmol) and ethylbis(propan-2-yl)amine (1.32 mL, 7.53 mmol, 3 eq) were added at room temperature and stirred at 130°C for 1h. After completion, reaction mixture quenched with ice cold water, solid was filtered and dried to afford methyl 3-[(3-methyloxetan-3-yl) amino]-4-nitrobenzoate (300 mg, 1.13 mmol) as a yellow solid. Yield: 0.30 g, 44% [00588] Step-2: To a stirred solution of methyl 3-[(3-methyloxetan-3-yl)amino]-4-nitrobenzoate (200 mg, 0.66 eq., 751 µmol) in methanol (10.0 mL), zinc (370 mg, 5 eq., 5.65 mmol) and ammonium chloride (302 mg, 5 eq., 5.65 mmol) were added at room temperature and the reaction mixture stirred for 2h at 40°C. After completion, the reaction mixture passed through celite bed. Filtrate was extracted with dichloromethane, dried over anhydrous sodium sulfate and concentrated under reduced pressure to get as methyl 4-amino-3-[(3-methyloxetan-3-yl)amino]benzoate (150 mg, 635 µmol) Violet color solid. Yield: 0.15 g (Crude) [00589] Step-3: To a stirred solution of 3,4-bis(benzyloxy)-2-fluoro-5-methoxybenzaldehyde (161 mg, 0.8 eq., 440 µmol) and methyl 4-amino-3-[(3-methyloxetan-3-yl)amino]benzoate (130 mg, 550 µmol) in methanesulfinylmethane (5.00 mL), disodium sulfinatosulfonate (157 mg, 1.5 eq., 825 µmol) was added at room temperature. The resulting mixture stirred for 12 h at 85 °C. After completion, ice cold water was added in the reaction mixture and solid was filtered and dried to get crude. The crude purified by flash chromatography. The desired fractions were concentrated to afford methyl 2-[3,4- bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methyloxetan-3 -yl)-1H-1,3-benzodiazole-6-carboxylate (180 mg, 300 µmol) as sticky solid. Yield: 0.18 g, 54% [00590] Step-4: To a solution of methyl 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-1H-1,3-benzodiazole-6-carboxylate (50.0 mg, 85.8 µmol) in ethanol (2.00 mL) , hydrazine hydrate monohydrate (333 µL, 4 eq., 343 µmol) was added to the reaction mixture and stirred at 80°C for 16 h . After completion of reaction, reaction mixture concentrated and extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulphate, filtered and concentrated to obtained crude. Yield: 0.08 g, 62% [00591] Step-5: To a solution of 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3-methylo xetan-3- yl)-1H-1,3-benzodiazole-6-carbohydrazide (110 mg, 189 µmol) in Triethylorthoformate (1 ml) was added to the reaction mixture and stirred at 80°C for 16 h . After completion of reaction, reaction mixture concentrated and extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulphate, filtered and concentrated to obtained crude. Yield: 0.10 g, 75% [00592] Step-6: To a stirred solution of 2-[3,4-bis(benzyloxy)-2-fluoro-5-methoxyphenyl]-1-(3- methyloxetan-3-yl)-5-(1,3,4-oxadiazol-2-yl)-1H-1,3-benzodiaz ole (60.0 mg, 101 µmol) in Tetrahydrofuran (5.00 mL), palladium hydroxide (50.0 mg, 408 µmol) was added and reaction mixture stirred for 4h at room temperature under H2 atmosphere . After completion, reaction mixture was passed through celite bed and filtrate was concentrated under reduced pressure to get the crude, further purified by reverse phase HPLC. The desired fractions were lyophilized to afford as an off white solid. Yield: 0.012 g, 28 % [00593] LCMS and NMR Data: ES MS M/Z= 413 (M+1), NMR (400 MHz, DMSO-d6) δ 9.58 (s, 1H), 9.51 (s, 1H), 9.37 (s, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.91 (d, J = 8.4 Hz, 1H), 7.80 (s, 1H), 6.65 (d, J = 6.0 Hz, 1H), 4.78 (d, J = 5.6 Hz, 2H), 4.44 (d, J = 5.6 Hz, 2H), 3.80 (s, 3H), 2.08 (s, 3H). Examples 239-335: Examples 239-335 were synthesized as described in examples 1-6 and 272-238. LC- MS data is found in table 1. Example A. Human TREX1 Enzymatic Assay with dsDNA Native Oligonucleotide [00594] Human TREX1 enzyme (amino acids 1-242) was diluted in assay buffer (20 mM Tris pH 7.7, 5 mM MgCl 2 , 0.01% human serum albumin, 0.01% Brij™-35, 2 mM dithiothreitol) to a final concentration of 0.8 nM to 0.16 nM and added to a 96-well low-binding polypropylene plate. Test compounds were diluted in DMSO to 50X concentration (final DMSO concentration in reaction mixture of 2%) and added to the wells with a concentration ranging from 300 µM to 13 nM or 30 µM to 1.5 nM. The reaction mixtures were incubated for 30 minutes at 25 °C and a solution of annealed dsDNA oligonucleotide (5’-ACATTTCCCCGAAAAGTGCCACCCTTGGCG-3’ and Comp: 5’- CAAGGGTGGCACTTTTCGGGGAAATGT-3’) was added to a final concentration of 50 nM. The reaction mixtures were incubated at 25 °C for 5-15 minutes and subsequently quenched by transferring part of the assay reaction to a solution of 100 mM ethylenediaminetetraacetic acid and 1:100 Picogreen™ (final concentration of 60mM ethylenediaminetetraacetic acid and 1:60 Picogreen™) in a black plate with an opaque bottom. The fluorescence (emission wavelength 480 nm / excitation wavelength 520 nm) was measured using a Molecular Devices SpectraMax plate reader. Wells containing oligonucleotide but no TREX1 enzyme were used as negative controls. Wells containing oligonucleotide, TREX1 enzyme, and DMSO were used as positive controls. [00595] The data is shown in Table 2 (IC 50 displayed in µM). Table 2 A is less than or equal to 100 nM; B is more than 100 nM and less than or equal to 1 µM; C is more than 1 µM and less than or equal to 10 µM; D is more than 10 µM and less than or equal to 100 µM; E is more than 100 µM. NT is not tested Example B: Gel assay [00596] A gel assay was conducted as an orthogonal control to confirm observations of TREX1 inhibitors determined with the fluorescence-based assay. Briefly, compounds were diluted in DMSO at 50X the final concentration. Human TREX1 was diluted to 120pM (2x concentration) in assay buffer (assay buffer: 20mM Tris pH 7.7 (Life Technologies), 5mM MgCl2 (Sigma), 0.01%HSA (Sigma), 0.01% Brij-35 (ThermoFisher), 2mM DTT (Sigma)). Oligonucleotide strand (IR-680- 5’ACATTTCCCCGAAAAGTGCCACCCTTG-3’) (Custom probe made by Trilink) was diluted in the same assay buffer to a working concentration of 25nM (final concentration of 12.5nM). Example 107 was added to 60 nM human TREX1 enzyme in clear 96 well plates. The plate was then incubated at 25°C for 30 minutes. Twenty five nM oligonucleotide strand was added to the plate, to a final concentration of 30pM TREX1, 12.5nM oligo, 1x compound and incubated at 25°C. Fifteen minutes later, the reaction was stopped by removing 10µl of the reaction and adding it to 20µl of a solution of 50mM EDTA/1.5x loading dye buffer (6x Orange DNA loading dye; ThermoFisher) in a 96 well PCR plate. The plate was then incubated for 3 minutes at 70°C and the reaction loaded on a Novex TBE polyacrylamide gel, 20% 10-well (ThermoFisher). The samples were run for 1 hour and a half at 150V using the Invitrogen mini gel box system. Gel was then visualized using Licor Odyssey, 700nm wavelength with 0.5 offset. The top band was quantified using Image Studio (Licor). Controls were Oligonucleotide strand with no TREX1 enzyme and Oligonucleotide strand with TREX1 enzyme and DMSO (final DMSO concentration of 2%). Prism (GraphPad) was used to calculate IC 50 . Fig.1A: Scan of a 20%polyacrylamide gel with the product from the TREX1 enzymatic reaction in the presence of different doses of inhibitor. The top band intensity was measured using the Odyssey scanner (Li-Cor) and ImageStudio software (Li-Cor) and Fig. 1B: Graph representing the percent of top band intensity degradation as a measure of human TREX1 activity. GraphPad Prism 8 software was used to produce this graph and measure IC 5 0. No TREX1 sample was used as the positive control and TREX1 with DMSO was as used as the negative control. [00597] The examples and embodiments described herein are for illustrative purposes only and in some embodiments, various modifications or changes are to be included within the purview of disclosure and scope of the appended claims.
Next Patent: THYROID CANCER-SPECIFIC BIOMARKER PANEL